





The influence of valproic acid and the role of 








In partial fulfillment of the requirements for the degree  
“Doctor rerum naturalium (Dr. rer. nat.)” 
in the Molecular Medicine Study Program  











Dr. Silke Kaulfuß, Department of Human Genetics, University Medical Center Göttingen 
 
Members of the Thesis Committee: 
 
Official Supervisor: 
Prof. Dr. Peter Burfeind, Department of Human Genetics, University Medical Center 
Göttingen 
 
Second member of the thesis committee: 
Prof. Dr. Matthias Dobbelstein, Department of Molecular Oncology, University Medical 
Center Göttingen 
 
Third member of the thesis committee: 



















Date of Disputation: 
AFFIDAVIT 
 
Herewith I declare that my doctoral thesis entitled “The influence of valproic acid and the role 
of cyclin D2 in prostate cancer” has been written independently with no other sources and aids 
than quoted. 
 
Göttingen, February 2016                                                  ___________________________ 
                                                                                            Claudia Morich 
Table of Contents I 
  
Table of Contents 
List of Abbreviations ................................................................................................. VI 
1. Introduction ..............................................................................................................1 
1.1 The prostate carcinoma- incidence and risk factors ................................................................... 1 
1.2 Diagnosis and standard therapy options for PCa ........................................................................ 2 
1.3 Therapeutic perspectives in PCa ................................................................................................... 5 
1.4 Cyclin D2 in general ........................................................................................................................ 9 
1.5 Cyclin D2 in PCa ............................................................................................................................ 10 
1.6 Aims of this study ......................................................................................................................... 12 
2. Materials and Methods .......................................................................................... 14 
2.1 Chemicals and Reagents .............................................................................................................. 14 
2.2 Biochemicals and enzymes .......................................................................................................... 16 
2.3 Usage ware ..................................................................................................................................... 17 
2.4 Technical equipment ..................................................................................................................... 18 
2.5 Sterilization of solutions and equipment .................................................................................... 19 
2.6 Ready-to-use reaction systems ................................................................................................... 19 
2.7 Solutions ........................................................................................................................................ 20 
2.8. Culture media, antibiotics, agar plates ...................................................................................... 22 
2.8.1 Culture media for bacteria ....................................................................................................... 22 
2.8.2 Agar plates .............................................................................................................................. 22 
2.8.3 Media for eukaryotic cell cultures ............................................................................................ 22 
2.9. Biologic material ........................................................................................................................... 24 
2.9.1 Bacterial strains ....................................................................................................................... 24 
2.9.2 Eukaryotic cell lines ................................................................................................................. 24 
2.9.3 Mouse strains .......................................................................................................................... 24 
2.9.4 Synthetic DNA oligonucleotides .............................................................................................. 25 
2.9.5 Synthetic RNA oligonucleotides .............................................................................................. 28 
2.9.6 Antibodies ................................................................................................................................ 29 
2.9.6.1 Primary antibodies ................................................................................................................ 29 
2.9.6.2 Secondary antibodies ........................................................................................................... 29 
2.9.7 Plasmids and Vectors .............................................................................................................. 30 
Table of Contents II 
  
2.10 Databases ..................................................................................................................................... 30 
2.11 Isolation, purification and concentration determination of nucleic acids ............................. 31 
2.11.1 Isolation of total RNA from cell cultures ................................................................................ 31 
2.11.2 Isolation of RNA from mouse tissue ...................................................................................... 31 
2.11.3 Determination of nucleic acid concentration.......................................................................... 31 
2.12 Cloning techniques ..................................................................................................................... 32 
2.12.1 pSingle-tTs-shRNA cloning ................................................................................................... 32 
2.12.2 Amplification of DNA for subcloning into pGEM®-T Easy vector .......................................... 32 
2.12.3 Purification of the PCR-product ............................................................................................. 32 
2.12.4 Subcloning of PCR products/ TA-cloning .............................................................................. 32 
2.12.5 Ligation .................................................................................................................................. 33 
2.12.6 Transformation ...................................................................................................................... 34 
2.12.7 Generation of bacterial glycerol stocks ................................................................................. 34 
2.12.8 Minipreparation of plasmid DNA ............................................................................................ 34 
2.12.9 Midipreparation of plasmid DNA ............................................................................................ 35 
2.12.10 Cleavage of DNA with restriction endonucleases ............................................................... 35 
2.12.11 Isolation of DNA fragments from agarose gels ................................................................... 35 
2.13 Agarose gel electrophoresis of DNA ......................................................................................... 36 
2.14 Polymerase-Chain-reaction (PCR) ............................................................................................. 36 
2.14.1 Standard PCR ....................................................................................................................... 37 
2.14.2 Amplification of DNA fragments for molecular cloning/ Touchdown PCR ............................. 37 
2.14.3 Colony PCR ........................................................................................................................... 38 
2.14.4 Genotyping PCR .................................................................................................................... 39 
2.14.5 Reverse Transcription ........................................................................................................... 40 
2.14.6 Quantitative real-time PCR .................................................................................................... 41 
2.14.7 Sequence analysis ................................................................................................................ 42 
2.15 Protein chemical techniques ...................................................................................................... 43 
2.15.1 Isolation of total protein from cell cultures ............................................................................. 43 
2.15.2 Isolation of protein from mouse tissue ................................................................................... 44 
2.15.3 Determination of protein concentration ................................................................................. 44 
2.15.4 Sodium Dodecyl Sulfate Polyacrylamide gel electrophoresis (SDS-PAGE) ......................... 45 
2.15.5 Transfer of proteins onto a PVDF membrane ....................................................................... 45 
2.15.6 Incubation of protein-bound membranes with antibodies ...................................................... 46 
2.16 Cell biological methods .............................................................................................................. 46 
2.16.1 Cell culture of eukaryotic cells ............................................................................................... 46 
2.16.2 Cryo-preservation and revitalization of eukaryotic cells ........................................................ 46 
Table of Contents III 
  
2.16.3 Test for Mycoplasma contamination ...................................................................................... 47 
2.16.4 Transfection of eukaryotic cells ............................................................................................. 47 
2.16.4.1 Transfection of plasmids into eukaryotic cells .................................................................... 47 
2.16.4.1.1 Generation of single-cell clones/populations ................................................................... 48 
2.16.4.2 Transfection of small interfering RNA (siRNA) into eukaryotic cells .................................. 49 
2.17 Functional analyses of eukaryotic cells.................................................................................... 49 
2.17.1 Migration assay ..................................................................................................................... 49 
2.17.2 Proliferation assay ................................................................................................................. 50 
2.17.3 Soft agar assay ...................................................................................................................... 51 
2.18 Immunohistochemistry ............................................................................................................... 51 
2.18.1 Immunofluorescent staining of eukaryotic cells ..................................................................... 51 
2.18.2 Immunohistochemical staining of cryo-sections from CAM tumors ...................................... 52 
2.19 In vivo studies .............................................................................................................................. 52 
2.19.1 In vivo treatment of TRAMP mice with VPA .......................................................................... 53 
2.19.2 Chicken chorioallantoic membrane (CAM) assay ................................................................. 53 
2.20 Statistics ....................................................................................................................................... 54 
3. Results .................................................................................................................... 55 
3.1 Molecular effects of VPA treatment in PCa therapy .................................................................. 55 
3.1.1 Verification of deregulated candidate gene expression in tumors of VPA-treated TRAMP mice
 .......................................................................................................................................................... 55 
3.1.1.1 Verification of deregulated candidate gene expression on RNA and protein level .............. 56 
3.1.1.2 In vivo VPA treatment of TRAMP mice ................................................................................ 59 
3.1.1.3 Ceruloplasmin expression in human PCa cells .................................................................... 61 
3.1.2 Effects of VPA treatment on the expression of angiogenesis markers ................................... 63 
3.1.2.1 Effect of in vitro VPA treatment on the expression of blood- and lymphangiogenesis markers
 .......................................................................................................................................................... 63 
3.1.2.1.1 Is the Vegfr2 signaling pathway activated by VPA treatment? ......................................... 68 
3.1.2.2 Effect of in vivo VPA treatment on the expression of blood- and lymphangiogenesis markers
 .......................................................................................................................................................... 69 
3.1.2.3 Studying the influence of VPA on angiogenesis in vivo – CAM experiments ...................... 72 
3.1.2.3.1 Macroscopic analysis of the CAM tumors ......................................................................... 73 
3.1.2.3.2 Analysis of CAM tumor volume ......................................................................................... 76 
3.1.2.3.3 Studying blood and lymphangiogenesis in the CAM tumors with the markers Mep21 and 
Prox1 ................................................................................................................................................ 78 
3.1.2.3.4 Expression analysis of angiogenesis markers in CAM tumors ......................................... 80 
3.2 Is cyclin D2 a tumor suppressor gene in PCa? .......................................................................... 86 
Table of Contents IV 
  
3.2.1 Cyclin D2 overexpression studies in human PCa cells ........................................................... 86 
3.2.1.1 Transient overexpression of cyclin D2 in human PCa cells ................................................. 86 
3.2.1.1.1 Generation of the pIRES2-EGFP-CCND2 expression vector ........................................... 86 
3.2.1.1.2 Studies on the proliferation rate of PCa cells with transient cyclin D2 over-expression ... 88 
3.2.1.2 Stable overexpression of cyclin D2 in human PCa cells ...................................................... 89 
3.2.1.2.1 Generation of the pEBTetD-CCND2 expression vector .................................................... 89 
3.2.1.2.2 Functional effects of stable and inducible cyclin D2 overexpression ................................ 95 
3.2.1.2.2.1 Studies on the proliferation rate of PCa cells with stable or inducible cyclin D2 
overexpression ................................................................................................................................. 95 
3.2.1.2.2.2 Studies on the migration rate of PCa cells with stable or inducible cyclin D2 
overexpression ................................................................................................................................. 97 
3.2.2 Cyclin D2 downregulation studies in NIH/3T3 cells ................................................................. 98 
3.2.2.1 Influence of reduced cyclin D2 expression on migration behavior of NIH/3T3 cells ............ 98 
3.2.2.2 Influence of siRNA-mediated reduced cyclin D2 expression on transformation potential of 
NIH/3T3 cells .................................................................................................................................. 101 
3.2.2.3. Cyclin D2 shRNA studies in NIH/3T3 cells ........................................................................ 102 
3.2.2.3.1 Generation of NIH/3T3 cell clones with a stable cyclin D2 downregulation .................... 102 
3.2.2.3.2 Studies on the proliferation rate of NIH/3T3 cells with shRNA-mediated cyclin D2 
downregulation ............................................................................................................................... 104 
3.2.2.3.3.3 Influence of shRNA-mediated reduced expression of cyclin D2 on the transformation 
potential of NIH/3T3 cells ............................................................................................................... 105 
3.2.3 Studies on the functional consequences of cyclin D2 downregulation in VPA- treated PCa 
cells ................................................................................................................................................. 106 
3.2.4 Generation of a conditional cyclin D2 knockout mouse model.............................................. 109 
3.2.4.1 Establishment of the Ccnd2fl/fl and PB-Cre4+ mouse lines ................................................. 109 
3.2.4.2 Generation of Ccnd2fl/fl/Cre+ mice ...................................................................................... 111 
3.2.4.3 Verification of the prostate-specific cyclin D2 knockout ..................................................... 113 
3.2.4.4 Mating of the putative conditional cyclin D2 knockout mice with TRAMP mice ................. 116 
4. Discussion ............................................................................................................ 119 
4.1 Summary of results ..................................................................................................................... 119 
4.2 The histone deacetylase inhibitor VPA ..................................................................................... 122 
4.2.1 Deregulated candidate genes after VPA treatment of mouse 2E PCa cells ......................... 126 
4.2.1.1 Candidate gene expression in prostate tumor tissue and prostate tissue of in vivo VPA-
treated TRAMP mice ...................................................................................................................... 128 
4.3 Tumor angiogenesis in general ................................................................................................. 131 
4.3.1 Antiangiogenic treatment in cancer ....................................................................................... 135 
4.3.1.1 VPA as a possible anti-angiogenic treatment .................................................................... 138 
Table of Contents V 
  
4.4 The role of cyclin D2 in PCa ....................................................................................................... 146 
4.4.1 The family of D-type cyclins................................................................................................... 146 
4.4.2 Does cyclin D2 act as an oncogene or a tumor suppressor gene in PCa? ........................... 147 
4.4.3 The physiological role of cyclin D2 ........................................................................................ 153 
4.5 Perspectives ................................................................................................................................ 157 
4.5.1 The histone deacetylase inhibitor VPA in PCa ...................................................................... 157 
4.5.2 The cell cycle regulator cyclin D2 in PCa .............................................................................. 159 
5. Summary ............................................................................................................... 162 
5.1 The histone deacetylase inhibitor valproic acid in PCa .......................................................... 162 
5.2 The cell cycle regulator cyclin D2 in PCa ................................................................................. 164 
6. Bibliography ......................................................................................................... 166 
7. Acknowledgements ............................................................................................. 191 
 
List of Abbreviations VI 
  
List of Abbreviations 




Ang1 Angiopoietin 1 
app. approximately 
ATP Adenosine triphosphate 
Bp Base pair 
BSA Bovine serum albumin 
C Nucleobase cytosine 
°C Degree Celsius 
CAM (Chicken) Chorioallantoic membrane 
CCND Cyclin 
Cdk Cyclin-dependent kinase 
cDNA Complementary DNA 
Cp Ceruloplasmin 
Ct Threshold cycle 
CTP Cytosine triphosphat 
Cxcl15 Chemokine (C-X-C motif) ligand 15 
DAPI 4',6-diamidino-2-phenylindole 
ddH2O Bi-destilled water 
DHT Dihydrotestosterone 
DMEM Dulbecco´s Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleoside triphosphate 
DPBS Dulbecco's phosphate-buffered saline solution 
DTT  Dithiothreitol 
E.coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
e.g. exempli gratia, for example 
EGFP Enhanced green fluorescent protein 
et al. et alteri 
List of Abbreviations VII 
  
Fig Figure 
FKS Fetal calf serum 
Flt-1 Vascular endothelial growth factor receptor 1 
Fw forward 
G Nucleobase guanine 
G Gram 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
H Hour 
Hif1α Hypoxia inducible factor 1, alpha subunit 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
HRP Horse radish peroxidase 
i.e. id est 
Kan Kanamycin 
Kb Kilo base pair 
Kdr Kinase insert domain receptor, Vascular endothelial growth 
factor receptor 2 
kDa Kilo Dalton 
Kras Kirsten rat sarcoma viral oncogene homolog 
LDS Lithium dodecyl sulfate 
Lif Leukemia inhibitory factor 
Luc Luciferase 









mRNA Messenger RNA 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium 
N Nano = 10-9 
NaCl Sodium chloride 
List of Abbreviations VIII 
  
Nm Nanometer 
OD Optical density 
Oligo(dT) 15–25 Desoxythymidine 
o/n Overnight 
P Pico = 10-12 
PAGE Polyacrylamide gel electrophoresis 
PBGD Porphobilinogen deaminase 
PBS Phosphate buffered saline solution 
PCa Prostate carcinoma 
PCR Polymerase chain reaction 
Pecam-1 Platelet endothelial cell adhesion molecule-1 
pH negative decimal logarithm of the hydrogen ion 
concentration  
PIN Prostatic intraepithelial neoplasia 
PMS Phenazine methosulfate 
P/S Penicillin/Streptomycin 
PSA Prostate-specific antigen 
Pten Phosphatase and tensin homologue 
Ptprn Protein tyrosine phosphatase, receptor type, N 
PVDF Polyvinylidene fluoride 
qRT-PCR 
Rb 





Regulator of chromosome condensation (RCC1) and BTB 
(POZ) domain containing protein 2 
Reverse 
RKI Robert Koch-Institute 
RNA Ribonucleic acid 
RNase Ribonuclease 
rpm rounds per minute 
RT room temperature  
RT-PCR reverse Transcriptase PCR 
SDS Sodium dodecyl sulfate 
sec Seconds 
shRNA short hairpin RNA 
siRNA small interfering RNA 
List of Abbreviations IX 
  
 
SV Simian virus 
sVegfr2 Soluble vascular endothelial growth factor receptor 2 
T Nucleobase Thymine, temperature 
Tab. Table 
Taq. Thermus aquaticus 
TBP TATA-binding protein 
TBS(-T) Tris-buffered saline solution (with Tween) 
Tie-1 Tyrosine kinase with immunoglobulin-like and EGF-like 
domains 1 
TRAMP Transgenic adenocarcinoma of mouse prostate 










Vascular endothelial growth factor  
Vascular endothelial growth factor A 
Vascular endothelial growth factor B 
Vascular endothelial growth factor C 
Vascular endothelial growth factor receptor 1 
Vascular endothelial growth factor receptor 2 
Vol. Volume 
vs. Versus 
VPA Valproic acid 
Wb Western blot 
w/o Without 
w/v Mass concentration 
x G Multiple of acceleration of gravity 
X-Gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 










1.1 The prostate carcinoma- incidence and risk factors 
 
Worldwide, prostate cancer (PCa) is with an estimated 1.1 million new cases the second most 
frequently diagnosed cancer in men and the fifth leading cause of cancer-related death in men 
with an estimated 307.500 deaths in 2012. Thereby, the majority of new cases (about two-thirds) 
was diagnosed in economically developed countries (American Cancer Society, Global cancer 
facts and figures, 3rd edition, 2015). In Germany, PCa is with 63.710 (25.7% of total cancer 
diagnosis, Fig. 1.1) newly diagnosed cases in 2011 still the most frequent diagnosed cancer in 
men, although the frequency decreased slightly from 67.300 newly diagnosed cases in the year 
2010. In the list of cancer-related deaths in men in Germany PCa is listed with 12.957 deaths 
(10.5%, Fig. 1.1) at the third place, preceded only by lung cancer (24.8%) and intestinal cancer 
(11.5%; Robert Koch-Institute (RKI) and German Centre for Cancer Registry Data (ZfKD), Krebs 
in Deutschland 2011/2012). Worldwide, the number of newly diagnosed PCa cases will even 
further increase due to recording of prostate-specific antigen (PSA) testing in countries where it 
was not yet commonly used for PCa diagnosis. In contrast, PCa death rates will decrease due 
to improved treatment and/or early detection. To date, the 5-year relative survival rate for PCa 
patients in the USA is 97%, whereas in Germany it is 91% (American Cancer Society, Global 
cancer facts and figures, 3rd edition, 2015). 
 
Fig.1.1: Most frequent tumor sites and most frequent cancer-related deaths as a percentage of all cancer 
cases in Germany, 2011. PCa is the most common newly diagnosed cancer in men in Germany with 25.7% of all 




new cancer cases. It is the third leading cause of cancer-related death with 10.5% of all cancer related deaths. 
Modified from: Robert Koch-Institute and German Centre for Cancer Registry Data (ZfKD), Krebs in Deutschland 
2011/2012. 
 
Several risk factors for the development of PCa are known and depicted in Fig. 1.2. The main 
risk factor for the development of PCa is increasing age. A 35-year old male in Germany has a 
0.1% risk to develop PCa in the next 10 years, whereas a 75-year old male has a 6% risk to 
develop PCa within 10 years (RKI and German Centre for Cancer Registry Data (ZfKD), Krebs 
in Deutschland 2011/2012). Other risk factors include the level of the male sex hormone 
testosterone, African ancestry and a family history of the disease, although the underlying 
molecular mechanisms remain unclear. In Asia, where the incidence rates for PCa are lowest 
(2012: 10.5% and 4.5% in East and South-Central Asia, respectively) the mortality rates are 
rising. Presumably this is due to an increased economic development and western lifestyle with 
increased consumption of animal fat, obesity and physical inactivity (American Cancer Society, 
Global cancer facts and figures, 3rd edition, 2015), indicating that diet and life style might also 
influence the risk to develop PCa. 
 
Fig.1.2: Risk factors involved in initiation and development of PCa and the role of the immune system. Risk 
factors collectively influence genetic and epigenetic factors, leading to dysregulation of tumor suppressor genes 
(TSGs), oncogenes, mismatch repair genes (MMR) and micro RNAs (miRNA). The balanced cell growth is shifted 
toward excessive cell growth leading to development of PCa. Immune cells, which are primarily responsible for the 
killing of tumor cells, are unable to take care of the great amount of cancer cells, resulting in tumor cells escape and 
further growth. Modified from Karan et al. 2008. 
 
1.2 Diagnosis and standard therapy options for PCa  
 
Since the late 1980s PSA testing is being used as a tumor marker for malignancy of the prostate. 
Today, it represents the most important tool to detect PCa in very early stages, even before the 




patient notices any symptoms. But its’ use is still controversially discussed, mainly due to 
frequent overdiagnosis (tumors which would never have become clinically evident; estimated 
23% - 42% for PSA screen-detected cancers, Draisma et al. 2009) and due to the large potential 
of serious side effects of treatment options once PCa has been diagnosed. Therefore, in 
Germany health insurance is not covering the PSA screening. But it is still offered as individual 
health service by many medical practices and the patient has to pay for it himself. Yearly routine 
early detection screening for PCa in Germany starts for men at the age of 45 years and includes 
questioning of health problems like experience with weak or interrupted urine flow, the inability 
to urinate or difficulty starting or stopping the urine flow, the need to urinate frequently, especially 
at night, blood in the urine and pain or burning with urination. Also the prostate gland and the 
lymph nodes will be examined by palpation (RKI and German Centre for Cancer Registry Data 
(ZfKD), Krebs in Deutschland 2011/2012). Once the PSA test reveals a conspicuous value the 
only way to find out whether the patient really has a PCa is by examination of prostate biopsies. 
An elevated PSA value can not only be caused by PCa, but also by benign prostatic hyperplasia 
(BPH).  
The treatment options for PCa depend on the patients’ age as well as on the stage of the cancer 
(Fig. 1.3). According to the International Union against Cancer (UICC) PCa can be described by 
four mayor stages, stage one (T1) being a tumor that cannot be felt and is not visible on imaging. 
Stage two (T2) describes a tumor that is confined to the prostate whereas stage three (T3) 
describes a tumor that has spread beyond the prostatic capsule. Stage four (T4) describes a 
tumor that has metastasized at distant organs. 
Men with a less aggressive tumor and older men will not be treated immediately since the 
treatment options cause severe side effects. Instead, they will be carefully observed (active 
surveillance/watchful waiting) and only when the tumor becomes more aggressive the treatment 
will be initiated. Early stage PCa (organ specific, no metastatic spread) that is not subject to 
careful observation can be treated by surgery (radical prostatectomy: open, laparoscopic or 
robotic-assisted), external beam radiation or radioactive seed implants (brachytherapy), which 
reduces radiation exposure of surrounding tissue compared to external beam radiation 
(American Cancer Society, Global cancer facts and figures, 3rd edition, 2015). But all three early 
stage treatment options are associated with severe side effects, mainly effecting urination and 
erection. For advanced early stage disease the hormone depletion therapy, which cause 
withdrawal of androgens (testosterone and dihydrotestosterone), is used alongside to surgery 
or radiation therapy. This therapy approach, which can be either chemically or surgically, is not 
curative anymore, it solely prevents PCa cells from growing. Thereby, it slows tumor progression 
down for 2-4 years before recurrence, marking the progression to metastatic castration-resistant 




PCa (mCRPC) because PCa cells gradually developed resistance to hormonal therapy. 
Advanced stages of PCa, indicated by metastatic spread or castration resistance, are also 
treated by hormone depletion therapy since the tumor shrinkage and/or limited expansion can 
help relieve pain and other symptoms. Other treatment options include radiation therapy in 
combination with hormone depletion therapy and chemotherapy with docetaxel. Docetaxel was 
the first known agent to extend survival in men with mCRPC, a cancer that has come back or 
has progressed while being treated with hormonal therapy and is invariably fatal (Harris et al. 
2009). 
During the last six years several new treatments have been tested in randomized phase III trials 
and approved for the treatment of mCRPC since they have been shown to improve survival (Fig. 
1.3, bottom). The new treatment options include the immunotherapy sipuleucel-T (removed from 
the German market for unknown reasons in June 2015, Kantoff et al. 2010), cabazitaxel, which 
is a novel tubulin-binding taxane drug with antitumor activity in docetaxel-resistant cancers (de 
Bono et al. 2010), abiraterone acetate, which is an inhibitor of androgen biosynthesis (de Bono 
et al. 2011), radium-223, which delivers cytotoxic radiation to the sites of bone metastases (El-
Amm and Aragon-Ching 2015) and enzalutamide, which targets multiple steps in the androgen–
receptor-(AR) signaling pathway, the major driver of PCa growth (Scher et al. 2012).  
 
Fig.1.3: Treatment options for patients with PCa. At the top, the traditional treatment options for early stage PCa 
and mCRPC are indicated. At the bottom, the newly approved treatment options for mCRPC are depicted, which were 
developed during the last six years. Although, sipuleucel-T was removed from the German market in June 2015 for 
unknown reasons. Modified from Jha et al. 2014. 




1.3 Therapeutic perspectives in PCa 
 
Current research is investigating the potential of several alternative treatment options in PCa 
prevention and therapy. A list of different treatment approaches under current investigation, 
including hormone therapy, chemotherapy and epigenetic modulators, together with examples 
of tested drugs and their targets are demonstrated in Table 1.1. The hormone therapy, especially 
the androgen deprivation therapy, is of great interest for the treatment of PCa treatment since 
androgens, such as testosterone and dihydrotestosterone (DHT), stimulate the growth of PCa 
cells. Established androgen receptor (AR) pathway-targeting agents display clinical efficacy in 
mCRPC, but dose-limiting side effects remain problematic for all current agents. One novel, 
promising agent under current investigation is ARN-509, a synthetic biaryl thiohydantoin 
compound and competitive AR inhibitor. It was shown to exhibit characteristics predicting a 
higher therapeutic index with a greater potential to reach maximally efficacious doses in man 
than current AR antagonists (Clegg et al. 2012). Another phase I study including thirty patients 
with progressive CRPC that received daily oral ARN-509, showed that this drug is safe and well 
tolerated, displayed dose-proportional pharmacokinetics and demonstrated anti-tumor activity 
(Rathkopf et al. 2013). Another promising strategy for PCa control is chemoprevention which is 
the use of naturally (e.g. dietary) occurring or synthetic agents as a way to prevent, delay, or 
slow the process of carcinogenesis. A clinical trial in which PCa patients were treated orally with 
the hormone vitamin D3 revealed an increase in prostate calcitriol levels and a modestly lowered 
PSA level (Wagner et al. 2013a). Calcitriol was shown to exert several anti-inflammatory actions 
in prostate cells which contribute to its potential as a chemopreventive and therapeutic agent in 
PCa (Krishnan et al. 2007).  
Epigenetic modulators, such as microRNA (miRNA)-based therapeutic strategies are also under 
intensive investigation. miRNAs modulate the activity of key cell signaling networks by regulating 
the translation of pathway component proteins. Therefore, pharmacological targeting of miRNAs 
that regulate cancer cell signaling networks, either by promoting (using miRNA-supplementation) 
or by suppressing (using antisense oligonucleotide-based strategies) miRNA activity is a 
promising opportunity for therapeutic intervention in cancer in general (Sharma and Ruppert 
2015). In PCa, miRNAs are rather implied in miRNA profiling which can be a useful diagnostic 
and prognostic tool to assist in the recognition of PCa with aggressive behavior (Schaefer et al. 
2010, Walter et al. 2013). Although, studies using miRNA-34a in PCa showed that it has a pro-
apoptotic effect and can suppress malignancy in human PCa cells by modulating c-Myc 
transcriptional complexes (Yamamura et al. 2012, Li et al. 2014).  




Phytochemicals such as sulforaphane (SFN) and 3,3'-diindolylmethane (DIM) are promising 
chemopreventive agents in PCa (Hsu et al. 2011, Wong et al. 2014). SFN and DIM, derived from 
glucosinolates in cruciferous vegetables like cabbage and broccoli, are epigenetic modulators 
which have been shown to alter promoter methylation in distinct sets of genes in PCa cells. SNF 
has been shown to de-methylate the cyclin D2 promoter in PCa cells, resulting in cyclin D2 re-
expression (Hsu et al. 2011). Hyper-methylation of the cyclin D2 promoter, a major regulator of 
the cell cycle, is correlated with PCa progression, and restoration of cyclin D2 expression exerts 
anti-proliferative effects in LNCaP PCa cells (Kobayashi et al. 2009).  
Regulation of gene expression as a therapeutic approach for PCa is also exerted by the histone 
deacetylase inhibitor valproic acid (VPA). Its therapeutic benefits have been studied for many 
tumor entities in vitro and in vivo, including cancer of the bladder (Ozawa et al. 2010, Vallo et al. 
2011, Byler et al. 2012), hepatocellular cancer (Machado et al. 2011), head and neck cancer 
(Gan et al. 2012), pancreatic cancer and colon cancer (Jones et al. 2008, Venkataramani et al. 
2010), renal cell carcinoma (Jones et al. 2009), small cell lung cancer (Hubaux et al. 2010), 
cervical cancer (Sami et al. 2008) and breast cancer (Fortunati et al. 2008) as well as in clinical 
trials for breast cancer, lung cancer, pancreatic cancer and ovarian cancer (Arce et al. 2006, 
Candelaria et al. 2007, Munster et al. 2009, Chateauvieux et al. 2010). 
Similar to SNF, VPA was shown to specifically re-express cyclin D2 in mouse PCa cells in a 
time- and concentration-dependent manner (Witt et al. 2013). Several VPA in vitro and in vivo 
studies in PCa resulted in inhibition of proliferation (Xia et al. 2006, Annicotte et al. 2006, 
Shabbeer et al. 2007, Gao et al. 2007, Chou et al. 2011). Thereby, proliferation inhibition was 
due to functional effects of VPA treatment inducing either growth arrest, cell death, senescence 
or anti-angiogenic properties (Shabbeer et al. 2007, Gao et al. 2007, Wedel et al. 2011). 
Nonetheless, the underlying molecular mechanisms for the VPA-induced inhibition of PCa cell 
proliferation remain unsolved. Witt et al. (2013) could also show that treatment of murine PCa 
cells 2E with VPA resulted not only in proliferation inhibition but also in migration and invasion 
inhibition. These functional effects were concentration- and time-dependent. Microarray analysis 
of 2E cells treated for 24 hours with VPA identified several candidate genes that were 
deregulated after VPA treatment, including the angiogenesis-related genes ceruloplasmin 1 and 
2 (Cp1, Cp2) and chemokine (C-X-C motif) ligand 15 (Cxcl15) among others (Witt et al. 2013). 









Table 1.1: Examples of therapy options under investigation for PCa treatment. PCa therapy can be approached 
in several ways, including hormone therapy, chemotherapy and epigenetic modulations. Here, therapy options under 
current investigation, along with their effect/target, example drugs and the corresponding studies are depicted.  
 
The anti-angiogenic effect of in vitro or in vivo VPA treatment has already been described in a 
few studies for PCa (Shabbeer et al. 2007, Gao et al. 2007, Sidana et al. 2012). Sidana et al. 
(2012) showed that DU145 and LNCaP xenografts showed a statistically significant decrease in 
microvessel density (MVD) following VPA treatment. MVD is a quantitative indication of the risk 
of tumor prognosis and metastases risk in various solid malignant tumors and it was evaluated 
by CD34 expression in the xenografts. CD34 is commonly used as a marker for tumor 
neovascularization since it is expressed by endothelial cells of blood vessels (Fina et al. 1990). 
Gao et al. (2007) could show that xenografts derived from the human PCa cell line PC-3 that 
were treated with VPA had a reduced expression of vascular endothelial growth factor (VEGF), 
the main angiogenic stimulator in normal and metastatic tissue (Ferrara 1995). For other cells 
and cancer types the anti-angiogenic effects of in vitro and in vivo VPA treatment have also been 
described (Michaelis et al. 2004), including gliomas (Osuka et al. 2012) and acute myeloid 
leukemia (Zhang et al., 2014).  
Therapy option Effect/Target Drug Studies 
Hormone 
therapies 





 androgen receptor 
(AR) antagonist 






 Krishnan et al. 2007, 




 Clegg et al. 2012, 
Rathkopf et al. 2013 
Chemotherapies 
 extended survival 
and inhibition of 
other tumorigenic 
effects 







 Antonarakis and 
Eisenberger 2013, Lei 










 gene silencing  
 
 
















 e.g.: valproic acid, 
vorinostat, 
panobinostat 
 Yamamura et al. 2012, 
Li et al. 2014, Sharma 
and Ruppert 2015 
 
 Hsu et al. 2011, Wong 




 Sharma et al. 2008, 
Braiteh et al. 2008, 
Munster et al. 2009, 
Kaushik et al. 2015 




Anti-angiogenic treatment is an emerging and promising approach for the treatment of CRPC 
(Kluetz et al. 2010, Mukherji et al. 2013). By inhibiting tumor angiogenesis the metastatic spread 
as well as the growth of the primary tumor itself will be inhibited. Angiogenesis seems to play an 
important role in the pathophysiology of PCa (Weidner et al. 1993) and many anti-angiogenic 
agents have proven to be effective in the treatment of several solid tumors, including renal-cell 
carcinoma (Motzer et al. 2007), colorectal cancer (Hurwitz et al. 2004) and non-small cell lung 
cancer (Sandler et al. 2006). Bevacizumab, a monoclonal antibody against VEGF, in 
combination with other chemotherapy drugs proved to be very effective in many different 
cancers, but not so in PCa. A large phase III study in patients with CRPC using bevacizumab in 
combination with docetaxel chemotherapy did not improve overall survival (OS) of these patients 
and was even associated with greater toxicity (Kelly et al. 2012). Docetaxel in combination with 
other anti-angiogenic agents also did not increase the OS or progression-free survival (PFS), as 
shown by several clinical trials with CRPC patients. In contrast, it might even increase the risk 
for treatment-related mortality (Lei et al. 2014). Clinical phase III trials investigating the benefits 
of the anti-angiogenic agents sunitinib, a receptor tyrosine kinase inhibitor, or lenalidomide, an 
immune-modulating agent, in CRPC patients were even discontinued due to futility (Mukherji et 
al. 2013). Nonetheless, the rationale for the use of anti-angiogenic therapy in patients suffering 
from CRPC remains strong since PCa progression is strongly dependent on angiogenesis. It 
was shown that angiogenesis measured as microvessel density (MVD) is associated with tumor 
stage as well as WHO grade and is an independent predictor of clinical outcome. Besides, VEGF 
expression correlates positively with tumor stage and outcome (Strohmeyer et al. 2000). 
Therefore, novel anti-angiogenic agents are being under constant investigation. One promising 
approach is targeting the dual VEGFR2/MET with the tyrosine kinase inhibitor cabozantinib, 
which showed improvements in bone scans and pain response (Lee and Smith 2013, Smith et 
al. 2013). Generally, the role of anti-angiogenic treatment in PCa has yet to be defined.  
The reduced Cp1, Cp2 and Cxcl15 expression after VPA treatment observed by Witt et al. 
(2013), together with the VPA-induced anti-angiogenic effects observed by Gao et al. (2007), 
Shabbeer et al. (2007) and Sidana et al. (2012) highlight the beneficial effects of VPA treatment 
in PCa by acting as an anti-angiogenic factor and thereby preventing the tumor from growing 
and spreading. To further investigate the molecular mechanisms underlying the VPA-mediated 








1.4 Cyclin D2 in general  
 
As mentioned above, for several PCa therapies, including treatment with the HDI VPA or with 
sulforaphane, it was shown that cyclin D2 will be specifically re-expressed, which usually is 
downregulated due to hypermethylation of the promoter, and might contribute to the anti-
cancerous effects observed. 
Cyclin D2 belongs to the highly conserved family of D-type cyclins, together with cyclin D1 and 
cyclin D3. Although the literature often refers to cyclin D in general, there are significant 
differences in the structure of the three D-type cyclins (Fig. 1.4) as wells as in their function.  
The D-type cyclins consist of different domains for which the percentage in homology to the 
cyclin D1 sequence is indicated in Fig. 1.4. The greatest homology occurs in the cyclin box which 
mediates the interaction with cyclin-dependent kinase 4 (CDK4) and CDK6 and is also needed 
for the interaction with cyclin-dependent kinase inhibitors. The interaction with the 
retinoblastoma (Rb) protein is mediated by the LXCXE motif, which is also conserved in all three 
D-type cyclins. Cyclin D1 contains as sole exception a LLXXXL motif which facilitates binding to 
specific transcription factors. Another common feature of all three D-type cyclins is a threonine 
residue near the C terminus which triggers ubiquitin-mediated degradation when 
phosphorylated. It is located within the PEST domain that is characteristic of proteins that are 
rapidly turned over (Musgrove et al. 2011). 
 
Fig. 1.4: Schematic presentation of the protein domain structure of the three D-type cyclins. The three D-type 
cyclins consist of different domains of which the percentage in homology to the sequence of cyclin D1 is indicated. 
Cyclin D1, cyclin D2 and cyclin D3 share a LXCXE motif which mediates interaction with the retinoblastoma (Rb) 
protein, a cyclin box which mediates the interaction with cyclin-dependent kinases (CDK4 and CDK6) and cyclin-
dependent kinase inhibitors and has the greatest homology between the D-type cyclins, a C-terminal PEST domain 
which is characteristic of proteins that are turned over rapidly, and a C-terminal threonine residue which triggers 
ubiquitin-mediated degradation once phosphorylated. Cyclin D1 comprises as sole exception a LLXXXL motif which 
facilitates binding to specific transcription factors. Modified from Musgrove et al. 2011. 
 




The D-type cyclins exhibit their major function in regulating the cell cycle. The cell cycle is divided 
into the G1, S, G2 and M phase plus the G0 rest phase. Transition of the cell from one phase to 
the next is strictly regulated by cyclins which serve as regulatory co-factors for cyclin-dependent 
kinases (CDKs) which are inactive in the absence of a partner cyclin. The specific complexes 
that result from binding of the cyclin to its′ particular CDK activate the catalytic subunit of the 
CDK resulting in phosphorylation of target genes (Matsushime et al. 1992). This leads to either 
activation or inactivation of target proteins which ultimately leads to the progression to the next 
phase of the cell cycle. Different combinations of cyclin-CDK complexes, as well as the 
expression of CDK-inhibitors operate during different phases of the cell cycle and determine the 
target genes. CDKs are expressed continuously whereas the cyclins are expressed at specific 
stages of the cell cycle (Voorzanger-Rousselot et al. 2007). For example, cyclin D2 binds 
specifically to CDK4 and CDK6. The resulting complex causes phosphorylation of the tumor 
suppressor gene retinoblastoma (Rb) growth-inhibitory complex. Once phosphorylated, this 
complex releases the E2F transcription factor which controls various genes required for DNA 
synthesis and cell cycle control and thus Rb is no longer able to prevent the G1 arrest and the 
cell progresses to the S phase (Weinberg 1995). In tumor cells many of the regulatory 
mechanism of the cell cycle can be deregulated. According to Musgrove et al. (2011), especially 
the abnormal expression of the D-type cyclins and their CDKs is linked to cancer development 
and progression. 
 
1.5 Cyclin D2 in PCa 
 
In different tumor entities different expression patterns of cyclin D2 are observed. On the one 
hand, in ovarian epithelial carcinomas (23 % of 81 patients, Milde-Langosch and Riethdorf 2003), 
colon cancer (53% of 57 patients, Mermelshtein et al. 2005) and gastric cancer (34.2% of 260 
patients, Takano et al. 2000) cyclin D2 is frequently overexpressed. On the other hand, in breast 
cancer (44% of 109 patients, Evron et al. 2001, Fischer et al. 2002), lung cancer (57% of 56 
patients with small cell lung cancer (SCLC), Virmani et al. 2003), pancreatic cancer (65.1% of 
109 patients, Matsubayashi et al. 2003) and some gastrointestinal tumors (48.9% of 23 patients, 
Yu et al. 2003) cyclin D2 expression is frequently downregulated. The downregulation of cyclin 
D2 in these cancers is mainly due to a hypermethylation of the cyclin D2 promoter region. In 
PCa patients it was shown that, depending on the stage of the tumor, the cyclin D2 promoter 
was increasingly hypermethylated resulting in epigenetic silencing (32% of 101 PCa samples, 
Padar et al. 2003). Henrique et al. could show a significant inverse correlation between the cyclin 
D2 methylation status and the expression levels in prostatic tissue (Henrique et al. 2006). 




Methylation of the cyclin D2 promoter in PCa correlates thereby with clinico-pathological features 
of faster tumor progression and poor prognosis (Padar et al. 2003, Rosenbaum et al. 2005). Witt 
et al. could show by immunohistochemistry of PCa sections that indeed only the PCa cell lack 
cyclin D2 expression and the cells of the intercellular space as well as of the surrounding healthy 
tissue still exhibit cyclin D2 expression (Witt et al. 2013). In contrast, cyclin D1 expression was 
increased in PCa tissue. This was also shown by Drobnjak et al. (2000). They could demonstrate 
that overexpression of cyclin D1 is associated with metastatic spread of PCa to the bone 
(Drobnjak et al. 2000) highlighting the function of cyclin D1 as an oncogene in PCa (Ewen and 
Lamb 2004). The role of cyclin D2 in PCa further remains unclear, but studies conducted by Witt 
et al. (2013) suggest that it could act as a tumor suppressor gene in PCa. Witt and coworkers 
could show that the mouse PCa cell line 2E as well as the human PCa cells DU145, LNCaP and 
PC-3 which displayed a very low, not detectable basal cyclin D2 expression due to 
hypermethylation of the promoter region, specifically re-expressed cyclin D2 (in a time- and 
concentration-dependent manner) when treated with VPA or other HDIs. Treatment of the PCa 
cells with the HDI VPA led to increased acetylation of the cyclin D2 promoter and thereby 
resulting in its activation (Witt et al. 2013). Simultaneously, the proliferation rate of VPA-treated 
PCa cells was significantly reduced. In contrast, fibroblast cells, such as NIH/3T3 cells among 
four other tested cell lines, exhibited a high basal cyclin D2 expression which was not further 
increased after VPA treatment. An inhibition of the proliferation rate after VPA treatment could 
solely be observed in one out of five fibroblast cell lines (L-cells, Witt et al. 2013). The hypothesis 
that cyclin D2 could act as a tumor suppressor in PCa is further supported by a publication by 
Kobayashi et al. (2009) in which it is stated that restoration of the cyclin D2 expression in the 
human PCa cells LNCaP inhibited cell proliferation (Kobayashi et al. 2009). Moreover, in non-
small cell lung cancer, a reduced cyclin D2 expression is correlated with a poor recurrence-free 
survival (Ko et al. 2012). The findings by Witt et al. (2013), Kobayashi et al. (2009) and Ko et al. 
(2012) support the hypothesis that cyclin D2 plays an important role in PCa and could be a 
putative tumor suppressor. During this study the possible connection between an increased 
cyclin D2 expression and a proliferation inhibition in PCa ought to be further investigated. 
Thereby, the role of cyclin D2 in PCa is further elucidated by overexpression studies, 
downregulation studies and generation of a mouse model with a prostate epithelium-specific 









1.6 Aims of this study 
 
In the present study VPA was investigated as a putative candidate for PCa therapy. Thereby, 
especially the influence of VPA treatment on tumor and tumor cell angiogenesis was studied in 
vitro and in vivo. Furthermore, the role of the candidate gene cyclin D2 as a possible tumor 
suppressor gene in PCa was subject of this thesis. 
 
The main aims were: 
 
 Analyses of the molecular effects of VPA treatment on candidate gene expression 
o Verification of deregulated candidate gene expression in mouse prostate tumor tissue 
o Performance of an in vivo VPA treatment experiment with isolation of prostate tissue 
to verify deregulated candidate gene expression in mouse prostate tissue 
o Verification of deregulated expression of one candidate gene in human PCa cell lines 
 
 Analysis of the molecular effects of VPA treatment on angiogenesis  
o In vitro expression analysis of markers for blood and lymphangiogenesis  
o In vivo expression analysis of markers for blood and lymphangiogenesis 
 
 Analysis of in vivo effects of VPA treatment on prostate tumor cells using the chicken 
chorioallantoic membrane (CAM) assay 
o Performance of CAM experiments  
o Macroscopic analysis of CAM tumors 
o Determination of the CAM-tumor volume  
o Immunohistological analysis of the CAM tumors by staining for the lymphatic vessel 
marker Prox1 and the blood vessel marker Mep21 
o Expression analysis of markers for blood and lymphangiogenesis in CAM tumors 
 
 Overexpression studies of cyclin D2 
o Cloning of cyclin D2 into pIRES2-EGFP and pEBTetD 
o Analysis of effects of transient cyclin D2 overexpression in human PCa cells on 
proliferation 
o Generation of human PCa cells with stable and inducible overexpression of cyclin D2 




o Analysis of effects of stable and inducible cyclin D2 overexpression in human PCa cells 
on proliferation and migration 
 
 Downregulation studies of cyclin D2 
o Effects of siRNA-mediated cyclin D2 and cyclin D1 downregulation on migration 
behavior in NIH/3T3 cells 
o Effects of siRNA-mediated cyclin D2 downregulation on transformation potential of 
NIH/3T3 cells  
o Generation of a pSingle-tTs-Ccnd2-shRNA expression plasmid for inducible 
downregulation of cyclinD2 
o Generation of NIH/3T3 cells with stable downregulation of cyclin D2  
o Analysis of effects of stable cyclin D2 downregulation in NIH/3T3 cells on proliferation 
o Analysis of effects of stable cyclin D2 downregulation in NIH/3T3 cells on 
transformation potential 
 
 Analysis of functional consequences of cyclin D2 downregulation in VPA-treated PCa cells 
 
 Generation of a conditional cyclin D2 knockout mouse model for cyclin D2 to study its 
physiological role in the prostate 
o Genotyping and establishment of purchased mouse lines PB-Cre4+ and Ccnd2fl/fl  
o Mating of the two mouse lines to generate a conditional cyclin D2 knockout mouse 
model 
o Verification of the prostate-specific deletion of cyclin D2  
o Mating of conditional cyclin D2 knockout mice with TRAMP mice for studies on 
prostate tumor development and progression




2. Materials and Methods 
2.1 Chemicals and Reagents 
 
Chemicals/ Reagents Manufacturer 
5-bromo-4-chloro-3-indolyl-β-D-galacto-
pyranoside galactopyranosid (X-Gal) 
Carl Roth GmbH, Karlsruhe,  Germany 
Adenosintriphosphate (ATP) Biomol GmbH, Hamburg, Germany 
Agar-Agar Carl Roth GmbH, Karlsruhe, Germany 
Agarose Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin Carl Roth GmbH, Karlsruhe, Germany 
Ampuwa Fresenius AG, Bad Homburg, Germany 
Bacto-Trypton  Carl Roth GmbH, Karlsruhe, Germany 
Boric acid Scharlau Chemie S.A., Barcelona, Spain 
Bromophenol blue Carl Roth GmbH, Karlsruhe, Germany 
Cell culture media 
PAN, Aidenbach, Germany, Gibco by Life 
Technologies, Darmstadt, Germany 
Crystal violet 
Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Dimethylsulfoxid (DMSO) Carl Roth GmbH, Karlsruhe, Germany 
Disodium phosphate (Na2HPO4) 
Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Dithiothreitol (DTT) Biomol, Hamburg, Germany 
DHT (Dihydrotestosterone) 
Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
DNA Stain G Serva GmbH, Heidelberg, Germany 
dNTPs (100 mM) Life Technologies, Darmstadt, Germany 
Doxycycline-Hyclat Biochemica AppliChem GmbH, Darmstadt, Germany 
Dulbecco's phosphate buffered sodium 
chloride solution (DPBS)  
PAN, Aidenbach, Germany 
Ethanol 
Chemie Vertrieb Hannover, Hannover, 
Germany 
Ethidiumbromid 
Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Ethylendiamine-tetraacetic acid (EDTA) ICN, Aurora, USA 
Ficoll® 400 AppliChem GmbH, Darmstadt, Germany 
Formaldehyde Carl Roth GmbH, Karlsruhe, Germany 
Formamide Carl Roth GmbH, Karlsruhe, Germany 





Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Fungizone Life Technologies, Darmstadt, Germany 
Geneticin disulfate (G418)-solution Carl Roth GmbH, Karlsruhe, Germany 
Gentamycin sulphate solution Carl Roth GmbH, Karlsruhe, Germany 
Glycerol Carl Roth GmbH, Karlsruhe, Germany 
Glycin Carl Roth GmbH, Karlsruhe, Germany 
L-Glutamine PAN, Aidenbach, Germany 
Hydrochloric acid, J.T.Baker® 
Avantor Performance Materials B.V., 
Deventer, Netherlands 
IGEPAL-CA-360 (NP-40) 
Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Isopropanol Carl Roth GmbH, Karlsruhe, Germany 
Kanamycin 
Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Methanol Carl Roth GmbH, Karlsruhe, Germany 
NaOH Merck KGaA, Darmstadt, Germany 
Natriumdeoxycholat AppliChem GmbH, Darmstadt, Germany 
N.N-Dimethylformamide 
Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
NuPAGE™ MES Running buffer (20x) Life Technologies, Darmstadt, Germany 
NuPAGE™ LDS Sample buffer (4x) Life Technologies, Darmstadt, Germany 
NuPAGETM See Blue Plus2 Life Technologies, Darmstadt, Germany 
OptiMEM®I PAN, Aidenbach, Germany 
Orange-G Sigma-Aldrich, Deisenhofen, Germany 
Penicillin/Streptomycin PAN, Aidenbach, Germany 
peqGREEN DNA/RNA Dye 
Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
Potassium dihydrogen phosphate (KH2PO4) AppliChem GmbH, Darmstadt, Germany 
Potassium acetate Carl Roth GmbH, Karlsruhe, Germany 
Potassium chloride (KCl) Carl Roth GmbH, Karlsruhe, Germany 
Powdered milk Carl Roth GmbH, Karlsruhe, Germany 
Puromycin InvivoGen, San Diego, USA 
Roti®-Nanoquant Carl Roth GmbH, Karlsruhe, Germany 
Simply Blue Safe Stain Life Technologies, Darmstadt, Germany 
Sodium chloride AppliChem GmbH, Darmstadt, Germany 




Sodiumdodecylsulfate (SDS) Serva GmbH, Heidelberg, Germany 
Sucrose (D(+)-Saccharose) Carl Roth GmbH, Karlsruhe, Germany 
Tris AppliChem GmbH, Darmstadt, Germany 
Triton X-100 Fluka, Deisenhofen, Germany 
Tween 20 Carl Roth GmbH, Karlsruhe, Germany 
Valproic acid Sigma-Aldrich, Deisenhofen, Germany 
VectaShield with DAPI VectorLab, Burlingame, USA 
Xylencyanol Sigma-Aldrich, Deisenhofen, Germany 
Yeast extract Carl Roth GmbH, Karlsruhe, Germany 
 
2.2 Biochemicals and enzymes 
 
Biochemicals/enzymes Manufacturer 
Albumin fraction V (BSA) Biomol GmbH, Hamburg, Germany 
BigDye® Life Technologies, Darmstadt, Germany 
Complete Mini Protease Inhibitor Cocktail 
Tablets 
Roche, Mannheim, Germany 
DH5α™ Competent Cells Life Technologies, Karlsruhe, Germany 
Direct PCR Lysis Reagent Peqlab, Erlangen, Germany 
Fetal bovine serum (SeraPlus) PAN, Aidenbach, Germany 
Immulase™ DNA Polymerase Bioline, Luckenwalde, Germany 
Lipofectamine® 2000 Thermo Fisher Scientific, Langenselbold, 
Germany 
MangoTaq-DNA-Polymerase Bioline, Luckenwalde, Germany 
Matrigel® Basement Membrane Matrix  Corning Inc., New York, USA 
Metafectene® Pro Biontex Laboratories GmbH, Munich, 
Germany 
MycoZap™ Spray Lonza, Cologne, Germany 
Nu-Serum™ Corning Life Sciences, Bedford, USA 
Oligofectamine™ Transfection Reagent Thermo Fisher Scientific, Langenselbold, 
Germany 
Phosphatase Inhibitor Mix II solution Serva GmbH, Heidelberg, Germany  
PolyFreeze (Tissue Freezing Medium) - 
Clear 
Polysciences Europe GmbH, Eppelheim, 
Germany 
Platinum® SYBR® Green qPCR SuperMix-
UDG with Rox 
Life Technologies, Darmstadt, Germany 
Proteinase K Carl Roth GmbH, Karlsruhe, Germany 




Phusion™ High-Fidelity DNA Polymerase Finnzymes, Espoo, Finnland 
Restriction enzymes New England Biolabs, Ipswich, USA 
Reverse Transcriptase SuperScript II Life Technologies, Darmstadt, Germany 
RNase A AppliChem GmbH, Darmstadt, Germany 
T4 DNA Ligase Life Technologies, Darmstadt, Germany 
Tet System Approved Fetal Bovine Serum Clontech-Takara, Saint Germain-en-Laye, 
France 
Trypsin/EDTA solution  PAN, Aidenach, Germany 
 
2.3 Usage ware 
 
Usage ware  Manufacturer 
10, 13, 50 ml Cellstar® Tubes 
Greiner-bio-one GmbH, Frickenhausen, 
Germany 
6-, 12, 24- or 96well cell culture plates Sarstedt, Nümbrecht, Germany 
96- well assay plates, white  Biozym, Hessisch Oldendorf, Germany 
384 well plates, white ABgene, Hamburg, Germany 
384 well plates, black 4titude, Surrey, UK 
4 chamber polystyrene vessel tissue culture 
treated glass slide 
Corning Life Sciences, Bedford, USA 
Amersham Hybond PVDF-Membran 
GE Healthcare Life Sciences, Freiburg, 
Germany 
Blotting Papier GB 002, 003, 004 Schleicher & Schüll, Dassel, Germany 
Cell culture flasks (T25, T75) Sarstedt, Nümbrecht, Germany 
Cover glass 24x60mm Menzel Gläser, Braunschweig, Germany 
Cryo.S™ cups with screw cap 
Greiner-bio-one GmbH, Frickenhausen, 
Germany 
FALCON culture slides Becton Dickinson GmbH, Heidelberg, 
Germany 
Flat-bottomed Nucleon™ surface 96- well 
cell culture plates  
Nunc A/S, Roskilde, Denmark 
Gloves 
Rösner- Mautby Meditrade GmbH, 
Kiefersfelden, Germany 
Membrane filter  Millipore, Billerica, USA 
Microcentrifuge tubes (0.2 ml) Sartedt, Nümbrecht, Germany 
Microscope slides SuperfrostPlus Schütt, Göttingen, Germany 
Migration assay inserts 
Millipore, Billerica, USA, Corning Inc., New 
York, USA 




Needle Eclipse™ with Smartclip Technologie  BD, Heidelberg, Germany 
Neubauer improved hemocytometer  Hartenstein, Würzburg, Germany 
Nunc® F96 Micro Well™ white Nunc A/S, Roskilde, Denmark 
NuPAGETM 4-12% Bis-Tris Gel Life Technologies, Darmstadt, Germany 
Pasteur pipette Brand GmbH&Co.KG, Wertheim, Germany 
Petri dishes  Sarstedt, Nümbrecht, Germany 
Petri dishes (cell culture), Nuncleon™ 
surface 
Nunc A/S, Roskilde, Denmark 
Pipet tips  Sarstedt, Nümbrecht, Germany 
Pipettes (1000μl, 200μl, 20μl, 10μl) Gilson, Limburg-Offheim, Germany 
PVDF-Membrane GE Healthcare, Munich, Germany 
Quarz- Cuvette Hellma, Mühlheim, Germany 
Reaction tubes (1.5ml, 2ml) Sartstedt, Nümbrecht, Germany 
Serological pipettes (5ml, 10ml) Sartstedt, Nümbrecht, Germany 
Sterile Single-use filter Minisart Sartorius, Göttingen, Germany 
Sterile surgical blades Braun, Tuttlingen, Germany 
Scissors (HSB-390-10/HSB-006-10) Hammacher, Solingen, Germany 
Stainless steel beads (Ø 5 mm) Quiagen, Hilden, Germany 
Syringe Discardit™ II (10ml/ 20ml) BD, Heidelberg, Germany 
Syringe disposable filters, 0.45µm/20µm Sartorius, Göttingen, Germany 
Tweezer (Wironit HWC 110-10) 
Hammacher, Solingen,Germany/ Inox, 
Dumont, Switzerland 
QPCR Adhesive Clear Seals 4titude, Surrey, UK 
 
2.4 Technical equipment 
 
Technical equipment Manufacturer 
3500XL Genetic Analyzer Applied Biosystems GmbH, Darmstadt, 
Germany 
ABI PRISM 7900 HT Sequence Detection 
System 
Applied Biosystems GmbH, Darmstadt, 
Germany 
Autoclaves Biomedis Laborservice GmbH, Gieβen, 
Webeco, Bad Schwartau, Germany 
Systec, Wettenberg, Germany 
C1000™ Thermal Cycler Bio-Rad Laboratories GmbH, Munich, 
Germany 
Centrifuges (1-15, 1-15K, 4K15) Sigma-Aldrich, Deisenhofen, Germany 




Centrifuge Heraeus Fresco21 Thermo Scientific, Langenselbold, Germany 
CO2 Water Jacketed Incubator Series II Systec, Wettenberg 
Electro Blotter (Fastblot B44) Biometra GmbH, Göttingen, Germany 
Electrophoresis power supply Power Pac 
3000 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
FluorChem® Q Alpha Innotech, Logan, Utah, USA 
Gel-image documentation system Doc-Print 
VX2 
Vilber Lourmat, Eberhardzell, Germany 
Heating block, MR Hei-Standard Heidolph Instruments, Schwabach, 
Germany 
Inverted microscope IX71 Olympus GmbH, Hamburg, Germany 
Fluorescence microscope BX60 Olympus GmbH, Hamburg, Germany 
Nanodrop 2000c Thermo Scientific, Langenselbold, Germany 
Mini centrifuge Sprout™ Heathrow Scientific, Illinois, USA 
RM5 Assistent 348 Roller Karl Hecht GmbH & Co KG, Sondheim, 
Germany 
Scale Quintix Sartorius, Göttingen, Germany 
Synergy Mx Bio Tek, Bad Friedrichshall, Germany 
Thermomixer 5436 Eppendorf AG, Hamburg, Germany 
TissueLyser LT Qiagen, Hilden, Germany 
Thermocycler 2720 Applied Biosystems, Carlsbad, USA 
Vortexer Schütt Labortechnik, Göttingen 
UV light table EXC-F20-M Vilber Lourmat, Eberhardzell, Germany 
 
2.5 Sterilization of solutions and equipment 
 
Laboratory equipment, solutions and culture media were autoclaved at 121 ̊C and 105 Pa for 60 
min or sterilized at 220 ̊C overnight. 
 
2.6 Ready-to-use reaction systems 
 
Reaction system Manufacturer 
CellTiter 96® AQuaous Non-Radioactive 
Proliferation Assay (MTS) 
Promega, Mannheim, Germany 
ECL Prime  GE Healthcare, Munich, Germany 
Myco Alert® Mycoplasma Detection Kit Lonza, Cologne, Germany 




MSB® Spin PCR apace Invitek, Berlin, Germany 
NucleoSpin® Extract II Machery & Nagel, Düren. Germany 
peqGold Total RNA Kit PeqLab, Erlangen, Germany  
PhosSTOP Phosphatase Inhibitor Roche, Mannheim, Germany 
PureLinkTM HiPure Plasmid Midiprep Kit Life Technologies, Darmstadt, Germany 




Solutions for routine applications were prepared according to Sambrook et al. (1989). Required 




Blocking Buffer I (Western blot) 1x TBS-Tween 
5 % low-fat dry milk 
Antibody solution (Immunohistochemistry) 1x TBS (0.05 M, pH 7.2 – 7.4) 
1 % BSA 
0.5 % Triton X-100 
Blocking Buffer II (Immunohistochemistry) 1x PBS with 3 % BSA 
Goat blocking reagent (Immuno-
histochemistry) 
1x PBS 
5 % goat serum 
1 % BSA 
0.2 % Triton X-100 
Lysis Buffer for Protein (modified RIPA) 150 mM NaCl 
1 mM EDTA 
50 mM Tris-HCl, pH 7.4 
1 % IGEPAL-CA-360 (NP-40) 
0.25 % sodium deoxycholate 
1 Tablet/10 ml Complete-Mini protease- 
inhibitor 
100 µl/10 ml Phosphatase-Inhibitor-Mix II 
solution 




P1 Buffer (Plasmid preparation) 50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
100 µg/ml RNase A 
P2 Buffer (Plasmid preparation) 200 mM NaOH 
1 % SDS 
P3 Buffer (Plasmid preparation) 3 M Potassium acetate, pH 5.5 
10x PBS 1.37 M NaCl 
81 mM Na2HPO4 
27 mM KCl 
14.7 mM KH2PO4 
10x TBS 1.37 M NaCl 
100 mM Tris 
Adjust to pH 7.6 with HCl 
1x TBS-Tween (TBS-T) 10 % 10x TBS 
0.1% Tween 20 
Stop Mix I 95 % Formamide 
20 mM EDTA 
0.05 % Bromophenol blue 
0.05 % Xylencyanol 
Stop Mix II 15 % Ficoll 400 
200 mM EDTA 
0.1 % Orange G 
Transfer Buffer IIa (Western blot) 25 mM Tris pH 8.3 
150 mM Glycin 
20 % Methanol 
20x Turbo-Puffer 0.2 M NaOH 
Adjust to pH 8.0 with H3BO3 (Boric acid) 
Washing Buffer I (Western blot) 1x TBS-Tween 
2.5 % low-fat dry milk 








2.8. Culture media, antibiotics, agar plates 
 
2.8.1 Culture media for bacteria 
 
Luria-Bertani medium (LB medium), pH 7.0:  1 % Bacto-Trypton 
       0.5 % Yeast extract 
       1 % NaCl 
 
The LB medium was prepared with bi-distilled water. Afterwards it was autoclaved and kept at 
4 ̊C. For selection, either ampicillin (50 µg/ml final concentration) or kanamycin (25 µg/ml final 
concentration) was added to the medium. 
 
2.8.2 Agar plates 
 
Agar plates were prepared by adding 1.5 % (w/v) Agar-Agar to the liquid LB medium before 
autoclaving. Following the autoclaving procedure the LB medium was cooled to 55°C on a 
stirring plate before the antibiotics were added in the corresponding concentration (ampicillin: 50 
µg/ml, kanamycin: 25 µg/ml). Finally, the medium was poured into petri dishes and set aside to 
cool out and harden. The ready-to-use agar plates were stored in a sterile plastic back at 4°C. 
 
2.8.3 Media for eukaryotic cell cultures 
 
Media used for the culture of eukaryotic cells was purchased from PAN, Aidenbach, Germany. 
Before use, fetal bovine serum (FBS), which was heat-inactivated for 30 min at 56 ̊C, and 
antibiotics (Penicillin/Streptomycin) were added. The following media were used for cell culture: 
 
Cell line  Components of the media 
2E Advanced DMEM 
8 % NuSerum 
10 % FBS 
100 nM Dihydrotestosterone (DHT) 
80 µg/ml Gentamycin 
1 % Glutamine 
  





20 % FBS 
1.2 % Penicillin/Streptomycin 
LNCaP, PC-3, DU145, SW620 RPMI 1640 
10 % FBS 
1.2 % Penicillin/Streptomycin 
LNCaP and PC-3 + pIRES2-EGFP-CCND2 See LNCaP, PC-3 
+ 400 µg/ml G418 
LNCaP + pEBTetD-CCND2 RPMI 1640 
10 % Tet System approved FBS 
1.2 % Penicillin/Streptomycin 
0.4 µg/ ml Puromycin 
PC-3 + pEBTetD-CCND2 RPMI 1640 
10 % Tet System approved FBS 
1.2 % Penicillin/Streptomycin 
1.4 µg/ ml Puromycin 
NIH/3T3 DMEM 
10 % FBS 
1.2 % Penicillin/Streptomycin 
NIH/3T3 + pSingle-tTs-Ccnd2-shRNA See NIH/3T3 
+ 400 µg/ml G418 
 
For cryopreservation of the cells in liquid nitrogen cryo-medium was diluted 1:1 with the 
appropriate medium. 
 
Cryo-medium:  7.5 ml medium of the corresponding cell line 
 + 12.5 ml FBS   
 + 5 ml DMSO 
 








2.9. Biologic material 
 
2.9.1 Bacterial strains 
 
The bacterial strain Escherichia coli DH5α was used for the transformation of plasmids (Hanahan 
1983). It was purchased form Life Technologies, Karlsruhe, Germany. 
 
2.9.2 Eukaryotic cell lines 
 
Cell line Description 
2E Murine prostate adenocarcinoma cell line,  generated from a 
prostate tumor of a TRAMP mouse in our research group, C57/Bl6 
background, (Hardenberg, 2010) 
CaCo-2 Human colorectal adenocarcinoma cell line, ATCC, Rockville, 
USA 
DU145 Human prostate adenocarcinoma cell line (brain metastasis), 
castration resistant (Stone et al. 1978) 
LNCaP Human prostate adenocarcinoma cell line (lymph node 
metastasis), androgen dependent (Horoszewicz et al. 1983), 
ATCC, Rockville, USA 
NIH/3T3 Murine embryonal fibroblast cell line, ATCC, Rockville, USA 
PC-3 Human prostate adenocarcinoma cell line (bone metastasis), 
castration resistant (Kaighn et al. 1979, Ohnuki et al. 1980), 
ATCC, Rockville USA 
SW 620 Human colorectal adenocarcinoma cell line (lymph node 
metastasis), ATCC, Rockville, USA 
 
2.9.3 Mouse strains 
 
All mice experiments were conducted according to the European and German protection of 
animals act. The number of sacrificed mice was kept to a minimum as well as the stress and 
pain level. The mice were euthanized by CO2-asphyxation and subsequent cranial dislocation. 
Keeping conditions were set to 12 hours light/dark cycles at 22 ̊C and 55 ± 5 % relative humidity. 
Animal food was ordered from ssniff Spezialdiäten GmbH, Soest, Germany.  




TRAMP mice with a C57/Bl6 background were ordered and obtained from Jackson Lab. (Bar 
Harbor, USA). C57/Bl6 mice came from a colony of our own department. 
Heterozygous Ccnd2flox/+ mice were kindly provided by Peter Sicinski from the Dana Faber 
Institute, Boston, USA. PB-Cre4+ mice were kindly provided by Xiantuo Wu from the Department 
of Pathology, Keck School of Medicine, University of Southern California, USA (Wu et al. 2001). 
 
2.9.4 Synthetic DNA oligonucleotides 
 
For the generation of PCR products as well as for quantitative RT-PCR (qRT-PCR) analysis 
synthetic oligonucleotides were purchased from Eurofins MWG Operon (Ebersberg, Germany). 
Sequences are listed from the 5´- to 3´- end. 
 
Human specific primers for quantitative real-time PCR 
 































































Mouse specific primers for quantitative real-time PCR 
 



























































CCC CGG ACG GGC CTC CGA AA 























Cyclin D2 shRNA oligonucleotides for cloning into pSingle-tTs-shRNA 
 
















Primers for amplification of cDNA designated for cloning 
 
Primer name Sequence 




CyclinD2-fw-XhoI (pIRES2-EGFP) CTCGAGATGGAGCTGCTGTGCCACGAGGTGG 
 
Mouse specific primers for genotyping 
 
Primer name Sequence 
Cyclin D2 flox 3´ 
Cyclin D2 flox 5` 




PB-Cre EII a cre fw 
PB-Cre EII a cre rev 
CCTGGAAAATGCTTCTGTCCG 
CAGGGTGTTATAAGCAATCCC 













2.9.5 Synthetic RNA oligonucleotides 
 
Synthetic mouse RNA oligonucleotides (siRNAs) 
 
Primer name Sequence 
Cyclin D2 A CAGCAGUUCCGUCAAGAGCAGCAUA 
Cyclin D2 B UAUGCUGCUCUUGACGGAACUGCUG 
Cyclin D2 C CCACACUGAUGUGGAUUGUCUCAAA 
Luciferase CGUACGCGGAAUACUUTGATT 
 
Synthetic human RNA oligonucleotides (siRNAs) 
 
Primer name Sequence 
Cyclin D2 A UGCUCCUCAAUAGCCUGCAGCAGUA 
Cyclin D2 B UGACGGAUCCAAGUCGGAGGAUGAA 
Cyclin D2 C GAUGAGGAAGUGAGCUCGCUCACUU 
 
Vector specific primers for sequencing 
 
































2.9.6.1 Primary antibodies 
 
Antibody Manufacturer Dilution 
Anti-α-Tubulin (clone B-5-1-
2), monoclonal antibody, 
mouse 





Abcam, Cambridge, UK 
1:2000 
Anti-Cyclin D1 (A-12), 
monoclonal antibody, mouse 
Santa Cruz, Heidelberg, Germany 
1:2000 
Anti-Cyclin D2 (M-20), 
polyclonal antibody, rabbit 
Santa Cruz, Heidelberg, Germany 
1:200 
Anti-Cyclin D2 (D52F9), 
monoclonal antibody, rabbit 
Cell Signaling, Danvers, USA 
1:2000 
Anti-HSC-70 (B-6), 
monoclonal antibody, mouse 
Santa Cruz, Heidelberg, Germany 
1:10000 
Anti-Mep21, mouse 
M. Williams, AbLab, University of 




polyclonal antibody, rabbit 




2.9.6.2 Secondary antibodies  
 
Antibody Manufacturer Dilution 
Anti-rabbit IgG, 
Cy3-conjugated, sheep 
Sigma-Aldrich, Deisenhofen 1:200 
Anti-rabbit IgG (H+L), HRP- 
(horse radish peroxidase) 
conjugated, goat 
Dianova Jackson ImmunoResearch, 
Hamburg, Germany 
1:5000  
Anti-mouse IgG1 (γ1), Alexa 
Fluor® 488-conjugated, goat 
Life Technologies, Darmstadt, 
Germany 
1:200 
Anti-rabbit IgG, Alexa Fluor® 
594-conjugated, goat 
Life Technologies, Darmstadt, 
Germany 
1:200 
Anti-mouse IgG (H+L), HRP-
conjugated, rabbit 









2.9.7 Plasmids and Vectors 
 
Plasmid/Vector Source 
pGEM®-T Easy Promega, Wisconsin, USA 
pIRES2-EGFP Clontech-Takara, Saint Germain-en-Laye, 
France 
pIRES2-EGFP-CCND2 Claudia Morich, 2013 
pEBTetD Bach et al. 2007 
pEBTetD-CCND2 Claudia Morich, 2013 
pSingle-tTs-shRNA 
Clontech-Takara, Saint Germain-en-Laye, 
France 
pSingle-tTs-shRNA-Ccnd2 Claudia Morich, 2014 
pEGFP Clontech-Takara, Saint Germain-en-Laye, 
France 
pEGFP-KRAS Silke Kaulfuß (unpublished data) 





Analysis of DNA and protein sequences 
BLAST-program, (Altschul et al. 1990) 
(http://www.ncbi.nlm.nih.gov) 
Restriction site analysis 
NEB Cutter 2.0 
(http://tools.neb.com/NEBcutter2/index.php) 
WEB Cutter 2.0 
(http://rna.lundberg.gu.se/cutter2) 
Bioinformatics 
Ensembl v32 (http://www.ensembl.org) 
National Center for Biotechnology 
Information (http://ncbi.nlm.nih.gov) 
Primer design Primer3 (http://bioinfo.ut.ee/primer3-0.4.0) 















2.11 Isolation, purification and concentration determination of nucleic acids 
 
2.11.1 Isolation of total RNA from cell cultures  
 
Total RNA from cell cultures was isolated and purified by using the peqGOLD Total RNA Kit 
according to the manufactures instruction (Peqlab, Erlangen, Germany). 
 
2.11.2 Isolation of RNA from mouse tissue 
 
RNA from mouse prostate or prostate tumor tissue was obtained via homogenization of the 
tissue using the TissueLyser LT (Quiagen, Hilden, Germany). A small sample of the tissue was 
transferred to a 2 ml reaction tube together with a stainless steel bead (Ø 5mm, Quiagen) and 
400 μl RNA lysis buffer T from the peqGOLD Total RNA Kit (Peqlab, Erlangen, Germany). The 
amount of used RNA lysis buffer T depended on the size of the tissue sample. The tissue was 
homogenized for 5 min at 50 1/s oscillation in the TissueLyser LT. Thereafter the cups were kept 
for 5 min on ice before centrifuging them for 10 min at 13000 rpm and 4°C. The supernatant 
containing the lysed cells was transferred to a new 1.5 ml reaction tube and RNA isolation and 
purification was continued by use of the peqGOLD Total RNA Kit according to the manufactures 
instruction. 
 
2.11.3 Determination of nucleic acid concentration 
 
The concentration of nucleic acids was measured by either one of three different methods. One 
approach was to use a spectral photometer (BioPhotometer, Eppendorf, Germany). The blank 
value was measured with water or whatever other substance the nucleic acid was eluted in. 
Then the absorption maximum of nucleic acids (260nm) was measured. Contaminations by 
proteins (280nm) or salts (320nm) were also detected. The nucleic acid concentration was 
calculated by the Lambert´s law. A Nanodrop-photometer (PeqLab, Erlangen, Germany) was 
also used to measure the concentration of nucleic acids, especially of RNAs. The blank value 
was measured similar to the spectral photometer with water or whatever other substance the 
nucleic acid was eluted in. Only 1 µl of the sample is needed to measure the absorption 
maximum of nucleic acids (260nm). Another method used to measure the nucleic acid 
concentration, especially of low concentrations, was by agarose gel electrophoresis. 2 µl of DNA 
were loaded onto an agarose gel and run with the MassRuler DNA standard (MassRuler DNA 
ladder, Thermo Scientific, Langenselbold, Germany). The ladder consists of a mixture of 




chromatography-purified individual DNA fragments and therefore the amount of DNA for each 
band was known. A picture was taken of the stained DNA when the gel was run for an 
appropriate time. The DNA concentration of the samples was based upon the band intensities. 
 
2.12 Cloning techniques 
 
2.12.1 pSingle-tTs-shRNA cloning 
 
Cyclin D2 shRNA oligonucleotides were designed using the shRNA Sequence Designer 
software (Clontech) and purchased. The shRNA oligonucleotides were annealed and cloned into 
the XhoI/HindIII-digested pSingle-tTS-shRNA vector according to the manufacturer instruction 
(Knockout™ Single Vector Inducible RNAi System, Clontech-Takara, Saint Germain-en-Laye, 
France). 
 
2.12.2 Amplification of DNA for subcloning into pGEM®-T Easy vector 
 
cDNA generated from RNA of either mouse or human cell lines was used for amplification of the 
open reading frame of the gene of interest using specific primers. The PCR reaction was 
conducted according to section 2.14.2. 
 
2.12.3 Purification of the PCR-product 
 
The generated PCR product was purified using the MSB® Spin PCR apace Kit (Invitek, Berlin, 
Germany). The purification was done according to the manufacturer’s instruction. 
 
2.12.4 Subcloning of PCR products/ TA-cloning 
 
Many polymerases, including the Taq DNA polymerase, possess a terminal transferase activity 
which results in the non-template addition of a single nucleotide to the 3´-ends of the PCR 
products (Clark 1988, Hu 1993). The Phusion™ High-Fidelity DNA polymerase (Finnzymes, 
Finnland) contains no such terminal transferase activity. Therefore, PCR products amplified with 
the Phusion™ High-Fidelity DNA polymerase contain no 3´-overhangs. Since the pGEM®-T 
Easy vector, which contains 5´-dT overhangs, was used for cloning of PCR products, the 
terminal dA had to be added to the PCR products. The following A-tailing reaction was carried 
out before the PCR product could be cloned into the pGEM®-T Easy vector (TA cloning): 




7 µl PCR product (purified)  
    1 µl 1x Immolase buffer 
    0.3 µl MgCl2  
    1 µl Immolase 
    2 µl dATPs (2 mM) 
 




During a ligation reaction, the T4 DNA ligase catalyzes the formation of a phosphodiester bond 
between the 3´-hydroxy- and 5´- phosphate group of linearized DNA, resulting in the generation 
of recombinant DNA molecules. 
 
Ligation with pGEM®-T Easy 
 
After adding A-overhangs to the PCR product the A-tailing mixture was cloned into the pGEM®-
T Easy vector (Promega, Wisconsin, USA). The A-overhangs of the PCR product anneal to the 
3´-thymidine overhangs of the T-cloning pGEM®-T Easy vector. The following reaction mixture 
with a total volume of 10 µl was used: 
 
1 µl pGEM®T-Easy vector 
    1 µl T4 DNA ligase 
    5 µl 2x rapid ligation buffer 
    1 µl PCR product (insert) 
 2 µl H2O 
 
The reaction was kept for 30 min at RT before it was transferred for overnight incubation to 4°C.  
The following day continued with the transformation of competent DH5α-cells. 
 
Ligation with pIRES2-EGFP or pEBTetD 
 
The pGEM®-T Easy-Ccnd2 plasmid was digested overnight with the corresponding enzymes. 
After the digestion was run on an agarose gel and the cyclin D2-insert DNA-band was excised 




and purified it was ligated into the corresponding vector pIRES2-EGFP or pEBTetD in multiple 
insert-DNA to vector-DNA ratios, ranging from 1:1, 2:1 to 3:1. 
 
1 µl vector (digested) 
    1-3 µl PCR product (insert) 
5 µl 2x rapid ligation buffer 
    ad. H2O to final volume of 9 µl 
 
The reaction mixture was incubated for 5 min at 65°C and then for 5 min on ice. Finally, 1 µl T4 
DNA ligase was added. The reaction was kept for 30 min at RT before it was transferred for 




A 50 µl aliquot of competent bacteria (E.coli DH5α) was thawed for 5-10 min on ice. 2-7 µl of the 
ligation reaction were added and gently mixed with the bacteria. After incubation for 30 min on 
ice a 45 sec. heat shock was performed at 42°C. The cells cooled down again for 5 min on ice 
before 200 µl LB medium were added and mixed by incubation on a thermomixer for 1 hour at 
37°C and 1000 rpm. Finally, the transformed bacteria were plated out on LB agar plates 
containing the appropriate antibiotic. The plates were incubated overnight at 37°C (Hanahan 
1983). Bacteria transformed with the pGEM®-T Easy plasmid had to be plated on LB agar plates 
not only containing the appropriate antibiotic but also X-Gal for blue and white screening (10 µl 
X-Gal in 100 µl H2O). A blue colored colony indicates that the lacZ gene in pGEM®-T Easy is 
intact (no insert) whereas a white colony indicates that the gene is disrupted (insert present, 
Langley et al. 1975, Vieira and Messing 1982). 
 
2.12.7 Generation of bacterial glycerol stocks 
 
10 % sterile glycerol was added to the bacterial suspension, mixed well by vortexing and stored 
at -80°C for future purposes. 
 
2.12.8 Minipreparation of plasmid DNA 
 
Small amounts of plasmid DNA were prepared for testing by restriction endonuclease digestion 
whether the plasmid contains the desired insert or not. Therefore, 1 ml LB medium, together with 




1 µl of the corresponding antibiotic, was inoculated with a single clone from the agar plate and 
incubated overnight on a thermomixer at 37°C and 600 rpm. The following day the bacterial 
overnight-culture was centrifuged at 5000 x g. The pellet was resuspended in 250 µl P1 buffer 
and 250 µl of P2 buffer (modified alkaline lysis) were added afterwards. The suspension was 
incubated for 5 min at RT before 250 µl P3 were added (for neutralization). The sample was 
centrifuged for 10 min at 4°C and 13000 rpm. The resulting supernatant was transferred to a 1.5 
ml reaction tube and 500 µl isopropanol were added. The solution was well mixed and 
precipitated by centrifugation for 30 min at 4°C and 13000 rpm. Thereafter the DNA pellet was 
washed with 200 µl of 70 % ethanol and centrifugation for 5 min at 13000 rpm. The supernatant 
was discarded and the plasmid DNA pellet was dried and resolved in 20 µl ddH2O. 
 
2.12.9 Midipreparation of plasmid DNA 
 
Large amounts of plasmid DNA were needed for restriction analysis, subcloning, sequencing or 
transfection of cell lines. To generate these large amounts of plasmid DNA, 50 ml LB medium 
together with 50 µl of the corresponding antibiotic were inoculated with either 50 µl bacterial 
overnight-culture (taken before Minipreparation and stored at 4°C) or with a swap of a glycerol 
stock. The solution was incubated overnight on a shaker at 37°C. Plasmid DNA of the resulting 
bacterial overnight-culture was isolated by using the PureLink™ HiPure Plasmid Midiprep Kit 
(Life Technologies, Darmstadt, Germany) which uses affinity chromatography columns to purify 
the DNA. The purification was performed according to the manufactures instructions.  
 
2.12.10 Cleavage of DNA with restriction endonucleases 
 
Enzymatic cleavage of DNA by restriction enzymes was prepared in volumes ranging from 10 µl 
for test digestions, up to 100 µl for isolation of DNA fragments from agarose gels. Per µg DNA 1 
U of the respective restriction enzyme was used together with the corresponding buffer. The 
reaction was incubated at 37°C for 30 min for test digestions or overnight for gel extractions. 
When two restriction enzymes had to be used, either a buffer was chosen that ensured sufficient 
activity of the endonucleases or a sequential restriction was performed. 
 
2.12.11 Isolation of DNA fragments from agarose gels 
 
DNA fragments resulting from cleavage with restriction enzymes were separated by gel 
electrophoresis on an agarose gel. The desired fragment was excised from the gel using a sterile 




scalpel and dissolved at 55°C in the appropriate amount of Binding Buffer NTI. Binding buffer 
NTI is supplied within the NucleoSpin™ Extract II Kit (Machery & Nagel, Düren, Germany), which 
was used for further isolation of the DNA from the gel slice according to the manufacturer’s 
instructions. The DNA was eluted in ddH2O. 
 
2.13 Agarose gel electrophoresis of DNA 
 
During agarose gel electrophoresis an electric field is used to separate charged 
macromolecules, such as nucleic acids, according to their size. Small fragments will move further 
through the gel than larger fragments. The resolution of the separation can be influenced by the 
concentration of the gel and the charge to mass ratio of the corresponding macromolecule. Gels 
with an agarose concentration of 0.5 - 2.0 % (w/v) were prepared, depending on the size of the 
fragments to be separated. The agarose was resolved in the appropriate amount of 1x Turbo 
buffer by boiling. DNA Stain G (Serva GmbH, Heidelberg, Germany), which intercalates with 
DNA, was added to visualize the DNA. The agarose gel was poured into a horizontal gel 
chamber to cool out. When the gel was completely hardened it was loaded with the samples and 
a length standard in order to be able to determine the length of the separated DNA fragments. 
The following length standards were used: 1 Kb Plus DNA-ladder (Life Technologies, Darmstadt, 
Germany) or MassRuler® (MBI Fermentas, St. Leon-Rot, Germany). The gel electrophoresis 
was performed in 1x Turbo buffer at a constant voltage of 200 V and 200 mA. For documentation 
a picture of the gel was taken on an UV table/transilluminator. 
 
2.14 Polymerase-Chain-reaction (PCR) 
 
The polymerase chain reaction is a standard method to amplify specific DNA fragments (Saiki 
et al. 1985, Mullis and Faloona 1987). Thereby double stranded DNA is denatured at high 
temperatures, which allows short oligonucleotides (primers) to bind to the single stranded DNA 
(annealing). Once bound, these oligonucleotides will be extended by the polymerase 
(elongation). The periodic repetition of the denaturation, annealing and elongation steps results 
in an exponential increase in DNA fragments. Whether the PCR was successful can be checked 
by agarose gel electrophoresis.  
 
 




2.14.1 Standard PCR 
 
The standard PCR was used to control the efficiency of the cDNA synthesis after reverse 
transcription PCR (Section 2.14.5). Therefore, specific primers for the housekeeping genes 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, for human samples) or hypoxanthine-
guanine phosphoribosyltransferase (Hprt, for mouse samples) were used. The following reaction 
was used: 
 
    1 µl cDNA 
   5 µl 5x buffer 
    2.5 µl dNTPs (2 mM) 
    0.5 µl Primer fw (10 pmol/µl) 
   0.5 µl Primer rev (10 pmol/µl) 
    0.75 µl MgCl2 (50 mM) 
    0.7 µl Mango Taq DNA-Polymerase (1 U/µl) 
    14.05 µl ddH2O 
 
The reaction mixture was afterwards incubated on a Thermocycler (2720 Thermal Cycler, 
Applied Biosystems, California, USA) using the following program: 
 
Initial denaturation  94°C 5 min 
Denaturation   94°C 30 sec 
Annealing   60°C 30 sec 
Elongation   72°C 30 sec 
Final elongation  72°C 7 min 
Storage   8°C  ∞ 
 
2.14.2 Amplification of DNA fragments for molecular cloning/ Touchdown PCR 
 
A specific pair of primers, defining the DNA-region of interest designated for cloning into the 
pGEM®-T Easy vector (Promega, Wisconsin, USA), was designed and purchased. DNA 
fragments selected for eventual cloning were amplified with the Phusion™ High-Fidelity DNA 
polymerase (Finnzymes, Finnland). This polymerase encompasses not only the 5´ 3´ DNA 
polymerase activity but also a 3´ 5´ exonuclease (proofreading) activity. The following PCR 
reaction mixture was used: 
30x 




1 µl cDNA 
   5 µl 5x Phusion™ HF buffer 
    2.5 µl dNTPs (2 mM) 
    0.5 µl Primer fw (10 pmol/µl) 
   0.5 µl Primer rev (10 pmol/µl) 
    0.75 µl MgCl2 (50 mM) 
    0.7 µl Phusion™ High-Fidelity DNA-Polymerase (0.02 U/µl) 
    14.05 µl ddH2O 
 
To increase specificity, sensitivity and yield, a touchdown PCR program was applied. The initial 
annealing temperature will be above the projected melting temperature (Tm) of the used primers, 
then it progressively transitions to a lower, more permissive annealing temperature over the 
course of successive cycles (Korbie and Mattick 2008). The primer will anneal at the highest 
temperature which is least-permissive of nonspecific binding. The generated fragments will be 
further amplified during subsequent rounds at lower temperatures and will out-compete the 
nonspecific sequences to which the primers may bind at those lower temperatures (Don et al. 
1991, Hecker and Roux 1996). 
The reaction was carried out in the Primus 25 advanced Thermocycler from Peqlab (Erlangen, 
Germany). The following Touchdown PCR program was used: 
 
Initial denaturation 98°C   30 sec 
Denaturation 98°C  10 sec 
Annealing 65°C  30 sec  -1°C  
Elongation 72°C  3 min  
Denaturation 98°C   10 sec 
Annealing 58°C  30 sec 
Elongation 72°C   3 min 
Storage 8°C   ∞ 
 
2.14.3 Colony PCR 
 
Colony PCR is a method used to examine many different clones in a short period of time. In this 
study, it was conducted to identify clones from an agar plate after ligation and transformation 








    1 µl Primer fw (10 pmol/µl) 
    1 µl Primer rev (10 pmol/µl) 
    2.5 µl dNTPs (2 mM) 
    5 µl 5x buffer  
    0.75 µl MgCl2 
    0.5 µl Mango Taq-Polymerase 
    14.25 µl ddH2O 
 
The reaction mixture was inoculated with a single clone picked from the agar plate with a pipette 
tip. As a backup, the pipette tip with the clone was also smeared on a fresh and sterile agar plate 
containing the appropriate antibiotic. The mixture was incubated on a thermocycler (2720 
Thermal Cycler, Applied Biosystems, California, USA) using the following program: 
 
Initial denaturation  95°C 5 min 
Denaturation   95°C 30 sec 
Annealing   60°C 30 sec 
Elongation   72°C 50 sec 
Final elongation  72°C 7 min 
Storage   8°C ∞ 
 
2.14.4 Genotyping PCR 
 
For the mouse genotyping PCR, DNA had to be isolated first from the tail biopsy. Therefore, the 
DirectPCR® Lysis Reagent Tail from Peqlab (Erlangen, Germany) was used. 200 µl of the lysis 
reagent were added to the biopsy as well as 6 µl Proteinase K (10mg/ml). For lysis, the reaction 
was incubated overnight at 55°C and 600 rpm on a thermomixer. The following day the reaction 
was incubated for 45 min at 55°C for heat inactivation and then transferred on ice and used for 













1 µl DNA 
   5 µl 5x buffer 
    2.5 µl dNTPs (2 mM) 
    0.5 µl Primer fw (10 pmol/µl) 
   0.5 µl Primer rev (10 pmol/µl) 
    0.75 µl MgCl2 (50 mM) 
    0.7 µl Mango Taq DNA-Polymerase (1 U/µl) 
    14.05 µl ddH2O 
 
The reaction mixture was afterwards incubated on a Thermocycler (2720 Thermal Cycler, 
Applied Biosystems, California, USA) using the following program: 
 
Initial denaturation  95°C 5 min 
Denaturation   95°C 30 sec 
Annealing   61°C 1 min 
Elongation   72°C 1 min 
Final elongation  72°C 10 min 
Storage   8°C  ∞ 
 
2.14.5 Reverse Transcription  
 
The reverse transcriptase used in the reverse transcription (RT) PCR transcribes RNA into 
cDNA. The principle of reverse transcription is, that the added oligo(dT)-primers anneal to the 
poly(A)-sequences of mRNAs. Corresponding to the standard PCR, the reverse transcriptase 
can elongate the strand to synthesize cDNA. For the generation of cDNA from total RNA the 
reverse transcriptase SuperScript II from Life Technologies (Darmstadt, Germany) was used. 
Eventually, the cDNA was subject to quantitative real-time PCR analysis. The reaction was 
performed in three following steps: 
 
1. Step:  1 – 5 µg RNA 
  Added to a 6 µl volume with ddH2O 
  + 0.5 µl oligo(dT)-primer (0.5 µg/ µl) 
  + 0.5 µl dNTPs (10 mM) 
  Incubation: 10 min at 65°C 
 
35x 




2. Step:  + 2 µl 5x First Strand Buffer 
  + 1 µl DTT (0.1 M) 
  Incubation: 2 min at 42°C 
 
3. Step:  + 0.25 µl SuperScript II 
  + 0.75 µl ddH2O 
  Incubation for reverse transcription: 50 min at 42°C 
  Heat-inactivation: 15 min at 75°C 
  Storage: 8°C ∞ 
 
The cDNA was diluted 1:10 with ddH2O. Before the generated cDNA was subjected to 
quantitative real-time PCR analyses, the quality of the reverse transcription was analyzed by 
standard PCR (Section 2.14.1) using specific primers for the housekeeping genes GAPDH or 
HPRT, depending on the source of the RNA. 
 
2.14.6 Quantitative real-time PCR 
 
Basically, the quantitative real-time PCR relies on the principal of the conventional PCR, but 
additionally, it enables the quantification of the PCR product during the PCR. This is possible 
due to the measurement of a fluorescent dye which binds to double stranded DNA and thereby 
increases its fluorescent signal (Pfaffl 2001, Ponchel et al. 2003). Thus, the increase in the 
measured fluorescent signal correlates to the amount of generated DNA. The fluorescent dye 
used in this study was PCR Mastermix Platinum® SYBR® Green qPCR SuperMix-UDG with 
Rox (Life Technologies, Darmstadt, Germany). Double stranded DNA bound with SYBR® Green 
can be excited using light of 480 nm wavelength resulting in an emission spectrum with a 
maximum at 520 nm. The Rox reference dye serves for normalization of non-PCR-related 
fluctuations in fluorescence. Using the ABI Prism 7900T Sequence Detection System the 
increase in the fluorescent intensity was measured after every PCR cycle and hence a graph 
was generated. During the exponential phase of the PCR reaction, in which the conditions are 
optimal by means of optimal polymerase activity and sufficient amount of reaction materials 
(primers, MgCl2), the threshold value is determined. This value defines the PCR cycle with the 
optimal conditions and it is used for further quantification calculations (Ct value). The generated 
data was evaluated with the Sequence Detection System software (SDS Version 2.1, PE Applied 
Biosystems). Usually, the used cDNA was diluted 1:20 with ddH2O prior to the quantitative real-
time PCR. The reaction for one well of a 396- well plate consisted of the following components: 




2.5 μl cDNA 
   2.5 μl Primer (fw + rev 100 pmol/µl) 
5.0 μl SYBR® Green 
 
The relative expression for one sample was measured in duplicates of which the mean value 
was used for the final calculations. The following program was used on the ABI Prism 7900T 
Sequence Detection system: 
 
50°C  2 min 
Taq activation: 95°C  3 min 
Denaturation: 94°C   15 sec 
Annealing: 60°C  30 sec 
Elongation: 72°C   30 sec 
95°C  15 sec 
60°C  15 sec 
Melting curve 60°C - 95°C 2°C/min  
 
After completion of the run, the data was evaluated with the SDS program and transferred to MS 
Excel (Microsoft) for further calculations. The relative expression was determined by ΔΔ-Ct-
method for which the following formulae were used: 
 
ΔCt = Ct (Gene of interest) – Ct (housekeeping gene) 
    ΔΔCt = ΔCt (Control) – ΔCt (sample of interest) 
    Relative expression = 2ΔΔCt 
 
The mRNA expression of two housekeeping genes, including TBP (TATA box binding protein), 
PBGD (porphobilinogen deaminase), LDHA (Lactate dehydrogenase A) or HPRT 
(Hypoxanthine-guanine phosphoribosyltransferase) for human samples was used as a 
reference. For murine samples Hprt (hypoxanthine-guaninephosphoribosyltransferase) und Tbp 
(TATA box binding protein) were used for normalization. 
 
2.14.7 Sequence analysis  
 
The standard, non-radioactive sequence analysis according to Sanger is based on the principle  
of chain termination (Sanger and Coulson 1975). During the sequence reaction not only deoxy- 
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nucleosides, but also dideoxynucleotides that have been labeled with different fluorescent dyes, 
will be incorporated into the DNA during the elongation step. Since the dideoxynucleotides do 
not possess a 3´- hydroxyl group no further nucleotides can be added by the polymerase 
resulting in a chain termination. Due to the detected dye the nucleotide can be determined and 
due to the length of the fragments to position of the nucleotides within the DNA strand could be 
determined. The used reaction consisted of the following components in a total volume of 10µl: 
 
1 µl DNA 
    2 µl 5x Buffer 
    1 µl BigDye®  
    1 µl sequence-specific primer, either the fw or rev (10 pmol/µl) 
    5 µl H2O 
  
The reaction was incubated on a Thermocycler (2720 Thermal Cycler, Applied Biosystems, 
California, USA) using the following program: 
 
Initial denaturation   95°C   1 min 
Denaturation    95°C   30 sec 
Annealing    60°C   2.5 min 
Elongation    60°C   5 min 
Storage    8°C  ∞ 
 
When the reaction was completed, 10 µl ddH2O were added to the sample. Gel electrophoresis 
by specific capillaries, which detect the fluorescent signals of the dideoxynucleotides, was 
performed in the automatic sequencer 3500XL (Applied Biosystems, Life Technologies, 
Darmstadt, Germany). 
 
2.15 Protein chemical techniques 
 
2.15.1 Isolation of total protein from cell cultures 
 
For isolation of total protein from cell cultures the medium was first removed and then the cells 
were washed with ice cold PBS. Depending on the confluency of the cells and the used culture 
flask/plate, the appropriate amount of protein lysis buffer (modified RIPA) was added to the 
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adherent cells; for example 150 μl lysis buffer were used for cells with a 90 % confluency in a 6-
well plate. The cells were incubated for 5 min on ice before they were scraped off the bottom 
with either a pipette tip or a cell scraper and transferred to a reaction tube. To pellet the cell 
debris the cells were centrifuged at 13000 rpm at 4°C for 10 min. The supernatant, which 
consists of the isolated protein, was transferred to a new reaction tube and the protein 
concentration was measured. For short-term storage the protein was kept at -20°C, for long-
term storage at -80°C. 
 
2.15.2 Isolation of protein from mouse tissue 
 
Proteins from mouse prostate or prostate tumor tissue was obtained via homogenization of the 
tissue using the TissueLyser LT (Quiagen, Hilden, Germany). A small sample of the tissue was 
transferred to a 2 ml reaction tube. A stainless steel bead (Ø 5mm, Quiagen) was added as well 
as 500 μl modified RIPA lysis buffer. The tissue was homogenized for 5 min at 50 1/s oscillation 
in the TissueLyser LT. Thereafter the cups were kept for 5 min on ice before centrifuging them 
for 10 min at 13000 rpm and 4°C. The supernatant was transferred to a new 1.5 ml reaction tube 
and the protein concentration was measured. For short-term storage the protein was kept at -
20°C and for long-term storage at -80°C. 
 
2.15.3 Determination of protein concentration 
 
The protein concentration was measured via Bradford protein assay (Bradford 1976). Roti®- 
Nanoquant (Carl Roth GmbH, Karlsruhe, Germany) was used, which consists of the Coomassie 
Brilliant blue dye. In acidic solutions, this dye binds unspecific to cationic and hydrophobic side 
chains of proteins. Once bound, the absorption maximum of the dye is shifted from 495 nm to 
595 nm since the binding reaction stabilizes the dye in its non-protonated and anionic form. A 
series of Roth Albumin Fraction V dilution was used for calibration according to the 
manufacturer’s recommendation. The protein concentration was determined by extrapolating to 
this standard curve.  
5x Roti®- Nanoquant dye was diluted with ddH2O to a final 1x concentration and stored at 4°C. 
Protein samples were diluted 1:100 with ddH2O. 50μl of the sample were added to a 96-well 
plate in triplicates. ddH2O was used as a control. 200μl of 1x Roti®- Nanoquant were added to 
samples and incubated for 5 min at RT. The protein concentration was measured using the 
SynergyMx plate reader spectrophotometer (BioTek, Friedrichshall, Germany) and calculated 
by inherent Gene5 software. 




2.15.4 Sodium Dodecyl Sulfate Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE gel electrophoresis (Western blot) is a useful biochemical method to separate 
proteins of a sample according to their molecular weight. The NuPage® Pre-Cast Gel System 
from Life Technologies (Darmstadt, Germany) was used which is based on the SDS-PAGE gel 
chemistry by Laemmli (Laemmli 1970). This polyacrylamide gel system, designed for high 
performance gel electrophoresis, consists of pre-cast gels and buffers with an operating pH of 
7.0, which increases stability in both proteins and gels. The samples consisted of 20-30 μg 
protein, 0.25 vol sample buffer (LDS Sample Buffer (4x), NuPAGE®, Life Technologies, 
Darmstadt, Germany) and 10 % 1M DTT (reducing agent). The samples were denatured at 70°C 
for 10 min and afterwards kept on ice for 5 min. Before the samples were loaded onto the 
gradient gel (NuPAGE® 4-12% Bis-Tris Gel, Life Technologies, Darmstadt, Germany), they were 
centrifuged briefly. 7 μl of the pre-stained molecular weight standard (See Blue® Plus2, Life 
Technologies, Darmstadt, Germany) were also loaded onto the gel to determine the size of the 
separated proteins. Gel electrophoresis was performed at 160 V and 160 mA in 1x MES buffer 
(Life Technologies, Darmstadt, Germany). Depending on the molecular weight of the protein of 
interest the gel was run for 1-3 hours. 
 
2.15.5 Transfer of proteins onto a PVDF membrane 
 
After SDS-PAGE gel electrophoresis the proteins were transferred onto a PVDF membrane (GE 
Healthcare, Freiburg, Germany) using the semi-dry blotting procedure. Thereby, the PVDF 
membrane (7 cm x 8 cm or 7 cm x 13 cm) was first activated for 10 sec in 100% methanol before 
it was equilibrated for 10 min in transfer buffer IIa. Six sheets of Whatman GB003 filter paper 
(Schleicher & Schull, Dassel, Germany) having the same size as the gel and the PVDF 
membrane, were also soaked in transfer buffer IIa. The electro-blotter (Biometra, Göttingen, 
Germany) was loaded in a sandwich system in the following order:  
 
Bottom of the blotter, Anode (+): Three sheets of filter paper 
     PVDF membrane 
     Gel 
Lid of the blotter, Cathode (-):  Three sheets of filter paper 
 
Before the blotter was closed, remaining air bubbles were removed from the sandwich system. 
The transfer was carried out at 25 V and 220 mA for 30 min to 1 hour, depending on the 
molecular weight of the proteins.  




2.15.6 Incubation of protein-bound membranes with antibodies 
 
The PVDF membrane was incubated in the western blot blocking buffer for 1 hour at RT to block 
unspecific binding sites. Thereafter it was thoroughly washed with western blot washing buffer. 
The membrane was incubated with the primary antibody overnight at the recommended dilution 
in TBS-T at 4 °C. The next day, unbound antibody was removed by washing twice for 10 min 
with the western blot washing buffer. The membrane was then incubated for at least 2 hours 
with the secondary alkaline phosphatase conjugated antibody, diluted accordingly to the 
manufacturer’s recommendation in western blot blocking buffer. It was washed three times for 
15 min in western blot washing buffer and 5 min in TBS-T to remove the remaining milk. ECL 
Prime Detection solution (GE Healthcare, Freiburg, Germany) was used to detect chemi-
luminescent signals. Therefore, the membrane was placed on a plastic film and the detection 
solution was pipetted onto the membrane according to the manufacturer’s instruction and 
incubated for 5 min. The signals were captured using the western blot detection system 
(FlourChem® Q Alpha Innotech, Logan, USA) and evaluated using the inherent AlphaView 
Software for FluorChem® systems (FlourChem® Q Alpha Innotech, Logan, USA). 
 
2.16 Cell biological methods 
 
2.16.1 Cell culture of eukaryotic cells 
 
Cells were cultured in their appropriate medium (see section 2.8.3) in surface-treated cell culture 
flasks (Sarstedt, Nümbrecht, Germany) at 37°C in a humidified incubator with 5 % CO2. 
Depending on the proliferation rate and confluency of the cells, they were splitted once or twice 
per week. For the splitting process the cells were first washed with DBPS (PAN Biotech GmbH, 
Aidenbach, Germany) and then incubated for a few minutes at 37 °C in a minimal amount of 
Trypsin/EDTA (PAN Biotech GmbH, Aidenbach, Germany) for detachment from the culture flask. 
Using an inverted microscope it was controlled whether all cells were detached. If this was the 
case, the trypsin reaction was stopped by adding growth medium. Depending on proliferation 
rate of the cells they were diluted either 1:5 or 1:10 with fresh culture medium. 
 
2.16.2 Cryo-preservation and revitalization of eukaryotic cells 
 
For cryo-preservation, the cells were grown to 80 % confluency and then trypsinized as 
described in 2.16.1. When all the cells had detached from the bottom of the cell culture flask the 




tryspin reaction was stopped with medium. The cells were transferred to a tube and centrifuged 
at 200 x g for 5 min to form a cell pellet and remove the remaining trypsin. The pellet was 
resuspended in the appropriate amount of culture medium and then diluted 1:1 with cryo-medium 
(see 2.8.3). Overnight, the cells were kept in Mr. Frosty (Thermo Scientific, Langenselbold, 
Germany) in a -80°C freezer where the cells were slowly cooled (1°C/min). The following day, 
the cells were transferred to liquid nitrogen for long-term storage. When cells were revitalized, 
they were quickly thawed and transferred to a tube containing 5 ml of the appropriate medium. 
The cells were centrifuged at 200 x g for 5 min, the supernatant was removed and the cell pellet 
was resuspended in pre-warmed culture medium. The cells were then transferred to a cell culture 
flask and kept in the incubator. The next day the medium had to be changed in order to fully 
remove remaining DMSO. 
 
2.16.3 Test for Mycoplasma contamination 
 
To detect a possible contamination by Mycoplasma, a routinely test was conducted every month. 
Therefore, the MycoAlert® Mycoplasma Detection Kit (Lonza, Cologne, Germany) was used 
according to the manufacturer’s instructions, except that only half of the recommended amounts 
were used. The principle of this test is the measurement of the activity of mycoplasma-specific 
enzymes before and after application of specific substrates.  
 
2.16.4 Transfection of eukaryotic cells  
 
2.16.4.1 Transfection of plasmids into eukaryotic cells 
 
Eukaryotic cells were transfected with plasmids in order to induce an overexpression of fusion 
proteins (pIRES2-EGFP-CCND2, pEBTetD-CCND2) or to induce a downregulation of the fusion 
protein by shRNA (pSingle-tTs-Ccnd2-shRNA). Two different transfection reagents were used: 
Lipofectamine® Transfection Reagent (Thermo Fisher Scientific, Langenselbold, Germany) or 
Metafectene® Pro (Biontex Laboratories GmbH, Munich, Germany). Both transfection reagents 
contain lipids which form vesicles with a bilayer sheet, so called liposomes, in aqueous solution. 
The liposomes can form nucleic acid lipid complexes with nucleic acids. These complexes can 
actively be taken up by the eukaryotic cells by a process called endocytosis. The nucleic acid 
can enter the nucleus only if the nuclear membrane dissolves during mitosis. Therefore, the 
division rate of cells is critical for DNA transfection and must be as high as possible for efficient 
transfection. The cells were plated in a sufficient number into 6-well cell culture plates or T-25 




cell culture flasks so that the following day a confluency of 70 – 90 % was reached. For the 
transfection, plasmid DNA was mixed with the transfection reagent according to the 
manufacturer’s instructions. The mix was incubated for 20 – 30 min and then applied dropwise 
to the cells in normal growth medium, which were prior washed with DPBS. The cells were 
incubated overnight at normal culture conditions. The following day, the transfection reagent- 
containing medium was replaced by fresh medium.  
 
2.16.4.1.1 Generation of single-cell clones/populations 
 
Cells transfected with the pEBTetD-CCND2 plasmid were treated from the next day on with 
puromycin for clonal selection of successfully transfected cells (see Chapter 2.8.3.). The 
surviving cells were further cultured until the amount of cells was sufficient to test by western 
blot analysis if the cells indeed exhibit a cyclin D2 overexpression. Total protein was isolated 
after the cells were treated with doxycycline in different concentrations (0.01 µg/ml – 1 µg/ml) for 
48 or 72 hours to induce cyclin D2 overexpression. Successfully generated cells with a 
doxycycline-inducible cyclin D2 overexpression were preserved by cryo-preservation and 
subject to proliferation studies. 
Cells transfected with the plasmid pIRES2-EGFP-CCND2 or pSingle-tTs-Ccnd2-shRNA 
underwent a serial dilution with normal growth medium, ranging from 1:10 – 1:80, in order to 
generate single-cell clones. This was done two days after the transfection. The diluted cells were 
plated in cell culture petri dishes and cultured under normal cell culture conditions. From the next 
day on the cells received Geneticin disulfate (G418)-solution with their normal growth medium 
in order to select positively transfected cells. Approximately three weeks after the serial dilution 
of the cells, single cells had formed clones which were picked with a pipette, transferred to a 96-
well plate and incubated at normal culture conditions. When a confluency of 70 – 90 % was 
reached the cells were transferred to the next bigger well until again a confluence of 70 – 90 % 
was reached and so on (96-well  24-well  12-well 6-well  T-25 flask), until finally the 
amount of cells was sufficient to fill a T-75 cell culture flask. Total protein was isolated from the 
cells and via western blot analysis the overexpression or downregulation of cyclin D2 within the 
transfected cells was tested. Cells transfected with pSingle-tTs-Ccnd2-shRNA had to be treated 
with doxycycline for 48 – 72 hours prior to protein isolation in order to induce transcription of the 
shRNA. Cells that were tested positive for cyclin D2 overexpression or cyclin D2 downregulation 
were conserved by cryo-preservation and were subjected to proliferation, migration or soft agar 
assays.  
 




2.16.4.2 Transfection of small interfering RNA (siRNA) into eukaryotic cells 
 
siRNAs were used for silencing of a specific gene. siRNAs bind to a specific mRNA, thereby 
marking it for degradation which results in a reduced gene expression. Three different mouse 
siRNAs against cyclin D2 (MSS236126, MSS236127, MSS236128, Stealth RNAi™ siRNA, Life 
Technologies, Darmstadt) and three different human siRNAs against cyclin D2 were used 
(HSS101452, HSS101453, HSS101454, Stealth RNAi™ siRNA, Life Technologies, Darmstadt). 
Human and mouse PCa cells were transfected with gene-specific siRNAs by using the siRNA 
transfection reagent Oligofectamine™ (Life Technologies, Darmstadt, Germany). Thereby 
complexes of lipids and siRNA oligonucleotides will be formed which facilitate the uptake of the 
siRNA molecule into mammalian cells. A sufficient amount of the cells were plated into a 6-well 
plate or T-25 culture flask so that the following day for transfection a confluence of 50 % was 
reached. The transfection reaction was pipetted according to the manufacturer’s instructions with 
a final concentration of 50 nM siRNA- duplexes. Control PCa cells were transfected with siRNA- 
duplexes against the luciferase gene Photinus pyralis. The transfection reaction was incubated 
for 30 min at RT in order to form the lipid-siRNA-complexes. In the meantime the cells were 
washed with DBPS (PAN, Aidenbach, Germany). OptiMEM I (Life Technologies, Darmstadt, 
Germany) was added to the cells as well the transfection reagent, which was applied dropwise. 
The cells were cultured overnight at normal culture conditions in the 37°C incubator. The 
following day the transfection reagent-containing medium was replaced by normal growth 
medium. Either protein or RNA was isolated from the transfected cells at different time points or 
the cells were further subjected to migration or soft agar assays. 
 
2.17 Functional analyses of eukaryotic cells  
 
2.17.1 Migration assay 
 
48 hours prior to the in vitro cell migration assay NIH/3T3 cells were transfected with the cyclin 
D2-specific siRNAs. For the cell migration assay, 20000 cells suspended in 200 µl medium were 
transferred to an insert of the assay (Millicell 8.0µm hanging PET inserts, Millipore, Billerica, 
USA). The assay was incubated overnight at normal cell culture conditions. The following day, 
cells that had migrated through the membrane of the insert were stained using the Diff-Quick 
Staining Set (Dade Behring GmbH, Marburg, Germany) according to the manufacturer’s 
instruction. The membranes were excised from the insert using a sterile scalpel and then fixed 
in oil on a slide. For evaluation, the number of cells that had migrated through the membrane 




overnight was counted per field of view of five pictures taken on the microscope (BX60, Olympus 
GmbH, Hamburg, Germany) at a 40x magnification.  
Cells transfected with pIRES2-EGFP-CCND2 or doxycycline-treated (48 hours) pEBTetD-
CCND2-transfected cells were plated right away into the inserts from Corning Transwell® 
Permeable Supports (8.0 µm pore size and 6.5 mm Transwell insert diameter, Corning Inc., New 
York, USA). 20000 cells suspended in 100 µl medium were transferred to the insert according 
to the manufacturer instruction. Cells were incubated overnight, stained, fixed and counted as 
described above. 
 
2.17.2 Proliferation assay 
 
The proliferation rate of PCa cells with cyclin D2 overexpression (transfected with pIRES2-
EGFP-CCND2 or pEBTetD-CCND2) or of NIH/3T3 cells with cyclin D2 downregulation 
(transfected with pSingle-tTs-Ccnd2-shRNA or siRNA) was studied. Therefore, the CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay (MTS, Promega, Mannheim, Germany) was 
used. This assay is based on the principle that faintly yellow stained tetrazoles (MTS) can be 
reduced to intensively purple stained formazan derivatives by living cells. MTS, in the presence 
of phenazine methosulfate (PMS), produces a formazan product that has an absorbance 
maximum at 490-500 nm. The intensity of the staining is measured from which conclusions on 
the cell proliferation are drawn. This reaction requires active mitochondria which are found only 
in living cells. 3000 cells were plated into a well of a flat-bottomed 96-well cell culture plate. In 
case of siRNA-transfected 2E, PC-3, LNCaP and DU145 cells, which were also treated with VPA 
to study the functional consequence, the day following transfection 10000 cells suspended in 
VPA-containing medium were plated per well. After two hours, when the cells were adherent, 
the PMS/MTS solution was added according to the manufacturer’s instruction. In case of cells 
transfected with the tetracycline inducible vectors pEBTetD and pSingle-tTs-shRNA doxycycline 
was simultaneously added. Cells were incubated in the PMS/MTS solution for 2 hours at 37°C 
and 5 % CO2 to let the color reaction develop. Then the intensity of the staining was measured 
using the SynergyMx plate reader spectrophotometer (BioTek, Friedrichshall, Germany). The 
generated data was transferred to MS Exel (Microsoft) for further calculation of the absolute and 
relative proliferation rate at a certain time point (t) according to the following formulas:   
 
Absolute Proliferation (t):         mean (t)/ mean (t=0)                   
                                                                  
Relative Proliferation:  absolute proliferation (t)/absolute proliferation of the control (t) 




2.17.3 Soft agar assay 
 
The soft agar assay is a detection method for the ability of cells to grow anchorage-independent 
in agarose in vitro. Transformed cells have the ability to grow independently of a solid surface, 
which is a hallmark of carcinogenesis (Borowicz et al. 2014). By contrast, mouse fibroblast cells 
NIH/3T3 are not able to grow anchorage-independent. Therefore, these cells were tested after 
cyclin D2 siRNA-transfection or transfection with the pSingle-tTs-Ccnd2-shRNA plasmid for 
malignant transformation by using the soft agar assay.  
A 5 % agar solution was prepared with DPBS and sterilized by autoclaving. This was the basic 
solution for the different agar concentrations needed. The agar was liquefied in a microwave and 
kept for the duration of the experiment at a 45°C water bath. Through careful but rapid pipetting, 
the appropriate amount of 5 % agar was mixed with pre-warmed cell culture medium to yield the 
agar concentration needed. The bottom of 6-well plates was covered with 1ml of the so called 
bottom layer which consisted of 1 % agar. The agar was applied carefully to avoid air bubbles. 
The plate was set aside for the bottom layer to solidify. Meanwhile, the top layer was prepared 
for which 5000 cells were added to 500 µl pre-warmed medium and then mixed with 500 µl of 
0.6 % agar to yield a 1 ml volume with 0.3 % agar concentration for the top layer. It was applied 
carefully but rapidly to the bottom layer and then the plate was kept for 10 min at RT before it 
was transferred to the incubator with normal cell culture conditions. There it was kept for up to 
four weeks so that colonies could form from the single cells. For visualization of colonies the 
agar was stained overnight with 0.001 % crystal violet. 
The NIH/3T3 cells used for this experiment were transfected 48 hours prior to the soft agar with 
cyclin D2-specific siRNA. Cells from the pSingle-tTs-Ccnd2-shRNA transfected NIH/3T3 clone 
No. 11 were either treated with doxycycline 48 hours before the soft agar assay or they were 
transfected with pEGFP, pEGFP-KRAS or pEGFP-KRAS-G12V and treated the following day 




2.18.1 Immunofluorescent staining of eukaryotic cells  
 
For the immunofluorescent staining the cells were plated into 4-chamber slides at a medium cell  
density of 25000 cells per chamber. The cells were cultured overnight in normal cell culture 
medium at 37°C and 5 % CO2. The following day the cells were fixed with 3.7 % formaldehyde 
in DPBS for 20 min at RT. Cells were washed briefly with DPBS and then incubated for 10 min 




with 0.1 % Triton-X-100 in DPBS to make the membrane permeable. After the cells were washed 
again with DPBS they were blocked for 20 - 30 min with blocking buffer II to block unspecific 
binding sites. The cells were incubated at 4°C overnight with the primary antibody (anti-cyclin 
D2 (M-20), Santa Cruz, Heidelberg, Germany) which was diluted 1:200 with blocking buffer II. 
The next day the cells were washed twice for 10 min with DPBS. Afterwards the secondary Cy-
3-coupled antibody, which was diluted 1:200 with blocking buffer II, was applied to the cells and 
incubated for 2 hours. The cells were washed twice for 10 min with DPBS and once for 10 min 
with H2O. Finally, the slides were covered with Vectashield/DAPI (VectorLab, Burlingame, USA) 
and the staining was documented with the fluorescence microscope BX60 (Olympus GmbH, 
Hamburg, Germany). 
 
2.18.2 Immunohistochemical staining of cryo-sections from CAM tumors 
 
The cryo-slides were removed from the -20°C freezer and kept for 1 hour at RT to dry. Unspecific 
binding sides were blocked by incubation with goat blocking reagent for 1 hour at RT. The 
primary antibodies, Mep21 (chicken CD34 homolog; M. Williams, AbLab, University of British 
Columbia, Vancouver, B.C., Canada) and Prox1 (ReliaTech GmbH, Wolfenbüttel, Germany) 
were diluted 1:500 with antibody solution. The slides were incubated overnight at 4°C with the 
primary antibodies. The following day the slides were briefly washed twice with PBS before the 
secondary antibodies were added, which were diluted 1:200 with antibody solution. Secondary 
antibodies used were Alexa 594-conjugated goat-anti-rabbit IgG (Life Technologies, Darmstadt, 
Germany) and Alexa 488-conjugated goat-anti-mouse IgG1 (Life Technologies, Darmstadt, 
Germany). DAPI (kept in aliquots of 1:20000 dilution in PBS) was also added to the secondary 
antibody solution in a 1:100 dilution. The slides were incubated for 90 min in the dark at RT with 
the secondary antibody/DAPI. Afterwards they were washed twice with PBS. Finally, the slides 
were covered with Fluoromount-G (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) and 
the staining was documented with a microscope.  
 
2.19 In vivo studies 
 
The experiments were performed according to the guidelines of the European Parliament 
(2010/63/EU) and the council for the protection of animals in science (§14 TierSchVersV). 
 
 




2.19.1 In vivo treatment of TRAMP mice with VPA 
 
TRAMP mice received VPA over the drinking water. A final concentration of 0.4 % w/v VPA was 
applied to the mice. Since the final concentration was not tolerated instantly by the mice, VPA 
had to be crept in during the first week by increasing the concentrationd from 0.1 % w/v VPA in 
0.1 %- steps every other day until the final concentration of 0.4 % w/v was reached. To make 
the drinking water more tasty, common household sweetner tablets from the brand "Das 
gesunde PLUS" (dm-drogerie markt GmbH + Co. KG, Karlsruhe, Germany) were added to the 
drinking water (1 tablet/100 ml drinking water). Mice that received drinking water only with 
sweetner served as controls. This experiment consisted of 11 VPA-treated and 11 control-
treated TRAMP mice. In Figure 2.1 the treatment scheme is depicted.  
 
Figure 2.1: In vivo VPA treatment scheme. VPA treatment started when TRAMP mice were 6 weeks old. Both 
groups received their treatment for the duration of 10 weeks. At the age of 16 weeks the mice were sacrificed, their 
prostates were isolated and stored at -80°C for molecular evaluation either by western blot analysis or quantitative 
real-time PCR. 
 
2.19.2 Chicken chorioallantoic membrane (CAM) assay 
 
The CAM assay was conducted in collaboration with Prof. Dr. Jörg Wilting in the Center of 
Anatomy, University Medical Center Göttingen. Specific pathogen-free fertilized White Leghorn 
chicken eggs were purchased from Valo BioMedia GmbH (Osterholz-Scharmbeck. Germany) 
and stored for up to 10 days in the refrigerator until the experiment was started. When beginning 
the experiment, the eggs were incubated for 72 hours at >80 % relative humidity and 37.8°C. 
On developmental day 3, a little window (0.5 cm x 0.5 cm) was sawed into the egg shell and 
afterwards sealed again with cellotape. The eggs were thereafter incubated again for seven 
days. On developmental day 10, the window was re-opened and 50 µl of PCa cells-matrigel 
mixture were applied to the CAM. For the murine PCa 2E cells, 2 × 106 cells were applied per 




egg and for the human PCa PC-3 cells 5 × 106 cells were applied per egg. The cells were 
resuspended in 50 % normal growth medium and 50 % Matrigel (Corning® Matrigel® Basement 
Membrane Matrix, LDEV-Free, Product #354234, Corning Inc., New York, USA). Before 
application to the CAM, the cells were pre-treated with either 1 mM or 3 mM VPA for 24 hours 
or seven days. On the day of application to the CAM the same concentration of VPA was added 
to the medium-Matrigel mixture. Control cells were not treated with VPA at all. After adding the 
cells to the CAM the window was sealed again with cellotape and the eggs were further 
incubated for seven days. Cells that were treated with VPA were re-treated after three days by 
applying 10 µl of cell culture medium with the appropriate amount of VPA onto the already 
developed tumor within the egg. On developmental day 17 the window was re-opened and 
enlarged so that the tumors that had grown from the applied cells could be excised. Tumors that 
were subjected to embedding and immunohistochemical analysis were first fixed with 4 % 
paraformaldehyde within the egg for 20 min. Tumors that were subjected to gene expression 
analyses by quantitative real-time PCR were excised right away without fixation, transferred to 
liquid nitrogen and then stored at -80°C until continuation with total RNA isolation. The fixed 
tumors were excised from the CAM, washed with PBS and then pictures were taken with the 
Leica MZ16FA microscope. Afterwards, the tumors were placed into little tubes filled with 10 % 
sucrose (in PBS). When the tumors were soaked with the sucrose they sank to the bottom. Only 
then the tumors were transferred for overnight incubation at 4°C to a tube filled with 30 % sucrose 
(in PBS). The following day tumors were embedded in clear PolyFreeze Tissue Freezing Medium 
(Polysciences Europe GmbH, Eppelheim, Germany) and stored for one night at -80°C before 
they were kept for long-term storage at -20°C. The embedded tissue was cut with a cryotome 
(Leica CM3050 S, Wetzlar, Germany) into 16 μm thick sections. Three to four sections were 
transferred to one slide. Until the slides were used for immunofluorescent staining they were 




To analyze the statistical significance of the experimental results the unpaired t test was used. 
The results were depicted as follows: 
 
* 0.01 < p ≤ 0.05, "significant"  
** 0.001 ≤ p < 0.01, "very significant"  
*** p ≤ 0.001, "extremely significant"




3.1 Molecular effects of VPA treatment in PCa therapy 
 
Witt et al. could show that VPA treatment of the murine 2E PCa cells reduced the migration, 
invasion and proliferation rate, all in a concentration-dependent manner (Witt et al., 2013). In 
vivo studies showed that TRAMP mice that received VPA with the drinking water had a reduced 
number and onset of tumors as well as an increased age of survival compared to control-treated 
mice (Witt, 2012). Microarray analysis of 2E cells treated for 24 hours with VPA identified several 
candidate genes that could be responsible for the observed effects of VPA treatment in vivo and 
in vitro (Witt, 2009). Eight candidate genes were chosen for further investigation because of their 
known expression in the prostate and their known connection to cancer. They included the 
downregulated genes chemokine (C-X-C motif) ligand 15 (Cxcl15), which codes for a cytokine 
of the CXC chemokine family, RCC1 and BTB domain-containing protein 2 (Rcbtb2) coding a 
member of the RCC1 related GEF family, both transcript variants of ceruloplasmin (Cp), which 
is the main copper transporting protein of blood, and leukemia inhibitory factor (Lif), which codes 
for a class 6 interleukin. Candidate genes that were upregulated after VPA treatment included 
ubiquitin carboxy-terminal hydrolase L1 (Uchl1), which codes for a de-ubiquitinising enzyme, 
tyrosine-protein phosphatase-like N (Ptprn), which codes for a member of the protein tyrosine 
phosphatase family and cyclin D2 (Ccnd2), which codes for a member of the strongly conserved 
D-type cyclin family. The up- and downregulation of the candidate genes was verified by 
quantitative real-time PCR on cDNA derived from VPA-treated 2E cells (Witt et al., 2013). 
In the present project TRAMP mouse tumors which were derived and isolated from previous in 
vivo VPA experiments (Witt, 2012) were now further evaluated in terms of deregulated candidate 
gene expression. 
 
3.1.1 Verification of deregulated candidate gene expression in tumors of VPA-treated 
TRAMP mice 
 
The expression of the candidate genes was investigated both on RNA and protein level in 
prostate tumors derived of VPA- and control-treated TRAMP mice.  
This first in vivo VPA treatment experiment was conducted by Witt during her dissertation (2012). 
Witt used three different study groups which were treated with a final concentration of 0.4% w/v 
VPA and sweetener over the drinking water. 
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Control-treated mice received drinking water with sweetener only. Two of the study groups were 
preventive study groups which received VPA treatment at the age of 6 weeks when the prostate 
shows no malignant changes yet. One of the groups was treated until the age of 30 weeks (group 
1), when tumor progression should still be ongoing, and then sacrificed. The second group was 
treated until the age of 40 weeks (group 2), when TRAMP mice should have developed a PCa, 
and then sacrificed. The third group received VPA as a curative treatment starting at the age of 
16 weeks, when tumor development should have initiated already in TRAMP mice, and at the 
age of 40 weeks they were sacrificed (group 3, Mentor-Marcel et al., 2001). If mice showed a 
weight loss of more than 20 % within 48 hours, exhibited behavioral problems (including apathy, 
increased aggressiveness, paralysis) or had a clearly palpable PCa, the mice were sacrificed 
immediately. Of all the sacrificed TRAMP mice the prostate tumors were isolated (Witt, 2012).  
 
3.1.1.1 Verification of deregulated candidate gene expression on RNA and protein level 
 
The expression of the candidate genes Cp1, Cp2, Ccnd2, Ptprn, Uchl1, Lif and Rcbtb2 was 
analyzed by quantitative real-time PCR on RNA derived from isolated prostate tumors of VPA- 
and control-treated TRAMP mice. In total, 12 prostate tumors were available for molecular 
evaluation. Six of the tumors were derived from VPA-treated TRAMP mice (group 1: 1 tumor, 
group 2: 3 tumors, group 3: 2 tumors) and the other six tumors were received from control mice 
(group 1: 1 tumor, group 2: 4 tumors, group 3: 1 tumor). 
In vivo VPA treatment led to a significant reduction of the Cp2 and Lif expression in prostate 
tumor tissue (Fig.3.1). Cp2 and Lif were also downregulated in the previous microarray 
experiment of VPA-treated 2E cells (Witt, 2009). The Ccnd2 expression after VPA treatment was 
not quite significantly decreased in the tumor tissue (p= 0.0511) which is contrary to the array 
result. The expression of Uchl1 and Ptprn was downregulated after VPA treatment, which is also 
contrary to the microarray results. Cp1 expression was downregulated after VPA treatment in 
the prostate tumors of TRAMP mice, though not statistically significant, which is in accordance 
to the microarray data. Rcbtb2 showed no expression differences in tumors of VPA and control-
treated TRAMP mice (Fig 3.1). 
By quantitative real-time PCR analysis on prostate tumor tissue the downregulation of three 
candidate genes could be confirmed (Cp1, Cp2 and Lif) whereas three genes showed a contrary 
expression pattern (Ccnd2, Uchl1 and Ptprn) and Rcbtb2 expression was not deregulated. 




Fig. 3.1: Candidate gene expression analysis in tumor tissue of VPA-treated TRAMP mice. RNA was isolated 
from prostate tumors of in vivo VPA-treated TRAMP mice (6 tumors) and from the prostate tumors of control-treated 
TRAMP mice (6 tumors). RNA was reverse transcribed into cDNA and quantitative real-time PCR analysis was 
conducted. VPA treatment led to a significant reduction of Cp2 expression (p= 0.0349) and Lif expression (p= 0.0176) 
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in prostate tumor tissue compared to tumor tissue of control-treated mice. The expression of Ccnd2, Cp1, Uchl1, 
Rcbtb2 and Ptprn was not statistically significant deregulated in prostate tumor tissue of VPA-treated and control 
TRAMP mice. Data are presented as mean +/- standard deviation of three quantitative real-time PCR analyses 
performed in triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001, n.s.: not significant 
 
On the protein level the expression of cyclin D2 was tested by western blot analysis (Fig.3.2A). 
Densitometrical evaluation of a single western blot showed that there is a statistically significant 
increase in the cyclin D2 expression in the prostate tumors of VPA-treated TRAMP mice as 
compared to control-treated mice (Fig. 3.2B). 
 
Fig. 3.2: Cyclin D2 expression in tumors of VPA and control-treated TRAMP mice. A) Whole protein lysate of 
prostate tumors derived from VPA-treated TRAMP mice was immunoblotted using a cyclin D2-specific antibody. 
Protein lysate of tumors derived from mice not treated with VPA served as controls. Immunoblotting of α-tubulin 
ensured equal protein loading. B) Densitometrical analysis revealed a significant increase in the cyclin D2 expression 
in prostate tumors of VPA-treated mice as compared to prostate tumors derived from control mice (p=0.0480). * 0.01 
< p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001 
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3.1.1.2 In vivo VPA treatment of TRAMP mice 
 
A new in vivo VPA treatment experiment of TRAMP mice was conducted due to the fact that in 
the previous in vivo experiment too many points were not consistent: tumors were isolated at 
different time points depending on either which of the three study groups the mice belonged to 
(two preventive groups sacrificed at weeks 30 or 40 and one curative group sacrificed also at 
week 40 but treatment started at week 16 and not at week 6 like for the other two groups), the 
size of the tumor or behavioral problems of the mice. The difference in the mice age when their 
prostate tumor was isolated could also lead to differential expression of the candidate genes. In 
addition, the few isolated tumors may have risen due to either failure of therapy or resistance to 
VPA treatment. To avoid the differences between mice mentioned above a new in vivo VPA 
treatment experiment of TRAMP mice was conducted. This time there was only one study group 
consisting of 11 VPA-treated and 11 control-treated mice. The treatment for the mice started at 
the age of 6 weeks. All mice were sacrificed at the age of 16 weeks, resulting in a 10 week 
treatment period (Fig. 2.1). The mice received 0.4% w/v VPA with the drinking water which was 
enriched with sweetener. Control-treated mice received water with sweetener only. When the 
mice were sacrificed their prostates were isolated for molecular evaluation. None of the TRAMP 
mice had developed a visible prostate tumor yet.  
The expression of the eight candidate genes from the microarray was analyzed on RNA derived 
from prostates of VPA- and control-treated TRAMP mice by quantitative real-time PCR. This 
analysis revealed a significant downregulation of Cp2 and a significant upregulation of Ptprn and 
Uchl1 in the prostate tissue of VPA-treated mice compared to prostate tissue of control-treated 
mice (Fig. 3.3). These results are in accordance to the microarray data (Witt, 2009). The other 
candidate genes showed no statistically significant expression differences in the prostates of 
VPA- and control-treated TRAMP mice although the expression of Rcbtb2 was not quite 
significantly upregulated after VPA treatment (p=0.0523, Fig. 3.3). 




Fig. 3.3: Candidate gene expression analysis in prostate tissue of VPA-treated TRAMP mice. RNA was isolated 
from prostate tissue of 11 TRAMP mice that were treated for 10 weeks with VPA over the drinking water and from 11 
control-treated TRAMP mice. RNA was reverse transcribed into cDNA and quantitative real-time PCR analysis was 
conducted. VPA treatment led to a significant reduction of Cp2 expression (p=0.0451) and a significant increase in 
Ptprn and Uchl1 expression (p=0.0011; p=0.0010) in the prostate tissue of TRAMP mice as compared to prostate 
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tissue of control-treated TRAMP mice. The expression of Ccnd2, Cp1, Rcbtb2, Lif and Cxcl15 was not statistically 
significant deregulated in prostate tissue of VPA-treated TRAMP mice compared to prostate tissue of control-treated 
TRAMP mice. Data are presented as mean +/- standard deviation of three quantitative real-time PCR analyses 
performed in triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001, n.s.: not significant 
 
3.1.1.3 Ceruloplasmin expression in human PCa cells 
 
The expression of the ceruloplasmin (CP) gene was investigated in human PCa cells LNCaP, 
DU145 and PC-3 because to date CP expression was only studied in mouse PCa 2E cells (Witt, 
2009). The PCa cells were treated in vitro for 72 and 144 hours with VPA, respectively, before 
RNA was isolated. Untreated PCa cells served as controls. The RNA was reversed transcribed 
into cDNA and the expression of CP was analyzed by quantitative real-time PCR. In the human 
genome only one isoform of CP exists whereas in mouse two transcript variants are known. For 
all three human PCa cell lines a reduced CP expression was observed after VPA treatment, 
mostly in a time- and concentration-dependent manner (Fig.3.4A). To confirm the quantitative 
real-time PCR result also at protein level western blot analyses for CP expression in murine and 
human PCa cells was performed. In 2E cells the protein level of CP did not change upon VPA 
treatment and in human PCa cells DU145, LNCaP and PC-3 the CP level was rather increased 
after VPA treatment (Fig.3.4B, depicted only for 2E and DU145 cells). Because the western blot 
analyses could not confirm the quantitative real-time PCR results, ceruloplasmin expression 
studies in PCa cells were discontinued.  





Fig. 3.4: Ceruloplasmin expression in human PCa cells. The human PCa cells LNCaP, DU145 and PC-3 were 
treated for 72 and 144 hours with two concentrations of VPA (1mM and 5mM) in vitro. Protein lysate and total RNA 
was isolated and the RNA was reverse transcribed into cDNA. The generated cDNA was subjected to subsequent 
quantitative real-time PCR analyses. A) For all three human PCa cell lines a reduced CP expression was observed 
after VPA treatment, mostly in a time- and concentration-dependent manner as compared to untreated cells. B) 
Protein lysate was subjected to western blot analysis using a ceruloplasmin-specific antibody. Immunoblotting of α-
tubulin ensured equal protein loading. In 2E cells the ceruloplasmin protein level of VPA-treated cells was comparable 
to controls whereas in human PCa cells DU145 the ceruloplasmin level increased after VPA treatment. This was also 
observed for the human PCa cells LNCaP and PC-3 (data not shown). Data are presented as mean +/- standard 
deviation of three quantitative real-time PCR analyses performed in triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, 
*** p ≤ 0.001 
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3.1.2 Effects of VPA treatment on the expression of angiogenesis markers 
 
Since three of the eight candidate genes from the previous microarray experiment (Witt, 2009), 
namely Cp1, Cp2 and Cxcl15, are associated with angiogenesis the effects of VPA treatment on 
angiogenesis were analyzed in the present study in more detail. Therefore, the expression of 
several so called angiogenesis markers was investigated by quantitative real-time PCR first in 
in vitro VPA-treated 2E PCa cells and then in prostate tumors and prostate tissue of in vivo VPA-
treated TRAMP mice. The angiogenesis markers were chosen from a publication by Shih et al. 
and included two angiogenic cytokines (vascular endothelial growth factor A (Vegfa) and 
angiopoietin 1 (Ang1), three endothelial cell receptor tyrosine kinases (vascular endothelial 
growth factor receptor 1 (Flt-1/Vegfr1), vascular endothelial growth factor receptor 2 
(Kdr/Vegfr2), tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (Tie-1)), and an 
endothelial cell adhesion molecule, platelet endothelial cell adhesion molecule (Pecam-1, Shih 
et al., 2002). 
 
3.1.2.1 Effect of in vitro VPA treatment on the expression of blood- and lymph-
angiogenesis markers 
 
The mouse PCa cells 2E were treated for 72 and 144 hours with two different concentrations of 
VPA (1mM and 5mM). RNA was isolated and reversed transcribed into cDNA. The cDNA was 
used for the subsequent quantitative real-time PCR analyses to test the expression of the 
angiogenesis markers Vegfa, Ang1, Flt-1/Vegfr1, Kdr/Vegfr2, Tie-1 and Pecam-1. Cells that 
were not treated with VPA served as controls.  
The angiogenic cytokines Vegfa and Ang1 as well as the receptor tyrosine kinase Tie-1 and the 
endothelial cell adhesion molecule Pecam-1 were statistically significant downregulated in 2E 
cells that were treated with VPA as compared to control treated cells (Fig. 3.5). The decrease in 
the expression was concentration-dependent and partially also time-dependent (Fig. 3.5). 
However, the two receptor tyrosine kinases Flt-1/Vegfr1 and Kdr/Vegfr2 were statistically 











Fig. 3.5: Expression analyses of angiogenesis markers in PCa cells after VPA treatment. The mouse PCa 2E 
cells were treated for 72 and 144 hours with either 1mM or 5mM VPA in vitro. Cells that were not treated with VPA 
served as control. RNA was isolated from which cDNA was generated by reverse transcription. Using this cDNA the 
expression of the following six angiogenesis markers was analyzed by quantitative real-time PCR analysis: two 
angiogenic cytokines (Vegfa and Ang1), three endothelial cell receptor tyrosine kinases (Flt-1/Vegfr1, Kdr/Vegfr2, Tie-
1), and one endothelial cell adhesion molecule (Pecam-1). In vitro VPA treatment resulted in a decreased expression 
of Vegfa, Ang1, Tie-1 and Pecam-1. The downregulation of these genes after VPA treatment was concentration- and 
also mostly time-dependent. The two receptor tyrosine kinases Flt-1/Vegfr1 and Kdr/Vegfr2 had an increased 
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expression after VPA treatment as compared to control cells. This effect was also concentration-dependent. Data are 
presented as mean +/- standard deviation of three quantitative real-time PCR analyses performed in triplicate. * 0.01 
< p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001 
 
Tumors grow and spread not only by blood angiogenesis but also by lymphangiogenesis. To 
differentiate between these two angiogenesis options the components of the VEGF-system are 
helpful because some components induce mainly blood angiogenesis, i.e. VEGFA when binding 
to the VEGFR2 receptor (Cursiefen et al., 2004). Other components induce mainly 
lymphangiogenesis, i.e. VEGFC when binding to VEGFR2 or VEGFR3 (Skobe et al., 2001) or 
inhibit lymphangiogenesis, like the soluble form of VEGFR2 (sVEGFR2, Albuquerque et al., 
2009). 
To study the effects of VPA treatment on blood- and lymphangiogenesis in vitro the expression 
of the different VEGF-system components was analyzed by quantitative real-time PCR. 
Therefore, the mouse PCa cells 2E and the human PCa cells PC-3 were treated for 72 and 144 
hours with different VPA concentrations (1mM and 5mM). RNA was isolated from the PCa cells 
and reverse transcribed into cDNA which was then used for quantitative real-time PCR analyses. 
The expression of the ligands Vegfa and Vegfc was analyzed as well as the expression of the 
receptors Flt-1/Vegfr1 and Kdr/Vegfr2 and of sVegfr2. Untreated PCa cells served as control. 
Some components of the VEGF-system were already analyzed for the murine 2E PCa cells 
within the set of angiogenesis markers (see Fig. 3.5) and are presented here again to visualize 
the relation of the different components of the VEGF-system.  
In 2E PCa cells the expression of the ligands Vegfa and Vegfc was decreased, whereas the 
expression of the receptors Flt-1/Vegfr1 and Kdr/Vegfr2 increased in a concentration-dependent 
manner after VPA treatment as compared to untreated control cells (Fig. 3.6A). In human PC-3 
PCa cells the expression of VEGFA decreased when cells were treated with 1mM VPA but 
increased after treatment with a 5mM concentration for 72 hours. After 144 hours of VPA 
treatment VEGFA expression was decreased compared to untreated PC-3 cells. The FLT-
1/VEGFR1 expression was decreased in PC-3 cells after VPA treatment for both time points. 
The VEGFC, KDR/VEGFR2 and sVEGFR2 expression was increased in PC-3 cells after VPA 
treatment for 72 hours as compared to untreated control cells. This effect was abolished after 
144 hours of VPA treatment (Fig. 3.6B). 
The differential expression of the VEGF-system components in PCa cells after VPA treatment 
compared to untreated cells highlights the beneficial effects of VPA treatment in PCa cells. 
Downregulation of the ligands and receptors of the VEGF-system after VPA treatment indicate 
that there is decreased expression of factors which play a role in blood or lymphangiogenesis. 
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Also by upregulation of sVEGFR2 there is a competition of VEGFC binding to either 
KDR/VEGFR2 or sVEGFR2 which would also result in reduced lymphangiogenesis. 
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Fig. 3.6: Expression analyses of VEGF-system components in PCa cells. The mouse 2E PCa cells (A) and the 
human PC-3 PCa cells (B) were treated for 72 hours and 144 hours with 1mM VPA and 5mM VPA, respectively. RNA 
was isolated and transcribed into cDNA on which the expression of some components of the VEGF-system was 
analyzed by quantitative real-time PCR. Cells without VPA treatment served as controls. A) In 2E cells the expression 
of Vegfa and Vegfc decreased in a concentration-dependent manner after VPA treatment as compared to untreated 
cells, whereas the expression of the receptors Flt-1/Vegfr1 and Kdr/Vegfr2 increased in a concentration-dependent 
manner after VPA treatment. B) In PC-3 cells the expression of VEGFA decreased when the cells were treated with 
1mM VPA but increased after treatment with a 5mM concentration of VPA for 72 hours. After 144 hours of VPA 
treatment the VEGFA expression was decreased compared to untreated cells. The FLT-1/VEGFR1 expression was 
decreased after VPA treatment for both time points. The VEGFC, KDR/VEGFR2 and sVEGFR2 expression was 
increased after VPA treatment for 72 hours as compared to untreated control cells. This effect was abolished after 
144 hours of VPA treatment. Data are presented as mean +/- standard deviation of three quantitative real-time PCR 
analyses performed in triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001 
 
3.1.2.1.1 Is the Vegfr2 signaling pathway activated by VPA treatment? 
 
Quantitative real-time PCR analysis of VPA-treated 2E cells revealed an increased expression 
of the two receptor tyrosine kinases Flt-1/Vegfr1 and Kdr/Vegfr2 as compared to control-treated 
cells (Fig. 3.5). In order to find out whether the increased expression is correlated to an increased 
activation of the VEGFR signaling pathway the phosphorylation status of one of the two 
receptors, namely pKDR/pVEGFR2 was analyzed on protein level by western blot analysis 
(Fig.3.7), which was then subject to densitometrical evaluation (Fig.3.7, the values are indicated 
underneath the western blot). Densitometrical evaluation of the western blot revealed an 
increased pKDR/pVEGFR2 expression in VPA-treated 2E cells as compared to controls. This 
effect was weak in cells that were treated for 72 hours with VPA but more pronounced in cells 
that were treated for 144 hours with VPA. This indicates that the increased Kdr/Vegfr2 
expression in VPA-treated 2E cells is accompanied with an increased activation of the VEGFR2 
signaling pathway as seen by increased pKDR/pVEGFR2 expression in the same cells. 
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Fig. 3.7: pKDR/VEGFR2 levels in VPA-treated 2E cells. Whole protein lysate of 2E cells treated with either 1mM or 
5mM VPA for 72 or 144 was immunoblotted using a pKDR/pVEGFR2-specific antibody. Protein lysate of untreated 
cells served as controls. Immunoblotting of HSC70 ensured equal protein loading. The western blot was evaluated 
densitometrically and the values are depicted underneath the western blot. Densitometrical analysis revealed an 
increase in pKDR/pVEGFR2 expression in VPA-treated 2E cells as compared to control-treated cells. This effect was 
more pronounced in cells that were treated for 144 hours with VPA then in cells that were treated for only 72 hours 
with VPA.  
 
3.1.2.2 Effect of in vivo VPA treatment on the expression of blood- and lymph- 
angiogenesis markers 
 
The expression of the six angiogenesis markers, namely Vegfa, Ang1, Tie-1, Flt-1/Vegfr1, 
Kdr/Vegfr2 and Pecam-1 was analyzed by quantitative real-time PCR on RNA isolated from the 
prostate of mice that received 10 weeks of in vivo VPA treatment. Only the expression of Flt-
1/Vegfr1 was statistically significant downregulated in the prostate of VPA-treated mice as 
compared to control-treated mice (Fig.3.8). All other factors, namely Ang1, Tie-1, Kdr/Vegfr2 and 
Pecam-1 showed a reduced expression after VPA treatment in the mouse prostate, but this 
effect was not statistically significant. Vegfa was not differentially expressed in the prostate of 
VPA-treated mice as compared to control-treated mice (Fig.3.8). 




Fig. 3.8: Expression analyses of angiogenesis markers in prostate tissue of in vivo VPA-treated TRAMP mice. 
RNA was isolated from prostate tissue of in vivo VPA-treated TRAMP mice and of control-treated mice. RNA was 
reverse transcribed into cDNA and quantitative real-time PCR analysis for expression of the angiogenesis markers 
Vegfa, Ang1, Tie-1, Flt-1/Vegfr1, Kdr/Vegfr2 and Pecam-1 was conducted. VPA treatment led to a statistically 
significant reduction of Flt-1/Vegfr1 expression (p= 0.0409). Ang1, Tie-1, Kdr/Vegfr2 and Pecam-1 also exhibited a 
reduced expression in the prostate tissue after VPA treatment but this effect was not statistically significant. Vegfa 
was equally expressed in the prostate of VPA- and control-treated TRAMP mice. Data are presented as mean +/- 
standard deviation of three quantitative real-time PCR analyses performed in triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p 
< 0.01, *** p ≤ 0.001, n.s.: not significant 
 
The expression of the six angiogenesis markers Vegfa, Ang1, Tie-1, Flt-1/Vegfr1, Kdr/Vegfr2 
and Pecam-1 was also analyzed by quantitative real-time PCR on RNA isolated from prostate 
tumor tissue of in vivo VPA-treated TRAMP mice and control-treated TRAMP mice (first in vivo 
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VPA experiment conducted by D. Witt, 2012). RNA was reverse transcribed into cDNA before it 
was subjected to quantitative real-time PCR (Fig. 3.9). In the prostate tumors of VPA-treated 
TRAMP mice a statistically significant reduction of Ang1, Vegfa, Tie-1 and Kdr/Vrgfr2 expression 
was observed as compared to control-treated mice. Pecam-1 expression was also 
downregulated after VPA treatment, although not statistically significant. The expression of Flt-
1/Vegfr1 was similar in prostate tumors of VPA-treated mice and control-treated mice (Fig.3.9). 
Taken together these results indicate that inhibition of expression of angiogenesis markers by 
VPA treatment could play a more important role during tumor progression than in the beginning 
of tumor development. 
 
Fig. 3.9: Expression analysis of angiogenesis markers in PCa tumors of in vivo VPA-treated TRAMP mice. 
RNA was isolated from prostate tumor tissue of in vivo VPA-treated TRAMP mice and of control-treated mice. RNA 
was reverse transcribed into cDNA and quantitative real-time PCR analyses were conducted for expression analysis 
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of the angiogenesis marker Vegfa, Ang1, Tie-1, Flt-1/Vegfr1, Kdr/Vegfr2, and Pecam-1. VPA treatment led to a 
statistically significant reduction of Vegfa (p=0.0226), Ang1 (p=0.0427), Tie-1 (p=0.0462) and Kdr/Vegfr2 (p=0.0410) 
as compared to prostate tumor tissue of control-treated mice. The expression of Flt-1/Vegfr1 and Pecam-1 was not 
statistically significant deregulated in prostate tumor tissue of VPA-treated TRAMP mice as compared to prostate 
tumor tissue of control-treated mice. Data are presented as mean +/- standard deviation of three quantitative real-
time PCR analyses performed in triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001, n.s.: not significant 
 
3.1.2.3 Studying the influence of VPA on angiogenesis in vivo – CAM experiments 
 
Both VPA in vitro and in vivo experiments point to the fact that VPA could have an important 
influence on angiogenesis during PCa progression. Therefore, to study the effects of VPA 
treatment on tumor angiogenesis in vivo, the chicken chorioallantoic membrane (CAM) assay 
was conducted in cooperation with Prof. Dr. Jörg Wilting from the Center of Anatomy, University 
Medical Center Göttingen. The chicken embryo CAM is an extraembryonic membrane rich of 
blood vessels and therefore suitable to study the effects of a substance on angiogenesis. Tumor 
cells applied to the CAM, together with matrigel as a carrier, will form solid tumors which can be 
harvested and used for molecular evaluation. 
For the CAM experiment the mouse PCa cells 2E and the human PCa cells PC-3 were used. 
Prior to the application to the CAM the PCa cells were either pre-treated with VPA for 24 hours 
(experiment 1), for 1 week (experiment 3) or not pre-treated at all (experiment 2). Also different 
concentrations of VPA were tested (1mM VPA or 3mM VPA, Table 3.1).  
 
Table 3.1: CAM experiments conducted with human and mouse PCa cells. Depicted are the three different CAM 
experiments conducted during the present study along with the respective PCa cell line and VPA concentration used 
to treat the cells. 
1. experiment 2E and PC-3 cells, 24 hours pre-treatment with 1mM VPA 
2. experiment 2E and PC-3 cell, no pre-treatment, 3mM VPA on the day of 
application to the CAM 
3. experiment 2E cells, one week pre-treatment with 3mM VPA 
 
Pre-treated or non-pre-treated PCa cells were applied to the CAM and three days thereafter the 
growing tumor was treated again with VPA in the corresponding concentration. The developed 
tumors were harvested after one week and fixed or otherwise prepared for further studies, 
including immunohistochemistry and molecular expression analysis by quantitative real-time 
PCR. Three different CAM experiments were conducted (Table 3.1).  
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3.1.2.3.1 Macroscopic analysis of the CAM tumors 
 
The macroscopic analysis revealed three different effects in which the angiogenesis of the CAM 
tumor could be influenced. First, untreated 2E and PC-3 cells as well as VPA-treated cells could 
severely disturb angiogenesis as seen by bloodshot tumors (Fig 3.10A). The second effect in 
which CAM tumor angiogenesis could be affected was observed by bloody spots within the CAM 
tumor (Fig 3.10B). Finally, the blood vessel formation around the CAM tumor could also be 
severely affected as seen by disturbed blood vessels (Fig 3.10C). 
 
Fig. 3.10: Three examples in which CAM angiogenesis can be affected. These exemplary pictures of CAM tumors 
derived from VPA-treated and untreated control 2E cells were chosen to demonstrate three different effects on CAM 
tumor angiogenesis compared to an unaffected tumor. The effects were generally observed in all tree CAM 
experiments for tumors raised from VPA-treated as well as from untreated control cells. A) Tumor angiogenesis could 
be influenced in that way, that the tumors were severely bloodshot as compared to unaffected tumors. B) Bloody 
spots within the CAM tumor, as indicated by the arrow, were also observed. C) Affected tumors displayed disturbed 
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blood vessel formation around the tumor, indicated by the arrow, as compared to an unaffected tumor. The pictures 
were taken at an inverted microscope, at a 9x magnification (A), 11x magnification (C) and 19x magnification (B). 
 
For the three CAM experiments the number of bloodshot tumors, tumors with bloody spots and 
tumors with disturbed vessel formation was calculated for tumors developed from VPA-treated 
and untreated control cells (Fig. 3.11). In the first experiment tumors resulting from VPA-treated 
2E cells showed bloody spots or were bloodshot, whereas tumors resulting from untreated 
control 2E cells only showed disturbed blood vessel formation (Fig. 3.11A). In the second 
experiment, where the cells were not pre-treated with VPA, only with 3mM VPA on the day of 
application to the CAM, tumors derived from VPA-treated 2E cells were more often bloodshot 
than tumors resulting from untreated control 2E cells (Fig 3.11A). This finding is in accordance 
to the first experiment with VPA-treated 2E cells. In the third experiment, VPA treatment of the 
2E cells resulted in a slightly reduced number of bloodshot tumors, a stronger reduction of 
tumors with bloody spots, and an increase in tumors with disturbed blood vessel formation 
(Fig.3.11B). These results from the third experiment are contrary to the observations from the 
previous two experiments. 
Tumors derived from VPA-treated PC-3 cells in the first experiment were not bloodshot at all, 
whereas tumors resulting from control PC-3 cells were bloodshot (Fig. 3.11B). VPA treatment of 
the PC-3 cells also resulted in an increased number of tumors with bloody spots as well as with 
disturbed blood vessel formation compared to tumors resulting from untreated control PC-3 cells 
(Fig. 3.11B). In the second experiment, tumors resulting from VPA-treated PC-3 cells showed a 
reduced number of bloodshot tumors compared to tumors derived from untreated control PC-3 
cells, as compared to the observation in the first experiment (Fig. 3.11B). Contrary to the first 
experiment, treatment of PC-3 cells with 3mM VPA resulted in reduced number of tumors with 
disturbed blood vessel formation as compared to tumors derived from untreated control cell (Fig. 
3.11B).  
Taken together, a general effect of VPA treatment in PCa cells on the phenotype of CAM tumors 
could not be observed, since within the experiments for one cell line the phenotypic 
characteristics did not correlate (except for PC-3 cell tumors, which in both experiments had a 
reduced number of bloodshot tumors when the cells were treated with VPA) and they also did 
not correlate within the two cell lines.  




Fig. 3.11: Macroscopic analysis of the CAM tumors. For three different CAM experiments the CAM tumors resulting 
from VPA-treated and control cells were macroscopically analyzed and the number of bloodshot tumors, tumors with 
bloody spots and tumors with disturbed blood vessel formation was calculated. In the first experiment, tumors resulted 
from 2E and PC-3 cells that were pre-treated with 1mM VPA for 24 hours. In the second experiment, tumors resulted 
from 2E and PC-3 cells that were not pre-treated with VPA, only on the day of application to the CAM with 3mM VPA. 
In the third experiment tumors resulted from 2E cells that were pre-treated with 3mM VPA for 1 week. A) Macroscopic 
analysis of the CAM tumors of all three CAM experiments conducted with 2E cells. B) Macroscopic analysis of the 
CAM tumors of the two CAM experiments using PC-3 cells. 
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3.1.2.3.2 Analysis of CAM tumor volume 
 
Based on the macroscopic pictures the tumor volume was calculated by use of the modified 
ellipsoid formula 1/2(length × width2). 2E cell and PC-3 cell tumors derived from cells that were 
pre-treated with 1mM VPA for 24 hours and treated again with 1mM VPA on the day of 
application to the CAM showed a slightly reduced but no statistically significant difference in the 
tumor volume as compared to tumors derived from untreated control cells (Fig. 3.12A). On the 
other hand, tumors derived from cells that were only treated with 3mM VPA on the day of 
application to the CAM had a slightly increased tumor volume as compared to tumors derived 
from untreated control cells, although this effect was also not statistically significant (Fig. 3.12B). 
2E cell tumors derived from cells that were pre-treated with 3mM VPA for one week and again 
treated with 3mM VPA on the day of application to the CAM had a not statistically significant 
reduced tumor volume as compared to untreated cells (Fig. 3.12C). These results indicate that 
only tumors derived from VPA pre-treated PCa cells led to a reduced tumor volume as compared 
to untreated control cells. PCa cells that were not pre-treated with VPA rather resulted in tumors 
with an increased tumor volume compared to untreated control cells. Since it is known that VPA 
treatment has an inhibitory effect on cell proliferation and this could not be confirmed in VPA-
treated CAM tumors it appears that the CAM model is not a suitable model for studies with VPA. 




Fig. 3.12: Tumor volume of CAM tumors derived from VPA-treated PCa cells. The tumor volume of CAM tumors 
derived from VPA- and control-treated 2E and PC-3 cells was calculated by the modified ellipsoid formula based on 
the macroscopic pictures of the tumors. Tumors derived from untreated PCa cells served as control. Cells that were 
applied to the CAM were either pre-treated with VPA for 24 hours (A), for 1 week (C) or not pre-treated at all (B). Also 
different concentrations of VPA were tested (1mM VPA (A) or 3mM VPA (B, C). A) 2E and PC-3 cell tumors derived 
from cell that were pretreated with 1mM VPA for 24 hours and again treated with 1mM VPA on the day of application 
to the CAM had a not statistically significant reduced tumor volume as compared to tumors derived from untreated 
control cells. B) 2E and PC-3 cell tumors derived from cells that were treated with 3mM VPA on the day of application 
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to the CAM had a slightly increased, also not statistically significant, tumor volume as compared to tumors derived 
from the control-treated cells. C) 2E cell tumors that were derived from cells that were pre-treated with 3mM VPA for 
one week and again treated with 3mM on the day of application to the CAM had reduced, but not statistically 
significant, tumor volume as compared to tumors derived from untreated control cells. 
 
3.1.2.3.3 Studying blood and lymphangiogenesis in the CAM tumors with the markers 
Mep21 and Prox1 
 
To differentiate the effect of in vivo VPA treatment on lymphatic and blood vessels 
immunofluorescence staining was performed on 2E and PC-3 cell-derived CAM tumors. 
Sections of the CAM tumors were stained by immunofluorescence with the blood vessel marker 
Mep21 (CD34 homolog) and with the lymphatic vessel marker Prox1 (Wigle et al. 2002, Wilting 
et al. 2002, Hong et al. 2002). The immunofluorescence analysis of tumors grown from untreated 
mouse 2E and human PC-3 PCa cells revealed that 2E cell tumors had a prominent Mep21 
staining and also some Prox1-positive vessels (Fig. 3.13B,C) whereas PC-3 cell tumors had a 
very prominent staining for Prox1- and Mep21-positive vessels (Fig.3.13F,G). This indicated that 
tumors of the 2E cell tumors grow mainly by blood angiogenesis and PC-3 cell tumors by blood- 
and lymphangiogenesis. 
 
Fig. 3.13: Immunofluorescence staining of blood and lymphatic vessels in untreated 2E and PC-3 tumors. 
Immunofluorescence staining of cryosections from 2E cell CAM tumors (A-D) and PC-3 cell CAM tumors (E-H). 
Pictures show staining of blood- and lymphatic vessels in CAM tumors. Cells were stained with DAPI (blue in A, E), 
anti-Mep21 (green in B, F) and anti-Prox1 (red in C, G). A, E) 2E and PC-3 cells can be discriminated from the chicken 
cells due to their large nuclei. B, F) Mep21 staining of chicken blood vessel capillaries is very prominent in the 2E and 
PC-3 cell tumors. C, G) Prox1 staining of chicken lymphatic endothelial cells. PC-3 cell tumors exhibit a very prominent 
Prox1 staining. D, H) Merged pictures.  
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CAM tumor cryo-sections derived from 3mM VPA-treated 2E and PC-3 cells were also subjected 
to Mep21 and Prox1 immunofluorescent staining. Analysis of VPA-treated 2E cell tumors 
showed no significant differences in the Mep21 and Prox1 staining as compared to tumors 
derived from untreated 2E cells (data not shown). Analysis of VPA-treated PC-3 cells tumors led 
to the impression that they had a reduced number of Prox1-positive cells as compared to tumors 
derived from untreated PC-3 cells, whereas the Mep21 expression seemed not to be different 
(data not shown). Since Prox1 stains the nuclei of lymphatic endothelial cells the number of 
Prox1-positive cells can be calculated. Therefore, the number of Prox1-positive cells in tumors 
derived from 3mM VPA-treated PC-3 cells und untreated control PC-3 cells was calculated (2. 
experiment). The tumor was divided in three sections in order to see differences in how far into 
the tumor lymphangiogenesis had progressed. The first section was above the CAM layer, the 
second section was the middle part of the tumor and the third part was the distal tumor part 
(Fig.3.14). 
 
Fig. 3.14: Schematic presentation of the three different sections of the CAM tumor. The CAM tumor was divided 
in three different sections in order to compare the number of Prox1-positive cells in each of the sections. Prox1 stains 
nuclei of chicken lymphatic endothelial cells. The CAM layer was designated as the first section. It can be 
discriminated from the tumor by the smaller nuclei of chicken cells compared to the bigger tumor cells as seen by 
DAPI staining. The designated second section was the middle part of the tumor. The distal tumor part was the third 
section, which contained the least Prox1-positive cells. 
 
Counting of Prox1-positive cells within the tumors did not reveal a statistically significant reduced 
number of Prox1-positive cells within the tumors of VPA-treated PC-3 cells as compared to 
tumors raised from control cells. But, in the distal tumor part a reduced number of Prox1-positive 
cells was observed when the tumor was raised from VPA-treated cells compared to control 
tumors. Whereas the number of Prox1-positive cells was rather increased in the layer right above 
the CAM and the middle tumor part (Fig. 3.15). However, increased Prox1 staining in the CAM 
part and in the middle tumor part is in accordance to the quantitative real-time PCR analysis of 
the VEGF-system components in untreated and VPA-treated PC-3 cells, where VPA treatment 
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resulted in an increased VEGFC expression, which induces mainly lymphangiogenesis by 
binding to VEGR2 or VEGFR3 (see Fig. 3.6B). 
 
Fig. 3.15: Number of Prox1 positive cells in the CAM tumors. The number of Prox1-positive cells in tumor sections 
of PC-3 cell CAM tumors was calculated. The number of Prox1-positive cells in tumors derived from 3mM VPA-treated 
PC-3 cells was compared to the number of Prox1-positive cells in tumors derived from untreated control PC-3 cells. 
The mean of Prox1-positive cells was calculated for three slides which each consisted of three tumor slices. VPA 
treatment of the PC-3 cells resulted in an increased number of Prox1-positive cells within the middle part of the tumor 
and the tumor part right on top of the CAM as compared to Prox1-positive cells in tumors derived from untreated 
control PC-3 cells whereas in the distal tumor part the number of Prox1-positive cells was reduced, although not 
statistically significant. 
 
3.1.2.3.4 Expression analysis of angiogenesis markers in CAM tumors 
 
RNA was isolated from a whole CAM tumor (1. experiment, 2E and PC-3) or from half of a  
CAM tumor (3. experiment, 2E). From the second CAM experiment no RNA was isolated. For 
the PC-3 cell tumors from the first experiment the expression of the members of the VEGF-
system and other angiogenesis markers was analyzed as well as the expression of CP and 
CCND2. No significant differences in the expression of the VEGF-system members nor CP and 
CCND2 was observed between tumors grown from untreated control PC-3 cells and VPA-treated 
PC-3 cells although VPA treatment of the cells seemed to slightly increase the expression of 
most of the genes tested (Fig. 3.16A). For the 2E cell tumors from the first CAM experiment the 
expression of the angiogenesis markers Vegfa, Vegfc, Ang1, Tie-1, Flt-1/Vegfr1, Kdr/Vegfr2 and 
Pecam-1 was analyzed, as well as the expression of the angiogenesis-related candidate genes 
Cp1, Cp2 and Cxcl15 from the microarray (Witt, 2009) and Ccnd2. The expression of Ccnd2 
was examined as a control for the VPA treatment of cells because it is known that VPA treatment 
leads to a dramatic (about 200x) increase in the Ccnd2 expression in 2E cells. Indeed an 
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increase in the Ccnd2 expression in the VPA-treated 2E cell CAM tumors could be observed, 
although this observation was not statistically significant (Fig. 3.16B). Cp1 expression in VPA-
treated CAM tumors was statistically significant downregulated (p=0.0347) and the expression 
of Vegfa had a strong tendency towards upregulation (Fig. 3.16B). The other tested genes were 
not significantly deregulated in the tumors of VPA-treated or untreated control 2E cells but their 
expression was rather increased. The only genes that were downregulated after VPA treatment 
in 2E cell CAM tumors were Cp1, Cp2 and Cxcl15, of which solely Cp1 was statistically 
significant.  








Fig. 3.16: Expression analyses of angiogenesis markers and members of the VEGF-system in CAM tumors of 
the first experiment. The expression of the angiogenesis markers, angiogenesis-related candidate genes from the 
previous array experiment (Witt, 2009) and of some members of the VEGF-system was analyzed on cDNA generated 
from CAM tumors that have either developed from VPA-treated PC-3 cells (A) or VPA-treated 2E cells (B) from the 
first experiment (24 hours pre-treatment with 1mM VPA). Tumors derived from untreated PCa cells served as control. 
3. Results  - 84 - 
 
 
The expression of the following genes was analyzed: VEGFA, ANG1, TIE-1, PECAM-1, FLT-1/VEGFR1, 
KDR/VEGFR2, sVEGFR2, VEGFC, Cp1 and Cp2 (mouse), CP (human) and CXCL15. The expression of CCND2 was 
analyzed to show that the VPA treatment was functional because it is known that VPA treatment leads to a major 
increase in Ccnd2 expression in mouse 2E cells. A) VPA treatment of PC-3 cells resulted in no statistically significant 
expression differences of the genes analyzed in the CAM tumors as compared to control tumors. B) CAM tumors 
derived from VPA-treated 2E cells had a statistically significant reduced Cp1 expression (p=0.0347) as compared to 
control tumors. The expression of the other genes analyzed was not statistically significant affected after VPA 
treatment in CAM tumors. Data are presented as mean +/- standard deviation of three quantitative real-time PCR 
analyses performed in triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001, n.s.: not significant 
 
The expression of angiogenesis markers and of some members of the VEGF-system was also 
analyzed for tumors of the third CAM experiment (2E cells only, 1 week pre-treatment with 3mM 
VPA, Fig. 3.17). Vegfa was statistically significant upregulated in tumors derived from VPA-
treated cells compared to tumors developed from untreated control cells (p=0.0373). The 
expression of Ccnd2 was also significantly upregulated (p=0.0428) which is in accordance to the 
microarray result of VPA-treated 2E cells, which also had an increased Ccnd2 expression 
compared to untreated control cells (Witt, 2009). Flt-1/Vegfr1 expression was not yet statistically 
significant (p=0.0874). The other genes were not statistically significant deregulated in tumors 
derived from VPA-treated cells as compared to controls (Fig. 3.17). Generally, the expression of 
all genes tested was increased after VPA treatment compared to controls in CAM tumors. 
Although it was shown in the previous experiments that in vitro and in vivo VPA treatment 
influences the expression of candidate genes and angiogenesis-related genes this could not be 
observed and confirmed in studies using the CAM model which further indicates that maybe the 
CAM model is not the appropriate model for VPA studies. 




Fig. 3.17: Expression analyses of angiogenesis markers and members of the VEGF-system in CAM tumors of 
the third experiment. The expression of angiogenesis markers, angiogenesis-related candidate genes from the array 
(Witt, 2009) and of some members of the VEGF-system was analyzed on cDNA generated from CAM tumors derived 
from VPA-treated or control-treated 2E cells from the 3. experiment (1 week pre-treatment with 3mM VPA). The 
3. Results  - 86 - 
 
 
expression of the following genes was analyzed: Vegfa, Ang1, Tie-1, Pecam-1, Flt-1/Vegfr1, Kdr/Vegfr2, Vegfc, Cp1 
and Cp2. The expression of Ccnd2 was analyzed to show that the VPA treatment was functional because it is known 
that VPA treatment leads to a major increase in Ccnd2 expression. CAM tumors risen from VPA-treated 2E cells had 
a statistically significant upregulated expression of Vegfa (p=0.0373) and Ccnd2 (p=0.0428) as compared to control 
tumors. The expression of the other genes analyzed was not statistically significantly affected after VPA treatment. 
Data are presented as mean +/- standard deviation of three quantitative real-time PCR analyses performed in 
triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001, n.s.: not significant 
 
3.2 Is cyclin D2 a tumor suppressor gene in PCa? 
 
3.2.1 Cyclin D2 overexpression studies in human PCa cells 
 
In order to verify the hypothesis that cyclin D2 is a tumor suppressor gene in PCa overexpression 
studies were conducted. Cyclin D2 is known to be downregulated in PCa due to 
hypermethylation of the promoter region. Witt et al. (2013) could demonstrate a VPA-induced 
re-expression of Ccnd2 due to increased acetylation of the Ccnd2 promoter region. Since the 
re-expression was accompanied with proliferation inhibition, which was only observed in PCa 
cells but not in fibroblast cells or other cancer cells, it is of great interest to investigate the role 
of cyclin D2 in PCa. 
Human PCa cell lines, which have an undetectable low basal cyclin D2 expression, were 
transfected with a cyclin D2 expression vector and the functional effects were analyzed. If cyclin 
D2 is indeed a tumor suppressor then these human PCa cells that overexpress cyclin D2 should 
exhibit less features of a cancer cell, e.g. reduced proliferation and migration rates. 
 
3.2.1.1 Transient overexpression of cyclin D2 in human PCa cells 
 
Initially the human PCa cells were transiently transfected with the generated pIRES2-EGFP-
CCND2 expression vector to investigate whether the transient overexpression of cyclin D2 might 
be sufficient to induce its supposed anti-tumorous effects as a putative tumor suppressor. 
 
3.2.1.1.1 Generation of the pIRES2-EGFP-CCND2 expression vector 
 
An 870 bp fragment of the cyclin D2 open reading frame was amplified from CaCo2 cDNA by 
touchdown PCR using the primers CCND2-Fw-Xho and CCND2-Rev-Eco. The amplicon was 
first cloned successfully into the pGEM®-T Easy vector (data not shown). Thereafter the cyclin 
D2 insert was excised from pGEM®-T Easy vector and ligated to the pIRES2-EGFP vector. Test 
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digestion with the restriction enzymes XhoI and EcoRI (Fig 3.18) and subsequent sequencing 
reaction (data not shown) of the clones 7 and 9 showed the successful integration of the 870 bp 
cyclin D2 insert into the pIRES2-EGFP vector. 
 
Fig. 3.18: Test digestion of two different pIRES2-EGFP-CCND2 clones. The pIRES2-EGFP-CCND2 clones were 
digested with the restriction enzymes XhoI and EcoRI. The cyclin D2 insert consisting of 870 bp could be successfully 
excised from the 5.3 kb pIRES2-EGFP vector. 1kb: 1Kb Plus DNA-ladder 
 
The established human PCa cells DU145, LNCaP and PC-3 were transiently transfected with 
the generated pIRES2-EGFP-CCND2 expression vector using Metafectene® Pro transfection 
reagent. Two days after transfection protein was isolated from the PCa cells to confirm the 
overexpression of cyclin D2 by western blot analysis. PCa cells that were transfected with the 
empty pIRES2-EGFP vector were used as controls. For all three human PCa cell lines a very 
strong expression of cyclin D2 could be detected after transient transfection with the pIRES2-
EGFP-CCND2 expression vector. In contrast, the control-transfected PCa cells showed no cyclin 
D2 expression (Fig. 3.19). 
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Fig. 3.19: Confirmation of the overexpression of cyclin D2 in human PCa cells after transient transfection with 
pIRES2-EGFP-CCND2. Whole protein lysates of the PCa cells DU145, LNCaP and PC-3 cells transiently transfected 
with the generated pIRES2-EGFP-CCND2 expression vector were immunoblotted using a cyclin D2-specific antibody. 
All three cell lines transfected with the empty pIRES2-EGFP expression vector had no cyclin D2 expression in contrast 
to the strong cyclin D2 expression in PCa cells transfected with the generated pIRES2-EGFP-CCND2 vector. 
Immunoblotting of α-tubulin ensured equal protein loading. 
 
3.2.1.1.2 Studies on the proliferation rate of PCa cells with transient cyclin D2 over-
expression 
 
The PCa cells DU145, LNCaP and PC-3 were transiently transfected with the pIRES2-EGFP-
CCND2 expression vector. Cells transfected with the empty pIRES2-EGFP vector served as 
controls. The following day the transfected cells were plated into 96- well plates and the 
proliferation rate was measured every 24 hours for 4 days by a MTT assay.  
DU145 cells overexpressing cyclin D2 had a statistically significant increase in the proliferation 
rate 24 hours after transfection as compared to control cells transfected with the empty pIRES2-
EGFP vector. The increase in proliferation rate was abolished over the next three days and no 
differences in the proliferation rate between cyclin D2 overexpressing and control cells could be 
detected (Fig.3.20). LNCaP and PC-3 cells with transient cyclin D2 overexpression also had a 
similar proliferation rate as compared to control cells (data not shown). 
 
Fig. 3.20: Analysis of the proliferation rate of DU145 cells transiently overexpressing cyclin D2. The human 
PCa cells DU145 were transiently transfected with the pIRES2-EGFP-CCND2 expression vector. The proliferation 
rate was measured by a MTT assay every 24 hours for 5 days beginning the day after transfection. After 24 hours 
there was a statistically significant increase in the proliferation rate of cells transfected with the cyclin D2 expression 
vector as compared to the control cells transfected with the empty pIRES2-EGFP vector. The increase in the 
proliferation rate was abolished over the next three days and no differences in the proliferation rate between cyclin 
D2 overexpressing and control PCa cells could be detected. Data are presented as mean +/- standard deviation of 
three proliferation assays. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001 
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3.2.1.2 Stable overexpression of cyclin D2 in human PCa cells 
 
Since the transient overexpression of cyclin D2 did not result in any changes or the expected 
reduction in the proliferation rate as compared to control transfected cells, a different approach 
was used to verify the hypothesis that cyclin D2 could serve as a tumor suppressor gene in PCa. 
Presumably a constant overexpression of cyclin D2 is necessary to exhibit its′ anti tumorous 
effects while the transient overexpression of cyclin D2 is not sufficient to induce any functional 
effects in PCa cells.  
Next, PCa cell clones were generated that exhibited a stable overexpression of cyclin D2. For 
this experiment two different strategies were used, i.e. on the one hand, PCa cell clones were 
generated where the overexpression of cyclin D2 was inducible by treatment with doxycycline 
(transfection with pEBTetD-CCND2) and on the other hand, cell clones were generated which 
constitutively overexpress cyclin D2 (transfection with pIRES2-EGFP-CCND2).  
 
3.2.1.2.1 Generation of the pEBTetD-CCND2 expression vector 
 
An 870 bp fragment of the cyclin D2 ORF was amplified from CaCo2 cDNA by touchdown PCR 
using the primers CCND2-Fw-Kpn and CCND2-Rev-Eco. The amplicon was first cloned 
successfully into the pGEM®-T Easy vector (data not shown). Thereafter the cyclin D2 insert 
was excised from pGEM®-T Easy vector and ligated to the pEBTetD vector. Test digestion with 
the restriction enzymes KpnI and NotI (Fig. 3.21) and subsequent sequence analysis (data not 
shown) of one clone showed the successful integration of the 870 bp cyclin D2 insert into the 
pEBTetD vector. 
 
Fig. 3.21: Test digestion of a pEBTetD-CCND2 clone. The pEBTetD-CCND2 clone was digested with the restriction 
enzymes KpnI and NotI. The 870 bp cyclin D2 insert could be successfully excised from the 11.5 kb pEBTetD vector. 
1kb: 1Kb Plus DNA-ladder 
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The established human PCa cells LNCaP and PC-3 were transfected with the generated 
pEBTetD-CCND2 expression vector using Metafectene® Pro transfection reagent for inducible 
overexpression of cyclin D2 by treatment with doxycycline. Starting the following day after 
transfection cells were selected by puromycin treatment. Since the vector does not integrate into 
the genome but exists as an episomal plasmid within the cytoplasm there was no need for clonal 
isolation of transfected cells (Bach et al., 2007). Cells that had taken up the pEBTetD-CCND2 
expression vector with the puromycin resistance cassette were further cultured in the presence 
of puromycin. To test for successful uptake of the expression vector and inducibility of cyclin D2 
expression protein was isolated and analyzed by western blot analysis. For this approach two 
different LNCaP cell populations with a doxycycline-inducible expression of cyclin D2 could be 
established (LNCaP+pEBTetD-CCND2-1 and LNCaP+pEBTetD-CCND2-2) as well as one 
LNCaP cell population that was transfected with the empty pEBTetD plasmid (LNCaP+pEBTetD) 
which served as a negative control (Fig. 3.22). There is a strong induction of cyclin D2 expression 
72 hours after the two LNCaP cell populations were treated with different concentrations of 
doxycycline. LNCaP cells not treated with doxycycline showed no cyclin D2 expression 
comparable to LNCaP cells transfected with the empty pEBTetD plasmid after doxycycline 
treatment. Doxycycline-inducible cyclin D2 overexpressing PC-3 cells could also be generated 
(Fig. 3.22, PC-3+D2) but after cryoconservation and subsequent repeated testing a loss of the 
doxycycline-inducible cyclin D2 overexpression had occurred (data not shown). Therefore, only 
LNCaP cells transfected with pEBTetD-CCND2 could be used for studies on the functional 
effects of inducible cyclin D2 overexpression. 
 
Fig. 3.22: Confirmation of the doxycycline-inducible overexpression of cyclin D2 in human PCa cells after 
transfection with pEBTetD-CCND2. Whole protein lysates of LNCaP and PC-3 cell populations transfected with the 
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generated pEBTetD-CCND2 expression vector and treated for 72 hours with doxycycline were immunoblotted using 
a cyclin D2-specific antibody. Different concentrations of doxycycline were tested, ranging from 0.05 µg/ml to 1 µg/ml 
doxycycline. Both LNCaP cell populations transfected with the pEBTetD-CCND2 expression vector as well as the one 
PC-3 cell population showed a strong induction of cyclin D2 expression after treatment with the indicated 
concentrations of doxycycline in contrast to the control cells that were not treated with doxycycline. Cells transfected 
with the empty pEBTetD vector, which served as a second negative control, had also no cyclin D2 expression. 
Immunoblotting of α-tubulin ensured equal protein loading.  
 
The established human PCa cells LNCaP and PC-3 were also transfected with the generated 
pIRES2-EGFP-CCND2 expression vector (see section 3.2.1.1.1) using Metafectene® Pro 
transfection reagent for constitutively overexpression of cyclin D2. Two days after transfection 
the cells were serially diluted and plated into petri dishes do generate single-cell clones. From 
the next day on selection of transfected cells occurred by treating them with 400µg/ml G418. 
After approximately 21 days single-cell clones were picked and further cultured in the presence 
of G418. To test for successful stable overexpression of cyclin D2 protein from different cell 
clones (clones 1-3) including one cell clone transfected with the empty pIRES2-EGFP vector as 
control (clone 4) was isolated. As seen in Fig. 3.23 the three LNCaP clones exhibit a very strong 
cyclin D2 expression in contrast to the control clone which exhibits no cyclin D2 expression. For 
the PC-3 cells only two stable cyclin D2 overexpressing clones could be generated, as seen in 
Fig. 3.23 by the strong cyclin D2 expression of clone 1 and 3. However, the control clone 4 
showed no cyclin D2 expression. 
 
Fig. 3.23: Confirmation of the stable overexpression of cyclin D2 in human PCa cells after transfection with 
pIRES2-EGFP-CCND2. Whole protein lysates of LNCaP and PC-3 cell clones stably transfected with the pIRES2-
EGFP-CCND2 expression vector were immunoblotted using a cyclin D2-specific antibody. All three LNCaP cell clones 
transfected with the pIRES2-EGFP-CCND2 expression vector showed a strong induction of cyclin D2 expression, 
whereas only two of the four tested PC-3 cell clones transfected with the pIRES2-EGFP-CCND2 expression vector 
showed a strong induction of cyclin D2 expression (clone 1 and 3) in contrast to the control clones transfected with 
the empty pIRES2-EGFP vector (clone 4, respectively). Immunoblotting of HSC70 ensured equal protein loading. 
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When cells transfected with the pIRES2-EGFP or pIRES2-EGFP-CCND2 vector indeed 
incorporated the plasmid DNA then these cells should be green fluorescent because of the 
EGFP gene transcription. The presence of green fluorescent cells was reviewed under the 
inverted fluorescence microscope. All three generated LNCaP cell clones with a stable cyclin D2 
overexpression (clone 1-3) exhibited about 100% green fluorescent cells (Fig. 3.24A). Cells of 
the control transfected clone (4) without the cyclin D2 construct were also green fluorescent (Fig. 
3.24A). Equally, the two generated PC-3 cell clones stably overexpressing cyclin D2 consisted 
only of green fluorescent cells as well as the cells of the control transfected clone (4) without the 
cyclin D2 construct (Fig. 3.24B). 
 




Fig. 3.24: Verification of the presence of green fluorescent cells after transfection with pIES2-EGFP-CCND2. 
The presence of the incorporated EGFP construct from the pIRES2-EGFP-CCND2 plasmid DNA in the human PCa 
cells LNCaP (A) and PC-3 (B) was verified by the presence of green fluorescent cells. For both cell lines the generated 
clones consisted to about 100% of green fluorescent cells. Pictures were taken on the inverse microscope at a 10x 
magnification. 
 
Another method used to show that the generated PCa-pIRES2-EGFP-CCND2 cell clones indeed 
exhibit cyclin D2 overexpression was by immunofluorescence staining. Therefore, cells were 
plated on glass culture slides, fixed with 3.7% formaldehyde after 24 hours and immunostained 
using a cyclin D2-specific antibody. Cells of clone 4 which were transfected with the empty 
pIRES2-EGFP plasmid served as controls. About 100% of the cells of the different clones 
stained positive for cyclin D2. Cells of two control clones (clone 4, respectively) showed no cyclin 
D2 overexpression (Fig. 3.25). 
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Fig. 3.25: Verification of cyclin D2 overexpression in the generated PCa cell clones by immunofluorescence 
staining. The generated cyclin D2 overexpressing LNCaP (A) and PC-3 (B) clones were tested by 
immunofluorescence staining for their cyclin D2 expression. The cells were fixed and stained by the use of a cyclin 
D2-specific antibody (anti-cyclin D2 (M-20)). Nuclei were stained with DAPI. About 100% of the cells stained positive 
for cyclin D2. Cells of control clones which were transfected with the empty pIRES2-EGFP plasmid showed no cyclin 
D2 overexpression (clone 4, respectively). The pictures were taken on a fluorescence microscope at a 20x 
magnification. 
 
3.2.1.2.2 Functional effects of stable and inducible cyclin D2 overexpression 
 
3.2.1.2.2.1 Studies on the proliferation rate of PCa cells with stable or inducible cyclin 
D2 overexpression 
 
The proliferation rate of the cell populations with doxycycline-inducible cyclin D2 overexpression 
and of the cell clones with stable cyclin D2 overexpression was measured every 24 hours for 4 
days by MTT assay. Cells of the two LNCaP+pEBTetD-CCND2 populations, which were treated 
with doxycycline (0.025µg/ml) to induce the cyclin D2 overexpression, showed a statistically 
significant increase in the proliferation rate as compared to LNCaP control cells transfected with 
the empty pEBTetD plasmid (Fig. 26A). 
All three LNCaP clones stably overexpressing cyclin D2 showed an increase in the proliferation 
rate as compared to the LNCaP control clone which did not show cyclin D2 overexpression (Fig. 
3.26B). The same result was observed for the two PC-3 clones overexpressing cyclin D2 which 
also exhibit a slight, but not statistically significant, increased proliferation rate compared to the 
PC-3 control clone (Fig. 26C). 




Fig. 3.26: Analysis of the proliferation rate of PCa cells stably overexpressing cyclin D2. The proliferation rate 
of the LNCaP+pEBTetD-CCND2 colonies (A), the LNCaP+pIRES2-EGFP-CCND2 cell clones (B) and the PC-
3+pIRES2-EGFP-CCND2 cell clones (C) was measured by MTT assay every 24 hours for 5 days. A) The 
LNCaP+pEBTetD-CCND2 cells were treated with 0.025 µg/ml doxycycline to induce cyclin D2 overexpression. After 
48 hours there was a significant increase in the proliferation rate of cells transfected with the cyclin D2 expression 
vector as compared to the control cells transfected with the empty pEBTetD vector. B) LNCaP-pIRES2-EGFP-CCND2 
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cell clones 1, 2 and 3 with a stable cyclin D2 overexpression have a slightly increased proliferation rate, although not 
statistically significant, as compared to cells of clone 4 without cyclin D2 overexpression. C) The two PC-3+pIRES2-
EGFP-CCND2 cell clones 1 and 3 with a stable cyclin D2 overexpression showed an increased proliferation rate, 
although not statistically significant, as compared to cells of clone 4 without cyclin D2 overexpression. Data are 
presented as mean +/- standard deviation of three proliferation assays. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 
0.001 
 
3.2.1.2.2.2 Studies on the migration rate of PCa cells with stable or inducible cyclin D2 
overexpression 
 
The migration ability of the generated LNCaP and PC-3 clones transfected with the pIRES2-
EGFP-CCND2 expression vector was tested by the transwell migration assay. The cyclin D2 
overexpressing clones of both cell lines had an unexpected increased migration rate as 
compared to control cells (Fig. 3.27). 
 
Fig. 3.27: Analysis of the migration rate of PCa cells stably overexpressing cyclin D2. The migration rate of the 
LNCaP+pIRES2-EGFP-CCND2 cell clones (A) and PC-3+pIRES2-EGFP-CCND2 cell clones (B) was measured by 
the transwell migration assay 24 hours after the cells were transferred to the assay. The cells were fixed, stained with 
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hemalum/eosin and counted under the microscope. A) All three LNCaP cyclin D2 overexpressing cell clones (clone 
1, 2, 3) showed an increase in the proliferation rate as compared to control cells (clone 4) not overexpressing cyclin 
D2. B) The two PC-3 cell clones with a stable cyclin D2 overexpression showed and increased proliferation rate as 
compared to cells of clone 4 without cyclin D2 overexpression. Data are presented as mean +/- standard deviation of 
three migration assays. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001 
 
3.2.2 Cyclin D2 downregulation studies in NIH/3T3 cells 
 
In order to verify the hypothesis that cyclin D2 serves as a tumor suppressor gene in PCa 
previous cyclin D2 overexpression studies were conducted with LNCaP and PC-3 PCa cells from 
which it was expected that they showed less functional effects of a cancer cell. However, 
contrary to the expectation and as demonstrated in the previous experiments, their proliferation 
and migration rate was rather increased. Simultaneously, cyclin D2 downregulation studies were 
conducted with the mouse fibroblast cell line NIH/3T3 to verify the hypothesis from the other 
direction. Here, it was expected that cells with reduced cyclin D2 expression exhibit more 
characteristics of a cancer cell, if cyclin D2 should be a tumor suppressor. 
NIH/3T3 cells, which have a high basal cyclin D2 expression, were transfected with different 
cyclin D2-specific siRNAs or transfected with a generated cyclin D2 shRNA plasmid (pSingle-
tTs-shRNA). Subsequently, the functional effects on migration and invasion behavior were 
analyzed. If cyclin D2 is indeed a tumor suppressor then these fibroblast cells in which the cyclin 
D2 expression is downregulated by either siRNA or shRNA should exhibit more features of a 
cancer cell, e.g. an increased proliferation and migration rate. 
 
3.2.2.1 Influence of reduced cyclin D2 expression on migration behavior of NIH/3T3 cells 
 
The murine fibroblast cells NIH/3T3 were treated with three different siRNAs against cyclin D2 
(siRNA A, B, C). Protein of the transfected cells was isolated to test the efficiency of the siRNAs 
by western blot analysis (Fig. 3.28A). Cyclin D2 siRNA-treated cells had a reduced cyclin D2 
expression as compared to luciferase transfected cells, demonstrating the effectiveness of the 
used siRNAs. Two days after transfection, the migration behavior of the cells was studied by the 
transwell migration assay. The migration rate of the siRNA-treated NIH/3T3 cells was increased 
for all three siRNAs tested in comparison to luciferase control transfected cells (Fig. 3.28B). For 
siRNA B and siRNA C transfected NIH/3T3 cells this effect was statistically very significant.  




Fig. 3.28: Analysis of the migration rate of NIH/3T3 cells after cyclin D2 downregulation. NIH/3T3 cells were 
treated with three different cyclin D2-specific siRNAs (siRNA A, B, C). 48 hours thereafter the cells were transferred 
to the transwell migration assay and incubated for 24 hours. The cells were fixed, stained with hemalum/eosin and 
counted under the microscope. A) Protein of the transfected cells was isolated to test the efficiency of the siRNAs by 
western blot analysis. Cyclin D2 siRNA-transfected cells had a reduced cyclin D2 expression as compared to 
luciferase transfected cells, demonstrating the effectiveness of the used siRNAs. B) Treatment of NIH/3T3 cells with 
either one of the three cyclin D2 siRNAs induced an increase in the migration rate compared to luciferase control 
transfected cells. Data are presented as mean +/- standard deviation of three independent migration assays. * 0.01 < 
p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001 
 
In order to determine whether the increase in the proliferation rate after cyclin D2 siRNA 
treatment in NIH/3T3 cells is specific for cyclin D2 downregulation, the effect of cyclin D1 
downregulation on the migration rate was also studied. The efficiency of the cyclin D1-specific 
siRNA was tested by western blot analysis (Fig.3.29A) and quantitative real-time PCR 
(Fig.3.29B). Both, total protein and total RNA lysates were isolated from NIH/3T3 cells 48 hours 
after cyclin D1 siRNA transfection. The cyclin D1 siRNA proved to be effective as seen by a 
reduced Ccnd1 expression compared to luciferase control transfected cells in the western blot 
analysis as well as in the quantitative real-time PCR (Fig. 3.29). 




Fig. 3.29: Confirmation of the effectiveness of the cyclin D1-specific siRNA. A) Whole protein lysate of NIH/3T3 
cells transfected with a cyclin D1-specific siRNA for 48 hours was immunoblotted using a cyclin D1-specific antibody. 
Cyclin D1 siRNA treatment reduced the expression of cyclin D1 in comparison to luciferase control transfected cells. 
Immunoblotting of α-tubulin ensured equal protein loading. B) RNA of NIH/3T3 cells transfected with a cyclin D1-
specific siRNA was isolated 48 hours after transfection and reverse transcribed into cDNA which was subjected to 
quantitative real-time PCR analysis to demonstrate the effectiveness of the cyclin D1-specific siRNA. Cyclin D1 
siRNA-treated cells had a significantly reduced Ccnd1 expression (p= 0.0088) as compared to luciferase-transfected 
cells. Data are presented as mean +/- standard deviation of three quantitative real-time PCR analyses performed in 
triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001 
 
After demonstrating that the cyclin D1 siRNA is effectively downregulating Ccnd1 expression the 
influence on the migration rate of NIH/3T3 cells was investigated. No significant difference 
between the migration rate of cyclin D1 siRNA-transfected and luciferase control-transfected 
cells was observed (Fig. 3.30). 
 
Fig. 3.30: Analysis of the migration rate of NIH/3T3 cells after cyclin D1 downregulation. NIH/3T3 cells were 
transfected with a cyclin D1-specific siRNA. 48 hours thereafter the cells were transferred to the transwell migration 
assay and incubated for 24 hours. The cells were fixed, stained with hemalum/eosin and counted under the 
microscope. Treatment of NIH/3T3 cells with cyclin D1 siRNA induced no changes in the proliferation rate as 
compared to control cells transfected with luciferase. Data are presented as mean +/- standard deviation of three 
migration assays. 
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3.2.2.2 Influence of siRNA-mediated reduced cyclin D2 expression on transformation 
potential of NIH/3T3 cells 
 
One feature of cancer cells is their ability to grow anchorage-independent which can be 
investigated by soft agar assay. If the hypothesis is true that cyclin D2 is a tumor suppressor 
gene, then cells with a reduced or no cyclin D2 expression should exhibit more characteristics 
of a cancer cell.  
To test whether NIH/3T3 cells transfected with a cyclin D2-specific siRNA indeed have the ability 
to grow anchorage-independent the cells were plated in soft agar and incubated for 4 weeks. 
During this period of time no anchorage-independent growth of the NIH/3T3 cells with a reduced 
cyclin D2 expression could be observed (Fig. 3.31). The colon carcinoma cells SW620 cells are 
known to grow anchorage-independent and served as a positive control (Fig. 3.31, Bullard et al., 
2003; Coffey et al., 1986).  
 
Fig. 3.31: Analysis of the anchorage-independent growth of NIH/3T3 cells after cyclin D2 downregulation. 
NIH/3T3 cells were transfected with three different cyclin D2-specific siRNAs (A, B, C). 48 hours thereafter the cells 
were plated into the top layer of a soft agar assay and incubated for 4 weeks. No anchorage-independent cell growth 
could be observed in the cyclin D2 siRNA-transfected NIH/3T3 cells. Luciferase control transfected NIH3T3 cells were 
also not growing in the soft agar assay. The colon carcinoma cells SW620 are known to grow anchorage-independent 
and served as a positive control. They formed visible colonies already after 2 weeks (red arrows). 
 
To exclude the possibility that anchorage-independent growth of cyclin D2 siRNA-transfected 
NIH/3T3 cells could not be observed because of a not proper function of the siRNAs the 
downregulation-efficiency of the three different siRNAs (siRNA A, B, C) on NIH/3T3 cells over a 
period of three weeks was investigated by western blot analysis. As seen in Fig. 3.32 the initial 
downregulation of cyclin D2 by either one of the three siRNAs in week one is abolished after 
three weeks of incubation with the cyclin D2-specifc siRNA. After three weeks siRNA A and C 
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can not efficiently suppress the cyclin D2 expression anymore which is seen by a stronger cyclin 
D2 band in the western blot analysis as compared to the luciferase control transfected cells. 
Therefore, stable downregulation of cyclin D2 is needed. 
 
Fig. 3.32: Testing the cyclin D2-specifc siRNA efficiency during a period of three weeks in mouse fibroblast 
cells. To find out whether siRNA treatment is the appropriate method to test the transformation potential of the mouse 
fibroblast cells NIH/3T3 with a reduced cyclin D2 expression the efficiency of three different cyclin D2-specific siRNAs 
(siRNA A, B, C) was tested. Therefore whole protein lysate of NIH/3T3 cells transfected with the cyclin D2-specific 
siRNA for one, two or three weeks was immunoblotted using a cyclin D2-specific antibody. In the first week, cells 
treated with either one of the siRNAs had a reduced cyclin D2 expression compared to luciferase control transfected 
cells. By week three, cells treated with siRNA A or C had an increased cyclin D2 expression compared to the luciferase 
control transfected cells. Immunoblotting of α-tubulin ensured equal protein loading. 
 
3.2.2.3. Cyclin D2 shRNA studies in NIH/3T3 cells 
 
3.2.2.3.1 Generation of NIH/3T3 cell clones with a stable cyclin D2 downregulation 
 
Since the downregulation of cyclin D2 in NIH/3T3 cells by the use of siRNAs is not effective and 
sufficient over longer periods of time (Fig. 3.32) NIH/3T3 cell clones with stable and inducible 
cyclin D2 downregulation were generated. Therefore, a cyclin D2-specific shRNA construct was 
cloned into the doxycycline-inducible pSingle-tTs-shRNA vector. Test digestion of isolated 
plasmid DNA with the restriction enzyme MluI which has a restriction site exclusively in the 
shRNA sequence ensured proper integration of the cyclin D2 shRNA in the pSingle-tTS-shRNA 
plasmid (Fig. 3.33) which was also verified by sequence analysis (data not shown). 




Fig. 3.33: Test digestion of pSingle-tTs-Ccnd2-shRNA clones. Competent DH5α cells were transformed with the 
pSingle-tTs-Ccnd2-shRNA vector. Plasmid DNA of single clones was isolated and digested with the restriction 
enzyme MluI. The single restriction site of MluI is located in the shRNA sequence. All of the five clones tested (1-5) 
could be successfully digested with the restriction enzyme MluI, indicating the effective integration of the shRNA 
construct into the pSingle-tTs-shRNA vector. 1kb: 1Kb Plus DNA-ladder 
 
NIH/3T3 cells were transfected with the pSingle-tTs-Ccnd2-shRNA vector using Metafectene® 
Pro transfection reagent. To generate single-cells clones, two days after transfection cells were 
serially diluted and plated into petri dishes. From the next day on transfected cells were selected 
by treatment with 400µg/ml G418. Colonies of NIH/3T3 fibroblast cells expressing the resistance 
marker could be generated by app. 21 days of growth in medium containing G418 selection 
agent. Single-cell clones were picked and further cultured in the presence of G418. Total RNA 
and whole protein lysate were isolated from cell clones to test by quantitative real-time PCR and 
western blot analysis whether stable transfection was successful and if the cells indeed exhibited 
a doxycycline inducible downregulation of cyclin D2 by RNA interference. NIH/3T3 cells not 
treated with doxycycline served as controls.  
Subsequently, several different NIH/3T3 clones were tested but only one clone (clone No. 11) 
showed an efficient downregulation of cyclin D2 after treatment with doxycycline. Quantitative 
real-time PCR (Fig. 3.34A) demonstrated a downregulation of cyclin D2 expression of about 60 
% in the NIH/3T3 cell clone No. 11 when treated with 0.1 µg/ml doxycycline, as compared to 
control cells without doxycycline treatment. The downregulation of cyclin D2 after doxycycline 
treatment with different concentrations was confirmed by western blot analysis (Fig. 3.34B). 




Fig. 3.34: Confirmation of the doxycycline-inducible downregulation of cyclin D2 in mouse fibroblast cells 
after transfection with pSingle-tTs-Ccnd2-shRNA. Cells of NIH/3T3 clone No. 11 stably transfected with the 
pSingle-tTs-Ccnd2-shRNA plasmid were treated with three different concentrations of doxycycline (0.01, 0.05 and 0.1 
µg/ml) to induce transcription of the cyclin D2 shRNA. 72 hours thereafter total RNA and whole protein lysate were 
isolated from the cells. A) Of the isolated RNA cDNA was generated by reverse transcription on which the expression 
of cyclin D2 was tested by quantitative real-time PCR using cyclin D2-specific primers. A reduced cyclin D2 expression 
of NIH/3T3-pSingle-tTs-Ccnd2-shRNA clone No. 11 after treatment with either one of three different tested 
doxycycline concentrations compared to the control cells without doxycycline treatment could be observed. Thereby 
the strongest downregulation of cyclin D2 was seen by the highest doxycycline concentration tested (0.1 µg/ml). 
Treatment of NIH/3T3 clone No. 11 cells with 0.1 µg/ml doxycycline reduced the cyclin D2 expression by about 60% 
as compared to cells that were not treated with doxycycline. B) Whole protein lysates were immunoblotted using a 
cyclin D2-specific antibody. Western blot analysis revealed a reduced cyclin D2 expression of NIH/3T3-pSingle-tTs-
Ccnd2-shRNA clone No. 11 after treatment with either one of three different tested doxycycline concentrations as 
compared to the control cells without doxycycline treatment, confirming the quantitative real-time PCR data. 
Immunoblotting of α-tubulin ensured equal protein loading. Data are presented as mean +/- standard deviation of 
three quantitative real-time PCR analyses performed in triplicate. * 0.01 < p ≤ 0.05, ** 0.001 ≤ p < 0.01, *** p ≤ 0.001 
 
3.2.2.3.2 Studies on the proliferation rate of NIH/3T3 cells with shRNA-mediated cyclin 
D2 downregulation  
 
In order to test the hypothesis that cyclin D2 displays the features of a tumor suppressor gene 
then NIH/3T3 cells with reduced cyclin D2 expression (in this case by shRNA) should exhibit 
more characteristics of cancer cells, e.g. an increased proliferation rate as compared to NIH/3T3 
cells with a normal cyclin D2 expression. Therefore, cells of the generated NIH/3T3-pSingle-tTs-
Ccnd2-shRNA clone No. 11 were plated into 96-well plates. The next day cells were treated with 
three different concentrations of doxycycline (0.05 µg/ml; 0.1 µg/ml; 1.0 µg/ml) as well as with 
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the PMS/MTS solution of the MTT assay. Two hours later the first proliferation was measured 
and then every 24 hours for 4 consecutive days by a MTT assay. The doxycycline treated cells 
had a slight tendency to a reduced, although not statistically significant, proliferation rate as 
compared to control cells which were not treated with doxycycline (Fig. 3.35). 
 
Fig. 3.35: Analysis of the proliferation rate of NIH/3T3 cells with an inducible cyclin D2 downregulation. The 
proliferation rate of NIH/3T3-pSingle-tTs-Ccnd2-shRNA clone No. 11 cells was measured by a MTT assay every 24 
hours after plating the cells to the 96-well plate for 5 consecutive days. On the first day of the measurement the cells 
were treated with three different concentrations of doxycycline (0.05 µg/ml; 0.1 µg/ml; 1.0 µg/ml) to induce cyclin D2 
shRNA expression. NIH/3T3 cells not treated with doxycycline served as a control. Overall, the doxycycline treatment 
of NIH/3T3-pSingle-tTs-Ccnd2-shRNA clone No. 11 resulted in a reduced, although not statistically significant, 
proliferation rate as compared to control cells which were not treated with doxycycline. Data are presented as mean 
+/- standard deviation of three proliferation assays. 
 
3.2.2.3.3.3 Influence of shRNA-mediated reduced expression of cyclin D2 on the 
transformation potential of NIH/3T3 cells 
 
The previous soft agar assay performed with cyclin D2 siRNA-transfected NIH/3T3 cells revealed 
no transformation potential of these cells, presumably because siRNA transfection is not 
effective for downregulation of cyclin D2 over a longer time period. Therefore, the soft agar assay 
was repeated with cells of NIH/3T3-pSingle-tTs-Ccnd2-shRNA clone No. 11 treated with 
doxycycline to induce stable cyclin D2 downregulation. Control cells were not treated with 
doxycycline. But again, even with stable cyclin D2 downregulation no transformation potential 
by anchorage-independent growth of the NIH/3T3-pSingle-tTs-Ccnd2-shRNA clone No. 11 cells 
after a four week incubation period could be observed (data not shown). Therefore, NIH/3T3-
pSingle-tTs-Ccnd2-shRNA clone No. 11 cells were additionally transiently transfected with 
pEGFP-KRAS and pEGFP-KRAS-G12V, which was shown to induce anchorage-independent 
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growth in fibroblasts (Barr and Johnson 2001, Song et al. 2002, Hoque et al. 2006). As a control 
cells of the NIH/3T3-pSingle-tTs-Ccnd2-shRNA clone No. 11 were transiently transfected with 
the empty pEGFP plasmid. The soft agar assay was done after 48 hours of doxycycline 
treatment with a concentration of 0.1 µg/ml. The NIH/3T3- pSingle-tTs-Ccnd2-shRNA clone 11 
alone acquired no transformation potential, since no colonies were growing in the soft agar (Data 
not shown). The soft agar assay with the KRAS oncogene transfected cells could not be 
evaluated since the transfection efficiency was not sufficient (data not shown). 
 
3.2.3 Studies on the functional consequences of cyclin D2 downregulation in VPA- 
treated PCa cells 
 
Witt et al. (2013) could show that VPA treatment of PCa cells specifically led to a re-expression 
of cyclin D2. Because the cyclin D2 promoter region is hypermethylated cyclin D2 expression is 
downregulated in PCa. Treatment of PCa cells with the histone deacetylase inhibitor VPA 
induced increased acetylation of the cyclin D2 promoter and consequently re-expression of 
cyclin D2 (Witt et al., 2013). Witt et al. could also show that VPA treatment of PCa cells reduced 
the ability of the cells to proliferate, a characteristic of cancer cells. To study the possible 
connection between the increased cyclin D2 expression and the reduced proliferation of PCa 
cells after VPA treatment an experiment was conducted where human and mouse PCa cells 
(LNCaP, DU145, PC-3 and 2E) were first transfected with two different cyclin D2-specific siRNAs 
and at the following day transfected cells were treated with different concentrations of VPA (1mM 
and 5mM). Simultaneously, the proliferation rate was measured by a MTT assay. Cyclin D2 
siRNA treatment was supposed to prevent the VPA-induced re-expression of cyclin D2 and 
should thereby lead to an increase in the proliferation in case cyclin D2 would be responsible for 
the VPA-induced reduced proliferation of PCa cells. Since the efficiency of the three mouse 
cyclin D2-specific siRNAs had already been tested by western blot on proteins isolated from 
mouse NIH/3T3 cells transfected with the siRNAs (see Fig. 3.28A), the human cyclin D2-specific 
siRNAs (siRNA A, B, C) still had to be tested regarding their efficient downregulation of cyclin 
D2. Therefore, the human colon epithelial cancer cell line CaCo-2, which is known to express 
human cyclin D2, were transfected with the human cyclin D2-specific siRNAs and 120 hours 
later total amount of protein was isolated and immunoblotted with a cyclin D2-specific antibody. 
Human cyclin D2 siRNA A and B led to a sufficient downregulation of cyclin D2 whereas siRNA 
C led only to a minor downregulation of cyclin D2 as compared to the luciferase control 
transfected cells (Fig. 3.36). For the following study of simultaneous cyclin D2 siRNA treatment 
and VPA treatment only human cyclin D2 specific siRNA A and B were used. 




Fig. 3.36: Testing the efficiency of three different human cyclin D2-specific siRNAs in CaCo2 cells. Human 
colon epithelial cancer cells CaCo-2 were transfected with three different cyclin D2-specific siRNAs (A, B, C) and 120 
hours later protein was isolated from the cells. Whole protein lysate was immunoblotted using a cyclin D2-specific 
antibody. Transfection with either siRNA A or siRNA B led to an efficient cyclin D2 downregulation as compared to 
the luciferase control transfected cells. Transfection with siRNA C had only minor effects on cyclin D2 downregulation. 
Immunoblotting of HSC70 ensured equal protein loading. 
 
After testing the efficiency of the human cyclin D2-specific siRNAs human and mouse PCa cells 
(LNCaP, DU145, PC-3 and 2E) were transfected with two different cyclin D2 specific siRNAs 
(LNCaP, DU145, PC-3 cells: human-specific siRNAs A and B; 2E cells: mouse-specific siRNAs 
B and C) and controls were transfected with luciferase. The following day, the transfected cells 
were treated with different concentrations of VPA (1mM and 5mM) before the proliferation rate 
was measured by a MTT assay for 96 consecutive hours (Fig 3.37).  
Control cells that were transfected only with the siRNA but were not treated with VPA exhibited 
a reduced proliferation rate as compared to luciferase transfected cells during the four day study. 
In PC-3 and LNCaP cells this effect was time-dependent. An increased proliferation rate as 
compared to the control was observed in 2E cells after 48 and 96 hours and in LNCaP cells 
during the first two days, although this was a minor effect (Fig.37, left panel). Upon VPA 
treatment of all four cell lines their proliferation rate decreased further as compared to the 
controls in a concentration-dependent manner (only shown four one time point (48 hours), 
Fig.37, right panel). The only exception here was observed in PC-3 cells transfected with siRNA 
B and treated with 1mM VPA, where the proliferation rate slightly increased. 
Here it was expected, that cells which have a reduced cyclin D2 expression due to siRNA-
transfection would have an increased or comparable proliferation rate to controls upon VPA 
treatment. The known increased cyclin D2 expression after VPA treatment should be prevented 
by the siRNA which should lead to an increased proliferation rate in case cyclin D2 is directly 
responsible for the decreased proliferation rate observed in 2E cells (Witt et al., 2013). But 
contrary to the expectation, VPA treatment of the siRNA-transfected cells further decreased the 
proliferation rate. This could be due to the fact that downregulation of cyclin D2 expression via 
siRNA is not sufficient to prevent VPA-induced re-expression of cyclin D2. This assumption is 
31 kDa 
70 kDa 
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supported by the observation from a quantitative real-time PCR analysis which showed that 
cyclin D2 siRNA-transfected 2E cells still exhibited an increased cyclin D2 expression upon VPA 
treatment as compared to controls by using quantitative real-time PCR analysis (data not 
shown).  
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Fig. 3.37: Analysis of the proliferation rate in VPA-treated PCa cells with a reduced cyclin D2 expression. The 
mouse PCa cells 2E and the human PCa cells PC-3, LNCaP and DU145 were transfected with two different cyclin 
D2-specific siRNAs (human: siRNA A and B; mouse: siRNA B and C). Cells transfected with luciferase served as 
control. The day following transfection the cells were treated with either 1mM or 5mM VPA. Controls were not treated 
with VPA. Simultaneously, PMS/MTS solution was added to the cells and two hours later the measurement of the 
proliferation rate started by a MTT assay, which was conducted for 96 consecutive hours. Here, the proliferation rate 
for transfected control cells (no VPA treatment) over the time course is depicted on the left panel. The human PCa 
cell lines transfected with either one of the two siRNAs exhibit a reduced proliferation rate as compared to luciferase-
transfected cells, which was time-dependent in PC-3 and LNCaP cells. In 2E cells, after 48 and 96 hours and in 
LNCaP cells during the first 48 hours the proliferation rate is slightly increased as compared to controls. On the right 
panel, the proliferation rate for the four cell lines upon VPA treatment is represented for one time point, namely after 
48 hours. In all cell lines analyzed, the proliferation rate decreased further upon VPA treatment in a concentration-
dependent manner as compared to untreated controls. Solely in PC-3 cells transfected with siRNA B and treated with 
1mM VPA a slight increase in the proliferation rate was observed. This experiment was conducted once. 
 
3.2.4 Generation of a conditional cyclin D2 knockout mouse model 
 
3.2.4.1 Establishment of the Ccnd2fl/fl and PB-Cre4+ mouse lines 
 
To investigate the function of cyclin D2 in vivo a conditional cyclin D2 knockout mouse model 
was generated. The Cre-Lox system relies on the DNA recombinase Cre and its recognition 
(loxP) sites. For conditional mutagenesis, a target gene is modified by the insertion of two loxP 
sites that enable the excision of the flanked (floxed) gene segment through Cre-mediated 
recombination. Conditional mutant mice are obtained by crossing the floxed strain with a Cre 
transgenic mouse line such that the target gene becomes inactivated in vivo within the 
expression pattern of Cre (Friedel et al., 2011).  
Two male homozygous Ccnd2fl/fl mice with a C57bl/6N background were obtained from Peter 
Sicinski at the Dana Faber Institute in Boston, USA. The scheme of the cyclin D2 floxed construct 
is depicted in Fig. 3.38A. Exon 1 and 2 are flanked by loxP sites and will be excised upon Cre-
mediated recombination. A male and a female heterozygous PB-Cre4+ mouse were obtained 
from Xiantuo Wu, Keck School of Medicine, University of Southern California, Los Angeles, USA 
(Wu et al., 2001). This established mouse line carries the Cre gene under the control of a 
composite promoter, ARR2PB, containing two tandem repeats of the androgen responsive 
region and PB, which is a derivative of the rat prostate-specific probasin (PB) promoter. It 
ensures specific post-natal expression only in prostate epithelial cells. The scheme of the 
constructed cassette (ARR2PB-Cre-SV40) is depicted in Fig. 3.38B. 




Fig. 3.38: Scheme of the cyclin D2 floxed construct and the Cre construct. A) The cyclin D2 target gene was 
modified by P.Sicinski (Dana Faber Institute, Boston, USA) by the insertion of two loxP sites flanking Exon 1 and Exon 
2. These loxP sites can be recognized by the Cre-recombinase and excised upon Cre-mediated recombination. B) 
The Cre transgene construct carries the Cre gene under the control of the composite ARR2PB promoter which is a 
derivative of the rat prostate-specific probasin (PB) promoter, followed by a SV40 polyadenylation sequence. The PB 
promoter ensures specific post-natal expression only in prostate epithelial cells. 
 
To establish a colony of the purchased Ccnd2fl/fl mice, the obtained two male mice were mated 
with female C56bl/6N wild type mice (Fig. 3.39A). In the F1 generation heterozygous Ccnd2fl/+ 
mice were obtained which were mated with heterozygous Ccnd2fl/+ mice from the second line to 
generate homozygous Ccnd2fl/fl mice (Fig.3.39A).  
For the establishment of a colony of the purchased PB-Cre4+ mice, the heterozygous male and 
female mice were mated with female and male C56bl/6N wild type mice, respectively 
(Fig.3.39B). The genotype of the offspring was determined by genotyping PCR. Therefore, 
genotyping-specific primers were used on genomic DNA isolated from a mouse tail biopsy. 
Cyclin D2 floxed-specific primers amplified a 260 bp product from the wild type allele and a 500 
bp product from the floxed allele (Fig. 3.39A).The Cre-specific primers amplified an app. 500 bp 
product from the Cre allele (Fig.3.39B). 




Fig. 3.39: Mating scheme for the establishment of the Ccnd2fl/fl and PB-Cre4+ mouse lines and genotyping 
PCR. The obtained Ccnd2fl/fl mice (A) as well as the PB-Cre4+ mice (B) were mated to C57bl/6N wild type mice to 
establish a colony of these lines. The genotype of the mice was determined by genotyping PCR using genotyping-
specific primers and genomic DNA derived from a tail biopsy. Cyclin D2-floxed specific primers identified a 260 bp 
product from the wild type (wt) allele and a 500 bp product from the floxed allele. The Cre-specific primers identified 
an app. 500 bp product from the Cre allele. A known heterozygous sample was used as positive control and ddH2O 
was used as negative control. A) Heterozygous Ccnd2fl/+ mice of the F1 generation were mated with heterozygous 
Ccnd2fl/+ mice to receive homozygous Ccnd2fl/fl mice again in the F2 generation. B) The obtained heterozygous PB-
Cre4+ mice were mated with C57bl/6N wild type mice to establish a colony of heterozygous PB-Cre4+ mice. 1kb: 1 
Kb Plus DNA-ladder 
 
3.2.4.2 Generation of Ccnd2fl/fl/Cre+ mice 
 
According to Birbach, female PB-Cre4 mice can display aberrant Cre activity due to Cre 
expression in the oocyte (Birbach, 2013). When transmitted through male mice the Cre 
expression cassette is exclusively expressed in the prostate epithelium. However, when 
transmitted through female mice, recombination with loxP-flanked alleles can occur in many 
different tissues, resulting in different outcomes for maternally or paternally transmitted loxP-
flanked alleles. Paternally transmitted loxP-flanked alleles will give rise to mosaic expression 
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patterns in the offspring since they undergo recombination inefficiently, whereas maternally 
transmitted loxP-flanked alleles undergo recombination very efficiently (monoallelic Cre deleted 
line, Birbach, 2013). To avoid aberrant Cre-activity in the conditional cyclin D2 knockout mice 
female Ccnd2fl/fl had to be mated to male PB-Cre4+ mice (Fig.3.40).  
For the main mating homozygous female Ccnd2fl/fl mice were bred with heterozygous male PB-
Cre4+ mice to generate heterozygous Ccnd2fl/+/Cre+ mice in the F1 generation. Male 
Ccnd2fl/+/Cre+ mice were then crossed again with homozygous female Ccnd2fl/fl mice to generate 
homozygous Ccnd2fl/fl/Cre+ conditional knockout mice in the F2 generation (Fig. 3.40A). The 
genotype of the offspring was determined by genotyping PCR using genotyping-specific primers. 
Genomic DNA was isolated from a mouse tail biopsy and then subjected to two different 
genotyping PCRs (Fig. 3.40B). Using cyclin D2 floxed-specific primers a 260 bp product from 
the wild type allele, a 500 bp product from the floxed allele and a 423 bp product from the deleted 
allele were amplified, respectively. The Cre-specific primers amplified an app. 500 bp product 
from the Cre allele. Animal numbers 123 and 124 show the desired Ccnd2fl/fl/Cre+ genotype (Fig. 
3.40B). 
 




Fig. 3.40: Mating scheme for the generation of homozygous conditional cyclin D2 knockout mice and 
genotyping PCR. A) Female homozygous Ccnd2fl/fl mice were mated with male heterozygous PB-Cre4+ mice. Male 
heterozygous Ccnd2fl/+/Cre+ mice obtained in the F1 generation were further mated to homozygous Ccnd2fl/fl. The F2 
generation yielded homozygous Ccnd2fl/fl/Cre+. B) The genotype of the offspring was determined by two different 
genotyping PCRs using genotyping-specific primers. Genomic DNA was derived from a tail biopsy. In one PCR cyclin 
D2 floxed-specific primers were used and amplified a 260 bp product from the wild type (wt) allele, a 500 bp product 
from the floxed allele and a 423 bp produced from the deleted allele. In the second PCR Cre-specific primers were 
used and amplified an app. 500 bp product from the Cre allele. ddH2O was used as negative control. Animal numbers 
123 and 124 have the desired Ccnd2fl/fl/Cre+ genotype. 1kb: 1 Kb Plus DNA-ladder 
 
3.2.4.3 Verification of the prostate-specific cyclin D2 knockout  
 
Genomic DNA of different mouse tissues, including testis, kidney, liver, intestine, spleen and 
prostate, from putative heterozygous and homozygous conditional cyclin D2 knockout mice was 
analyzed to verify the prostate-specific cyclin D2 knockout. 
For the PCR analysis of conditional knockout mice the genotypic-specific primers were used: D2 
FLOX 3', D2 FLOX5' and D2 Delta. These primers amplified a 500 bp product from the D2 floxed 
allele, a 423 bp product from the knockout allele (both encircled in green, Fig.3.41) and a 260 
bp product from the wild type sequence in the tissue of heterozygous Ccnd2fl/+/Cre+ mice (Fig. 
3.41). The tissue of homozygous Ccnd2fl/fl/Cre+ knockout mice showed two bands in the prostate 
where only one band for the deleted cyclin D2 allele was expected (423 bp, Fig. 3.41). This 
observation is probably due to the fact that DNA from a mixture of cells (e.g. epithelial cells and 
stromal cells) from the mouse prostate was analyzed and not exclusively pure epithelial cells 
from the prostate gland. 




Fig. 3.41: Results of genotyping PCR on tissue DNA isolated from heterozygous and homozygous conditional 
cyclin D2 knockout mice. Genomic DNA of different tissues, including testis, kidney, liver, intestine, spleen and 
prostate, was isolated from Ccnd2fl/+/Cre+ and Ccnd2fl/fl/Cre+ mice. PCR analysis using the specific D2 FLOX 3', D2 
FLOX5' and D2 Delta primers amplified a 500 bp product from the cyclin D2 floxed allele, a 260 bp product from the 
wild type sequence and a 423 bp product from the knockout allele. The heterozygous Ccnd2fl/+/Cre+ knockout mice 
showed three bands in the prostate. As expected, the 500 bp band for the floxed allele and the 423 bp band for the 
deleted allele (green circle) as well as the band for the wild type (wt) allele are visible. The homozygous Ccnd2fl/fl/Cre+ 
knockout mice showed two bands in the prostate (red circle) where only one band for the deleted allele was expected. 
1kb: 1 Kb Plus DNA-ladder 
 
Since by PCR analysis the prostate-specific cyclin D2 knockout could only partially be confirmed, 
two other methods were applied to show that the generated conditional cyclin D2 knockout mice 
indeed show a prostate-specific deletion of cyclin D2. On the one hand the expression of cyclin 
D2 in different tissues of heterozygous and homozygous conditional cyclin D2 knockout mice 
was tested on the RNA level by quantitative real-time PCR analysis (Fig. 3.42A) and on the other 
hand on the protein level by western blot analysis (Fig. 3.42B). But again, both methods did not 
reveal a reduced cyclin D2 expression in prostate tissue of Ccnd2fl/fl/Cre+ mice compared to 
Ccnd2fl/+/Cre+ mice (Fig. 3.42, red circle). This result was predictable, because also in the 
present experiment a mixture of prostate cells from the Ccnd2fl/fl/Cre+ was analyzed and not pure 
prostate epithelial cells. 




Fig. 3.42: Quantitative real-time PCR and western blot analyses of Ccnd2fl/+/Cre+ and Ccnd2fl/fl/Cre+ mice. A) 
RNA was isolated from different tissues of heterozygous and homozygous Ccnd2fl/+/Cre+ and Ccnd2fl/fl/Cre+ mice. 
RNA was reverse transcribed into cDNA and the expression of cyclin D2 was analyzed by quantitative real-time PCR. 
A reduced cyclin D2 expression in the prostate tissue of Ccnd2fl/fl/Cre+ mouse as compared to the prostate tissue of 
Ccnd2fl/+/Cre+ mouse could not be observed. B) Whole protein lysate of different mouse tissues from Ccnd2fl/+/Cre+ 
and Ccnd2fl/fl/Cre+ mice was immunoblotted using a cyclin D2-specific antibody. In the prostate tissue of Ccnd2fl/fl/Cre+ 
mice cyclin D2 expression was still detectable (red circle) and similarly expressed as compared to prostate tissue of 
heterozygous Ccnd2fl/+/Cre+ mice. Immunoblotting of HSC70 ensured equal protein loading. Data are presented as 
mean +/- standard deviation of three quantitative real-time PCR analyses performed in triplicate. P: prostate, T: testis, 
K: kidney, L: liver, C: colon 
 
Immunohistochemistry was also applied to verify the prostate-specific cyclin D2 knockout in 
epithelial cells of the prostate from Ccnd2fl/fl/Cre+ mice. Therefore paraffin sections of the 
prostate of Ccnd2fl/fl/Cre+ mice were stained with a cyclin D2-specific antibody. Due to the fact 
that the cyclin D2-specific antibody used for this experiment showed an unspecific staining 
pattern, a specified conclusion of the cyclin D2 expression could not be drawn from the 
immunohistochemistry data (data not shown). Because the verification of the prostate-specific 
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cyclin D2 knockout in Ccnd2fl/fl/Cre+ mice could only partially be confirmed by PCR analysis, but 
not quantitative real-time PCR studies as well as western blot analyses, respectively, these 
methods are not appropriate to detect a cyclin D2 conditional knockout. Therefore, a still ongoing 
approach is to verify the cyclin D2 conditional knockout in prostate epithelial cells of 
Ccnd2fl/fl/Cre+ mice on the RNA level by in situ hybridization. 
 
3.2.4.4 Mating of the putative conditional cyclin D2 knockout mice with TRAMP mice 
 
To study the influence of cyclin D2 on the development and progression of PCa putative male 
Ccnd2fl/fl/Cre+ were mated with heterozygous TRAMP mice (T+). Male heterozygous F1 offspring 
was mated again to homozygous Ccnd2fl/fl mice to generate TRAMP mice with a homozygous 
conditional cyclin D2 knockout (Ccnd2fl/fl/Cre+/T+, Fig.3.43A). TRAMP mice are an established 
PCa mouse model in which the oncogene SV40 T/t antigen is specifically expressed in prostate 
epithelial cells under the control of the rat probasin promoter (Gingrich et al., 1997). The prostate-
specific expression of the oncogene results in the development of a prostate adenocarcinoma 
which is reported to develop around week 18 in TRAMP mice (Gingrich et al., 1997)). If cyclin 
D2 is expected to display tumor suppressive functions in PCa then it can be presumed that in 
double transgenic TRAMP mice which lack prostate-specific cyclin D2 expression 
(Ccnd2fl/fl/Cre+/T+) the prostate tumor development and progression would be enhanced as 
compared to the tumor development of single transgenic TRAMP mice. 
From the above described mating there is only a minor chance of 12.5% to receive male TRAMP 
mice with a prostate epithelium-specific homozygous conditional cyclin D2 knockout. The 
genotype of the offspring was determined by genotyping PCR using genotyping-specific primers. 
Genomic DNA was isolated from a mouse tail biopsy and then subjected to three different 
genotyping PCRs (Fig. 3.43B). Using cyclin D2 floxed-specific primers a 260 bp product from 
the wild type allele, a 500 bp product from the floxed allele and a 423 bp product from the deleted 
allele were amplified, respectively. Cre-specific primers amplified an app. 500 bp product from 
the Cre allele. TRAMP mouse-specific primers amplified a 200 bp product from the TRAMP 
allele. Animal number 103 displayed the desired Ccnd2fl/fl/Cre+/T+ genotype (Fig. 3.43B). 




Fig. 3.43: Mating scheme for the generation of TRAMP mice with conditional homozygous cyclin D2 knockout 
and genotyping PCR. A) Homozygous Ccnd2fl/fl/Cre+ were mated with heterozygous TRAMP mice (T+). In the F1 
generation heterozygous Ccnd2fl/+/Cre+/T+ mice were generated and further mated to homozygous Ccnd2fl/fl mice. 
There is a 12.5% chance to receive TRAMP mice with the desired genotype Ccnd2fl/fl/Cre+/T+ in the F2 generation. 
B) The genotype of the offspring was determined by three different genotyping PCRs using genotyping-specific 
primers. Genomic DNA was derived from a tail biopsy. One PCR used cyclin D2 floxed-specific primers and amplified 
a 260 bp product from the wild type (wt) allele, a 500 bp product from the floxed allele and a 423 bp produced from 
the deleted allele. The second PCR used Cre-specific primers that amplified an app. 500 bp product from the Cre 
allele. In the third PCR TRAMP mouse-specific primers were used and a 200 bp product from the TRAMP allele was 
amplified. A known heterozygous sample as well as ddH2O was used as positive and negative controls, respectively. 
Animal number 103 showed the desired Ccnd2fl/fl/Cre+/T+ genotype. 1kb: 1Kb Plus DNA-ladder 
 
Until now, only seven mice with the correct Ccnd2fl/fl/Cre+/T+ genotype could be obtained, of 
which the oldest mice is 18 weeks old. These animals are subject to routinely palpation of the 
prostate in order to determine the onset of tumor development and to study the progression of 
the prostate tumor. To date, none of the seven Ccnd2fl/fl/Cre+/T+ have developed a PCa. In 
contrast, three heterozygous Ccnd2fl/+/Cre+/T+ mice had a palpable PCa and had to be sacrificed. 
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It turned out that two of these heterozygous Ccnd2fl/+/Cre+/T+ mice had seminal vesicle 
carcinoma and one had a macroscopic PCa. The mouse which had a PCa was just 16 weeks 
old. 
Due to the small number of Ccnd2fl/fl/Cre+/T+ mice and their young age no conclusions can be 
drawn at the moment on the physiological role of cyclin D2 in PCa development and progression. 




4.1 Summary of results 
 
One of the two main parts of the present study was the investigation of VPA as a putative 
candidate for the therapy of PCa. In a previous study, using microarray analysis several 
candidate genes were identified which were deregulated in mouse 2E PCa cells when treated 
with VPA (Witt, 2009). These genes included the downregulated genes chemokine (C-X-C motif) 
ligand 15 (Cxcl15), which codes for a cytokine of the CXC chemokine family, RCC1 and BTB 
domain-containing protein 2 (Rcbtb2) coding for a member of the RCC1-related GEF family, both 
transcript variants of ceruloplasmin (Cp), which is the main copper transporting protein of blood, 
and leukemia inhibitory factor (Lif), which codes for a class 6 interleukin. Candidate genes that 
were upregulated after VPA treatment included ubiquitin carboxy-terminal hydrolase L1 (Uchl1), 
which codes for a de-ubiquitinising enzyme, tyrosine-protein phosphatase-like N (Ptprn), which 
codes for a member of the protein tyrosine phosphatase family and cyclin D2 (Ccnd2), which 
codes for a member of the strongly conserved D-type cyclin family (Witt, 2009). 
In the present study, the expression of these candidate genes was analyzed by quantitative real-
time PCR analyses in prostate tumor tissue and prostate tissue of VPA-treated TRAMP mice. 
The prostate tumor tissue was derived from an in vivo VPA experiment conducted by Witt during 
her Ph.D. thesis (Witt, 2012). Since in this first in vivo VPA treatment experiment the tumors 
were isolated at different time points of age and different treating durations, which could result 
in differential expression of genes, a new in vivo VPA treatment experiment was conducted 
during this study. The mice were sacrificed at the age of 16 weeks after 10 weeks of VPA 
treatment and their prostates were isolated for molecular investigation.  
In prostate tumor tissue of VPA-treated TRAMP mice Cp2 and Lif were statistically significant 
downregulated compared to control-treated mice as revealed by quantitative real-time PCR. 
Uchl1, Ptprn and Ccnd2 exhibited a different expression pattern to the array result (Witt, 2009). 
Using western blot analysis the increased Ccnd2 expression after VPA treatment observed in 
the microarray could be confirmed in prostate tumor tissue. 
In prostate tissue derived from the second in vivo VPA treatment experiment, the expression 
pattern was more similar to the microarray data. The downregulation of Cp2 as wells as the 
upregulation of Ptprn and Uchl1 in prostate tissue of VPA-treated mice compared to prostate 
tissue of control-treated mice could be confirmed. This indicates that VPA treatment is more 
effective in the deregulation of the candidate genes at the onset of PCa development. 
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In human PCa cells, including LNCaP, DU145 and PC-3, the expression of the candidate gene 
CP was investigated by quantitative real-time PCR analysis. For all three human PCa cell lines 
a concentration- and time-dependent decrease in CP expression after VPA treatment could be 
observed, whereas by western blot analysis the opposite effect was detected.  
Since two of the above mentioned candidate genes, namely Cp and Cxl15, are associated with 
angiogenesis, a major project of the present study was the investigation of the influence of in 
vitro and in vivo VPA treatment on tumor- and tumor cell angiogenesis as well as on 
lymphangiogenesis. Primarily, these studies consisted of expression analyses of angiogenesis 
and lymphangiogenesis markers. The markers included the angiogenic cytokines vascular 
endothelial growth factor A and C (Vegfa, Vegfc) and angiopoietin 1 (Ang1), three endothelial 
cell receptor tyrosine kinases (vascular endothelial growth factor receptor 1 (Flt-1/Vegfr1), 
vascular endothelial growth factor receptor 2 (Kdr/Vegfr2) and tyrosine kinase with 
immunoglobulin-like and EGF-like domains 1 (Tie-1)), the soluble form of Vegfr2 (sVegfr2) and 
an endothelial cell adhesion molecule, platelet endothelial cell adhesion molecule (Pecam-1).  
In VPA-treated 2E PCa cells almost all angiogenesis markers mentioned above were 
significantly downregulated in a concentration- and partially time-dependent manner as 
compared to control cells, except for the two receptors Flt-1/Vegfr1 and Kdr/Vegfr2, which were 
statistically significant upregulated. By western blot analysis it was shown that the VEGFR2 
receptor signaling pathway gets activated after 144 hours of VPA treatment in 2E cells as seen 
by an increased level of the phosphorylated receptor. 
VEGFA expression was also shown to be statistically significant downregulated in human PC-3 
PCa cells upon VPA treatment and in prostate tumor tissue of in vivo VPA-treated TRAMP mice. 
Solely in prostate tissue of VPA-treated TRAMP mice it exhibited a similar expression pattern to 
controls. Ang1, Tie-1, Kdr/Vegfr2 and Pecam-1 were downregulated in both, prostate tissue and 
prostate tumor tissue of VPA-treated TRAMP mice. KDR/VEGDR2 expression was increased 
after VPA treatment in PC-3 cells, similar to 2E cells. FLT-1/VEGFR1 expression was also 
downregulated in PC-3 cells upon VPA treatment and in prostate tissue of in vivo VPA-treated 
TRAMP mice, but its expression was unchanged in prostate tumor tissue. The expression of 
VEGFC and the lymphangiogenesis inhibitor sVEGFR2 in PC-3 cells was dependent on the time 
of VPA treatment: it increased after 72 hours of VPA treatment but decreased after 144 hours.  
Taken together, these data confirm that VPA is an alternative treatment option for PCa, mainly 
because of the induced deregulation of the above mentioned candidate genes associated with 
PCa and especially because it exerts anti-angiogenic properties, for both, blood and 
lymphangiogenesis, which has not been described to date for the latter.  
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To confirm the influence of VPA treatment on angiogenesis several chicken chorioallantoic 
membrane (CAM) experiments were conducted using the human PCa cells PC-3 and the mouse 
PCa cells 2E. These cells underwent different VPA pre-treatment strategies using different VPA 
concentrations. Macroscopic analysis of the CAM tumors revealed that tumors could be affected 
in three different ways: either by bloody spots within the tumor, by bloodshot tumors or by 
disturbed blood vessel formation. VPA treatment of PC-3 cells resulted in a reduced number of 
bloodshot tumors in two experiments. The other observations for 2E and PC-3 cell tumors were 
not consistent within the experiments for one cell line and also not comparable within the two 
cell lines.  
CAM tumor volume was not significantly altered in tumors derived from VPA-treated cells as 
compared to controls. Immunofluorescent staining with the lymphatic vessel marker Prox1 and 
the blood vessel marker Mep21 of untreated tumors showed that 2E cell tumors grow mainly by 
blood angiogenesis and PC-3 cell tumors by blood- and lymphangiogenesis. In VPA-treated 
CAM tumors raised from PC-3 cells treated with 3mM VPA, but without pre-treatment, Prox1 
staining was slightly reduced in the distal tumor part. 
In CAM tumors derived from PC-3 cells that were pre-treated for 24 hours with 1mM VPA no 
statistically significant expression differences of the tested angiogenesis markers (VEGFA, 
VEGFC, ANG1, FLT-1/VEGFR1, KDR/VEGFR2, sVEGFR2, PECAM-1, TIE-1 and CP) could be 
observed as compared to controls. In CAM tumors derived from 2E cells that were pre-treated 
for 24 hours with 1mM VPA only Cp1 was statistically significant downregulated. The other tested 
genes were not significantly deregulated except VEGFA which showed a tendency to an 
upregulated expression. CAM tumors derived from 2E cells which were pre-treated for 1 week 
with 3mM VPA exhibited increased expression of Ccnd2 and Vegfa. Taken together, the CAM 
assay could only partially confirm the anti-angiogenic features of VPA in PCa. 
The second major project of the present thesis was the investigation of the role of the candidate 
gene cyclin D2 as a putative tumor suppressor gene in PCa. 
Human LNCaP and PC-3 PCa cell clones with stable overexpression of cyclin D2 were 
generated. The incorporation of the expression vector was confirmed by the presence of about 
100% EGFP-positive cells. Cyclin D2 overexpression was confirmed by immunofluorescent 
staining and western blot analysis. LNCaP colonies with a doxycycline-inducible cyclin D2 
overexpression were also generated and the overexpression was verified by western blot 
experiments.  
Human PCa cells with a transient, stable or inducible cyclin D2 overexpression had a similar or 
slightly increased proliferation rate as compared to controls. Surprisingly, both PC-3 and LNCaP 
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cell clones with stable cyclin D2 overexpression had an increased migration rate as compared 
to controls.  
NIH/3T3 cells with endogenous cyclin D2 expression were transfected with cyclin D2-specific 
siRNAs and showed an increased migration rate compared to luciferase control transfected cells, 
whereas cells transfected with a cyclin D1-specific siRNA had a similar migration behavior as 
compared to control cells. Cyclin D2 siRNA transfected NIH/3T3 cells had acquired no 
transformation potential, which was investigated by soft agar assay. 
Since it was shown that siRNA transfection is not effective over a longer time period NIH/3T3 
clones with doxycycline-inducible cyclin D2 downregulation were generated. Their proliferation 
rate was similar to that of control cells not treated with doxycycline. Besides, they also acquired 
no transformation potential, not even when double transfected with the oncogene KRAS. This 
can be explained by the fact, that the transfection efficiency was very low. 
Contrary to the expectation, the functional consequence of siRNA-mediated cyclin D2 
downregulation in VPA-treated 2E, LNCaP, PC-3 and DU145 cells was a reduced proliferation 
rate. 
To elucidate the physiological role of cyclin D2 in the organism a conditional cyclin D2 knockout 
mouse model was generated. The purchased Ccnd2fl/fl and PB-Cre4+ mouse lines were 
established and bred to generate homozygous Ccnd2fl/fl/Cre+ mice. The knockout was partially 
confirmed by PCR analysis of prostate tissue, but could not be confirmed by quantitative real-
time PCR and western blot analyses. To definitely verify the prostate-specific deletion of cyclin 
D2 other experiments, including RNA in situ hybridization, are still ongoing. 
Ccnd2fl/fl/Cre+ mice were further bred to TRAMP mice to study the influence of the prostate-
specific cyclin D2 deletion on prostate tumor development and progression. To date, there are 
seven homozygous Ccnd2fl/fl/Cre+/T+ mice, which are too young to have even developed a PCa 
yet. Therefore, no conclusions can be drawn at the moment on the physiological role of cyclin 
D2 in the mouse prostate. 
 
4.2 The histone deacetylase inhibitor VPA 
 
Valproic acid is a histone deacetylase inhibitor (HDI) that selectively inhibits the catalytic activity 
of class I histone deacetylates (HDACs) and induces proteasomal degradation of class II histone 
deacetylates (Göttlicher et al. 2001, Krämer et al. 2003). Histones are the primary protein 
components of chromatin, which compact the DNA. The chromatin structure can exist in two 
states, either acetylated or de-acetylated. Acetylated chromatin is structurally loose and strongly 
de-condensed to allow binding of RNA and DNA polymerases to transcribe and replicate the 
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DNA. HDACs catalyze the deacetylation of histones in chromatin, making it strongly condensed 
and transcriptionally inactive. Condensed chromatin can be transformed again into the more 
relaxed, de-condensed structure by histone acetyltransferases (HATs, Gillet et al. 2007). 
Treatment with HDIs, such as VPA, inhibits the activity of HDACs, thereby increasing the level 
of acetylated chromatin since HATs are still active, resulting in increased gene expression. 
VPA was licensed in Europe in 1960 and in the United States in 1978 for the treatment of 
epilepsy. Now it is widely available throughout the world and became the drug of choice in 
primary generalized epilepsies. In the mid-1990s, VPA was approved for treatment of partial 
seizures. Its potential is exerted in the human brain, where VPA acts on the neurotransmitter 
Gamma-Aminobutyric acid (GABA) by potentiating the inhibitory activity of GABA in several 
ways, for example by inhibition of GABA degradation, increased synthesis of GABA and 
decreased GABA turnover (Johannessen 2000, Johannessen and Johannessen 2003, Owens 
and Nemeroff 2003, Kostrouchová et al. 2007).  
This makes VPA a long known drug which has been extensively studied and its side effects are 
well known. Common clinical side effects of VPA include dyspepsia, weight gain, dysphoria, 
fatigue, dizziness, drowsiness, hair loss, headache, nausea, sedation and tremor. VPA can also 
impair liver function and prolong blood coagulation times. Although very rare, side effects such 
as spina bifida and other defects of neural tube closure are observed when used in early 
pregnancy, indicating that valproic acid interferes with the developmental regulatory pathway 
(Lammer et al. 1987, Koren and Kennedy 1999, Koren et al. 2006, Kostrouchová et al. 2007). 
HDIs important role in regulating transcription makes them also very promising drugs for the 
therapy of cancer. Not only did studies using neuroblastoma-, glioma- and promyelotic leukemia 
cells lines reveal a promising proliferation inhibition after VPA treatment (Fischkoff and Walter 
1984, Regan 1985) but also studies on several solid tumors, including cancer of the bladder 
(Ozawa et al. 2010, Vallo et al. 2011, Byler et al. 2012), hepatocellular cancer (Machado et al. 
2011), head and neck cancer (Gan et al. 2012), pancreatic cancer and colon cancer (Jones et 
al. 2008, Venkataramani et al. 2010), renal cell carcinoma (Jones et al. 2009), small cell lung 
cancer (Hubaux et al. 2010), cervical cancer (Sami et al. 2008) and breast cancer (Fortunati et 
al. 2008). VPA treatment alone proved to be beneficial but also in combination with other anti-
cancer therapeutics, like cytotoxic agents among others, which exhibited synergistic anti-cancer 
effects (summarized in Sun and Coy, 2014). To date, VPA is already commonly prescribed for 
brain tumor patients (glioma, Zhou et al. 2014) and suberoylanilide hydroxamic acid (SAHA, also 
known as Vorinostat), another HDAC inhibitor, is approved to treat patients with cutaneous T 
cell lymphoma (Edelstein et al. 2009). 
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In PCa, several in vitro studies using VPA also resulted in proliferation inhibition (Xia et al. 2006, 
Annicotte et al. 2006, Shabbeer et al. 2007, Gao et al. 2007, Chou et al. 2011, 2015). In vivo 
studies using PC-3-, DU145-, LNCaP- or C4-2-Z xenografts demonstrated a reduced tumor 
volume after VPA treatment (Xia et al. 2006, Shabbeer et al. 2007, Gao et al. 2007, Angelucci 
et al. 2008). Thereby, proliferation inhibition observed in in vitro and in vivo studies was due to 
functional effects of VPA treatment inducing either growth arrest, cell death, senescence or anti-
angiogenic properties (Shabbeer et al. 2007, Gao et al. 2007, Wedel et al. 2011). Although, the 
underlying molecular mechanism for the VPA-induced proliferation inhibition remain unsolved. 
Shabbeer et al. (2007) reported an increase in p21 expression, but this is a general effect not 
only observed in cancer cells but also in non-malignant cells. Besides, Brinkmann et al. (2001) 
could show that after HDI treatment with suberic bishydroxamate (SBHA) the expression of p21 
was upregulated in human fibroblast cells, whereas the proliferation rate was not affected 
(Brinkmann et al. 2001).  
Thus, the molecular mechanism for the VPA-induced proliferation inhibition in the tumor further 
remained unresolved and was subject to investigation during the present study. Besides, the in 
vivo VPA treatment studies conducted so far were carried out with xenografted mice instead of 
a PCa mouse model, thereby the natural situation will not be resembled. In the present study, in 
vivo VPA treatment was conducted with the Transgenic Adenocarcinoma of the Mouse Prostate 
(TRAMP) PCa mouse model and its molecular mechanisms were analyzed on prostate and 
prostate tumor tissue of these mice. The TRAMP mouse is one of the first PCa models and one 
of the most widely used mouse model in PCa research since it represents the course of the 
human disease (Fig 4.1). Using this model, conclusions on tumor initiation and progression can 
also be drawn and not only on tumor growth like in conventional xenograft models (Mentor-
Marcel et al. 2001). The transgene of TRAMP mouse model comprises the minimal probasin 
promoter (-426/+28, 426 basepairs of the rat probasin (PB) gene promoter and 28 basepairs of 
5'-untranslated region driving viral SV40 large-T and small t antigens which results in prostate 
epithelium-specific inactivation of the two tumor suppressors pRb and p53 (Murphree and 
Benedict 1984, Greenberg et al. 1994, Gingrich et al. 1996, Surget et al. 2013). Thus, TRAMP 
mice will develop prostatic intraepithelial neoplasia (PIN) by 8 weeks which will progress to high 
grade PIN by 18 weeks and poorly differentiated and invasive adenocarcinoma by 28 weeks of 
age. With nearly 100% of penetrance at the age of 40 weeks TRAMP mice have developed an 
adenocarcinoma (Fig. 4.1, Gingrich et al. 1997, Mentor-Marcel et al. 2001). The TRAMP mouse 
model also displays metastasis to distant organs, including the lung and lymph nodes (Gingrich 
et al. 1997), although rarely to the bone which in human PCa is the major side for metastasis. 
The majority of PCa patients die due to the development of a metastatic disease of which 80% 
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is primarily localized in the bone (Coleman 2006, Ganguly et al. 2014). 5-12% of prostate cancer 
patients with clinically organ-confined cancer exhibit regional lymph node metastasis (Cai et al. 
2009). More rarely, prostate cancer metastases can occur in the adrenal gland, lung, liver and 
brain. 
 
Fig. 4.1: Schematic presentation of PCa progression in humans and in the TRAMP mouse. A) The course of 
the human PCa disease is depicted. Normal prostatic epithelium develops into prostatic intraepithelial neoplasia (PIN) 
which progresses into a latent adenocarcinoma and a clinically relevant, castration resistant adenocarcinoma which 
metastasizes preferably to the bone. B) The timeline represents the course of PCa development and progression in 
the TRAMP mouse model. Starting after puberty at the age of 8 weeks TRAMP mice develop PIN which progresses 
into high grade PIN by 18 weeks and into poorly differentiated and invasive adenocarcinoma by 28 weeks. With nearly 
100% penetrance TRAMP mice develop an adenocarcinoma at the age of 40 weeks which also displays prevalent 
metastasis to distant organs, although rarely to the bone. The TRAMP mouse model reproduces the course of the 
mouse PCa disease and is therefore suitable for studies on PCa initiation, progression and treatment. Modified from 
Irshad and Abate-Shen 2013. 
 
The positive effects observed during in vitro and in vivo VPA treatment studies prompted the 
initiation of several clinical trials investigating the effect of VPA treatment in hematological tumor 
diseases (Wagner et al., 2010), breast cancer, lung cancer, pancreatic cancer, cervical cancer, 
testicular and ovarian cancer (Arce et al. 2006, Candelaria et al. 2007, Munster et al. 2009, 
Chateauvieux et al. 2010), as well as in glioblastoma (Weller et al. 2011) and melanoma (Rocca 
et al. 2009). Generally, patients responded well to VPA treatment, which was partially combined 
with chemo- and radiotherapy. 
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To date, only a single phase 2 study was conducted with PCa patients that received oral VPA 
treatment. Merely 10 patients were included in this study of which one died due to PCa 
progression. Two patients exhibited reduced PSA levels and no tumor progression (Sharma et 
al. 2008) but due to toxicity this trial had to be discontinued early.  
In male patients that received long term antiepileptic treatment with VPA, it was shown that they 
exhibited lower age-correlated PSA levels as compared to control groups. VPA treatment also 
exerted anti-proliferative effects on neoplastic PCa cells in vitro (LNCaP) and in vivo (Stettner et 
al. 2012), further highlighting the beneficial effect of VPA treatment in PCa patients. 
 
4.2.1 Deregulated candidate genes after VPA treatment of mouse 2E PCa cells  
 
In order to investigate the molecular mechanism underlying the VPA-induced inhibition of 
proliferation described in section 4.2 the expression of previously identified candidate genes 
(Witt, 2009) was analyzed in prostate and prostate tumor tissue of in vivo VPA-treated TRAMP 
mice. Witt et al. (2013) could show that treatment of murine PCa 2E cells with VPA resulted not 
only in inhibition of proliferation, but also in inhibition of migration and invasion. These functional 
effects were concentration- and time-dependent. Microarray analysis of 2E cells treated for 24 
hours with VPA identified several genes that were deregulated after VPA treatment (Witt, 2009). 
Eight candidate genes were chosen for further investigation because of their known expression 
in the prostate and their connection to cancer (Table 4.1). Their deregulation in 2E cells was 
confirmed by quantitative real-time PCR. Thereby it was shown that VPA treatment had a 
concentration- and time-dependent effect on the expression of these candidate genes (Witt et 
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Connection to cancer/PCa 
Expression 





 belongs to the CXC chemokine family of which members containing an 
ELR-(Glu-Leu-Arg-) motif can induce angiogenic activity (Strieter et al. 
1995) 
 in multiple myeloma patients the plasma level of these chemokines was 
reported to be increased (Pappa et al. 2011) 
 
Rcbtb2 
 reduced expression in PCa (Latil et al. 2002), in B cell chronic 
lymphocytic leukemia (CLL, Dewald et al. 2003) and multiple myeloma 
(MM, Fonseca et al. 2004)  
 novel tumor suppressor for histiocytic sarcoma and histiocyte-associated 




 transcription is dependent on high copper concentration as well as 
Hif1α initiation (Martin et al. 2005) 
 PCa patients have a significantly increased plasma level of CP (Nayak 
et al. 2003) and serum CP was even suggested as a marker for PCa 
(Fotiou et al. 2007) 
 
Lif 
 undergoes a functional transition from paracrine growth inhibitor to 
autocrine growth stimulator during progression of PCa to the hormone-
refractory phenotype (Chung et al. 1999) 
 stimulates breast and kidney cancer cell proliferation (Kellokumpu-
Lehtinen et al. 1996) 
 
Uchl1 
 potential tumor suppressor in PCa that is frequently silenced by 
promoter methylation 
 restored expression in LNCaP cells decreased the rate of cell 
proliferation and suppressed anchorage-independent growth (Ummanni 
et al. 2011) 
 
Ptprn 
 Ptprf decreased survival in PCa when overexpressed (DaSilva et al. 
2013, Du and Grandis 2015) 
 Ptprn is overexpressed in gastrointestinal neuroendocrine carcinomas 
(Leja et al. 2008) 
 
Ccnd2 
 abnormal expression of D-type cyclins and CDKs is linked to cancer 
development and progression (Musgrove et al. 2011) 
 in PCa, the CCND2 promoter is frequently hypermethylated, which is 
associated with loss of mRNA expression and tumor development 
(Henrique et al. 2006) 
 
 
To date, the analyses on the effect of VPA treatment on PCa were solely conducted with 
xenografted mice, thereby the natural situation is not resembled like in a PCa mouse model, 
such as the TRAMP model which is a more similar model to the human situation. Witt et al. 
(2013) could show that in vitro VPA treatment also exerts effects on PCa progression in the 
murine PCa 2E cells, which were derived from a PCa of a TRAMP mouse. This raised the 
question of whether the in vitro observed effects are replicable in vivo. Therefore, in the present 
study the expression of the above mentioned candidate genes was investigated by quantitative 
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real-time PCR and western blot analyses in prostate tumor tissue and prostate tissue of VPA- 
and control-treated TRAMP mice.  
 
4.2.1.1 Candidate gene expression in prostate tumor tissue and prostate tissue of in 
vivo VPA-treated TRAMP mice 
 
In vivo studies are essential for research on a putative new therapeutic agent. For the treatment 
of PCa some VPA in vivo studies have already been conducted. Thereby it was shown that 
treatment of mice with 0.4 % w/v VPA over the drinking water was well tolerated and resulted in 
a constant plasma level of 0.4mM VPA (Shabbeer et al. 2007). 
The first in vivo VPA treatment experiment in our research group was conducted by D. Witt 
(Dissertation, 2012). She used three different TRAMP mice study groups that were treated with 
a final concentration of 0.4% w/v VPA and sweetener over the drinking water. Control-treated 
mice received drinking water with sweetener only. Two of the study groups received preventive 
VPA treatment at the age of 6 weeks when the prostate shows no malignant changes yet. Of 
these, one group was treated until the age of 30 weeks, when tumor progression should still be 
ongoing, and then sacrificed. The second group was treated until the age of 40 weeks, when 
TRAMP mice should have developed a PCa, and then sacrificed. The third group received VPA 
as a curative treatment starting at the age of 16 weeks, when tumor development should have 
initiated already in TRAMP mice, and at the age of 40 weeks they were sacrificed (Mentor-Marcel 
et al., 2001). Prostate tumors were isolated for molecular evaluation and subjected to 
quantitative real-time PCR analysis to confirm in vivo the deregulation of the chosen candidate 
genes after VPA treatment (Table 4.2).  
In prostate tumor tissue of VPA-treated TRAMP mice the expression of Cp2 was statistically 
significant reduced as demonstrated by quantitative real-time PCR analysis, which is in 
accordance to the previously obtained array data (Table 4.2). The expression of the other 
candidate genes was also decreased, although not statistically significant. Rcbtb2 expression 
was comparable to controls. By densitometrical evaluation of a western blot the upregulation of 
CCND2 after VPA treatment could also be confirmed in prostate tumor tissue of VPA-treated 
TRAMP mice as compared to controls (Table 4.2). 
Quantitative real-time PCR of prostate tumor tissue of in vivo VPA-treated TRAMP mice solely 
confirmed the downregulation of Cp1, Cp2 and Lif as observed after in vitro VPA treatment of 
2E cells (Table 4.2). 
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Table 4.2: Summary of the results concerning candidate gene expression in 2E cells after VPA treatment and 
in prostate tumor tissue of VPA-treated TRAMP mice. Expression patterns that differ from those observed in VPA-
treated 2E cells are marked with a red arrow. The ones that are similar expressed after in vitro and in vivo VPA 
treatment are marked with a gray arrow. An unchanged expression pattern as compared to untreated controls is 
marked with a blue arrow. n.d: not determined 
 
Several aspects can be responsible for the poor correlation of the candidate gene expression 
profile observed after in vitro and in vivo VPA treatment. 
Since no non-pathologic prostate tissue of in vivo VPA-treated TRAMP mice was isolated for 
expression comparison, it cannot be excluded that the few PCa tumors may have risen due to 
failure of therapy or resistance to VPA treatment. Besides, tumors were isolated at different time 
points depending on which of the three study groups the mice belonged to. To date, resistance 
to in vivo or in vitro VPA treatment has not yet been described for PCa. But, it is known that VPA 
induces irreversible resistance in human colon cancer cells (Fedier et al. 2007) and in renal cell 
carcinoma in vivo (Juengel et al. 2013). In the latter case resistance is associated with elevated 
AKT activation (Juengel et al. 2013). 
The difference in the mice age, when their prostate tumor was isolated, could also lead to 
differential expression of the candidate genes. This initiated implementation of a new in vivo VPA 
treatment experiment of TRAMP mice in the present study, in which the mice were sacrificed at 
the same age, namely at 16 weeks of age (see section 2.19.1). The prostates were isolated for 
molecular evaluation by quantitative real-time PCR analysis to confirm the in vitro observed 
deregulation of the candidate genes in vivo (Table 4.3).  
Candidate gene Expression in murine 2E PCa cells 
after VPA treatment 
Expression in prostate tumor 
























 real-time PCR:          
western blot: 
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In prostate tissue of VPA-treated TRAMP mice the downregulation of Cp2 as well as the 
upregulation of Uchl1 and Ptprn after VPA treatment could be confirmed. Rcbtb2 was not quite 
statistically significant upregulated, which is the only contrary result to the array data. The other 
genes displayed an unchanged expression pattern as compared to the controls (Table 4.3).  
 
Table 4.3: Summary of the results concerning candidate gene expression in 2E cells after VPA treatment, in 
prostate tumor tissue of VPA-treated TRAMP mice and in prostate tissue of VPA-treated TRAMP mice. 
Expression patterns that differ from those observed in VPA-treated 2E cells are marked with a red arrow. The ones 
that are similar expressed after in vitro and in vivo VPA treatment are marked with a gray arrow. An unchanged 
expression patterns as compared to untreated controls is marked with a blue arrow. n.d.: not determined 
Candidate gene Expression in murine 
2E PCa cells after VPA 
treatment 
Expression in prostate 
tumor tissue of VPA-
treated TRAMP mice 
Expression in prostate 






























Expression analysis of prostate tissue from the second in vivo VPA treatment experiment 
confirmed the deregulation of more candidate genes, including Cp1, Cp2, Uchl1 and Ptprn, as 
compared to the expression analysis of prostate tumor tissue from the first in vivo VPA treatment. 
More genes had a similar expression pattern as compared to controls, but only one gene, namely 
Rcbtb2, exhibited a contrary expression pattern to the previously obtained array data (Witt, 
2009). This indicates that VPA treatment has already a clear influence on the expression of 
genes when adenocarcinomas have not yet developed. It has to be mentioned that it was not 
possible to evaluate the analyzed prostates histopathologically. Due to the small size of the 
prostate gland, the complete tissue was used for RNA isolation. Therefore, it cannot be excluded 
that in some TRAMP mice the development of prostatic intraepithelial neoplasia (PIN) had 
already taken place. 
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Taken together, molecular effects observed by in vitro VPA treatment of mouse PCa cells (2E) 
could be partially confirmed in prostate tumor tissue of in vivo VPA-treated TRAMP mice and to 
a greater extend in prostate tissue of in vivo VPA-treated TRAMP mice. In the latter, the only 
contrary result as compared to the in vitro studies was the observed upregulation of Rcbtb2 
expression in prostate tissue of VPA-treated mice. Interestingly, Rcbtb2 is a known tumor 
suppressor whose expression is frequently lost or downregulated in PCa (Latil et al. 2002). 
Therefore, increased Rcbtb2 expression upon VPA treatment should be favorable for PCa 
patients, nonetheless. In conclusion it can be stated, that in vitro and in vivo VPA treatment 
influences the expression of PCa-associated genes positively, which might inhibit or reduce 
tumor progression. These results further highlight the beneficial effects of VPA as an alternative 
treatment opportunity for PCa. 
One candidate gene, namely ceruloplasmin (Cp), was chosen for further, more profound studies 
due to its clinical relevance in PCa. PCa patients have a significantly increased plasma level of 
ceruloplasmin (Nayak et al. 2003) and serum ceruloplasmin was even suggested as a marker 
for PCa (Fotiou et al. 2007). Ceruloplasmin, the main copper carrier in blood, is known to be 
indirectly involved in angiogenesis, but only when copper is bound (Raju et al. 1982). Its 
transcription is initiated by high copper concentrations and hypoxia-inducible factor-1α (Hif1α) 
activation (Martin et al. 2005). Hypoxic conditions favor angiogenesis as the heterodimeric 
transcription factor HIF-1 induces the expression of vascular endothelial growth factors (Vegfs), 
the main angiogenic cytokines (Banerjee et al. 2007).  
VPA treatment of mouse 2E PCa cells resulted in a statistically significant decreased Cp 
expression in a concentration- and time-dependent manner, accompanied with reduced Vegfa 
expression and increased Hif1α expression (Witt, 2012). In the present study it was confirmed 
by quantitative real-time PCR that the expression of human CP also mostly decreased in a time- 
and concentration-dependent manner in human PCa cells after VPA treatment. In contrast, by 
western blot analysis the downregulation of CP after VPA treatment of human PCa cells could 
not be confirmed. Since no consistent results of ceruloplasmin expression after VPA treatment 
in human PCa cells could be observed, studies on ceruloplasmin were discontinued.  
 
4.3 Tumor angiogenesis in general 
 
Angiogenesis, the formation of new blood vessels from existing blood vessels, was identified as 
one of the ‘hallmarks of cancer’ by Hanahan and Weinberg (2000; 2011) due to the recognition 
that this process is of crucial importance during the transition from benign hyperplastic nodules 
to malignant lesions (Folkman, 1971). The importance of angiogenesis for tumor growth and 
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metastasis was also shown in 1982 by Muthukkaruppan et al. who infused cancer cells in the 
iris, which is supplied with blood circulation, and into the anterior chamber of the eye, which is 
not supplied with circulation. The cancer cells without blood circulation grew to 1–2 mm3 and 
then stopped. When placed in an area where angiogenesis was possible they grew beyond 2 
mm3 (Muthukkaruppan et al. 1982). It was even shown that without vascular support, tumors 
may become necrotic or even apoptotic (Holmgren et al. 1995, Parangi et al. 1996). 
Angiogenesis is indispensable for tumor growth and metastatic spread, since without adequate 
supply of oxygen and nutrients and the removal of waste products the tumor could not grow past 
a few millimeters in diameter (Fig. 4.2). Not only blood vessels but also lymphatic vessels are 
thereby essential. New lymphatic vessels grow by a process called lymphangiogenesis.  
 
Fig. 4.2: Process of tumor angiogenesis. When the tumor requires oxygens and nutrients for further growth the 
angiogenic switch shifts the balance of angiogenic activators and inhibitors to the activators. 1) The tumor produces 
growth factors, such as VEGF, in response to gene mutation or hypoxia and releases them. 2) Growth factors bind to 
endothelial cell receptors thereby inducing signal transduction pathways and causing cell proliferation for the 
generation of new blood and lymphatic vessels. 3) Once cancer cells penetrate blood or lymphatic vessels, they 
receive oxygen and nutrients for further growth and they are able to remove waste products. Cancer cells are also 
able to circulate through the intravascular stream and then proliferate at another site by formation of metastases. 
Modified from the Angiogenesis Foundation, http://www.dianasaville.com, 17.01.2016. 
 
Tumors remain dormant in an avascular state at diameters of 1 to 2 mm (Folkman 1974) and 
proceed to a vascular state when the angiogenic switch is turned on. Further growth is possible 
only after new capillaries form a network to supply the tumor with oxygen, nutrients and immune 
cells (Folkman 1971). Once cancer cells penetrate blood or lymphatic vessels they circulate 
through the intravascular stream and then proliferate at another site by formation of metastases 
(Folkman 1971). Angiogenesis is regulated by the balance of angiogenic activators and 
inhibitors. When the tumor requires fuel, the angiogenic switch shifts the balance of angiogenic 
activators and inhibitors to the activators. Their expression will be upregulated and 
4. Discussion - 133 - 
 
 
simultaneously the expression of the inhibitors or negative regulators will be decreased 
(Dameron et al. 1994). Pro-angiogenic factors will be released from the tumor to stimulate 
angiogenesis and lymphangiogenesis. It has been shown that expression levels of angiogenic 
factors reflect the aggressiveness of tumor cells (Weidner et al. 1993). 
The process of neovascularization, which is the formation of new vessels in tissue not normally 
containing them, including tumor angiogenesis, can be categorized into ten steps. During the 
first step angiogenic factors produced in the tumor will be released, which then during the second 
step bind to endothelial cell receptors located on a vessel, thereby inducing an intracellular 
signaling cascade. In the third step the capillary basement membrane will be enzymatically 
degraded, resulting in hypoxia. During the fourth step, endothelial cells activated by angiogenic 
factors proliferate and then during the fifth step migrate directional. In the sixth step the 
extracellular matrix will be remodeled so that during the seventh step the tube can be formed. 
During the eighth step a loop for circulation is formed. The ninth step encompasses stabilization 
of the vessel by smooth muscle cells or pericytes and finally the tenth step includes the 
continuous stimulation of the angiogenic process by angiogenic factors since vascular 
endothelial cells divide only about every 1000 days on average (Denekamp 1993, Nishida et al. 
2006, Adair and Montani 2010).  
Naturally occurring proteins that are able to inhibit angiogenesis include angiostatin, endostatin, 
interferon, platelet factor 4, thorombospondin, prolactin 16 kd fragment and tissue inhibitor of 
metalloproteinase-1, -2 and -3 (Nishida et al. 2006).  
The main angiogenic activators, of which more than a dozen have been identified, include growth 
factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), 
angiogenin, transforming growth factor (TGF)-α, TGF-β, tumor necrosis factor (TNF)-α, platelet-
derived endothelial growth factor, hepatocyte growth factor, epidermal growth factor, granulocyte 
colony-stimulating factor and placental growth factor, cytokines like interleukin-8, and other 
endogenous modulators like angiopoetin-1 (Ang-1, Nishida et al. 2006, Kluetz et al. 2010, 
Mukherji et al. 2013). 
The angiogenic activators of the VEGF family and their receptors (VEGFRs, depicted in Fig. 4.3) 
are receiving the most attention since VEGF is a powerful angiogenic agent in neoplastic tissues, 
as well as in normal tissues. Among the VEGF family, VEGF-A, VEGF-B and VEGF-C are known 
to induce proliferation of blood vessels when acting on their respective receptors, while VEGF-
C and VEGFD are involved in lymphangiogenesis when binding to their respective receptors 
(Neufeld et al. 1999, Mandriota et al. 2001, Pepper 2001, Rafii and Skobe 2003).  
VEGF-A is overexpressed in a variety of tumors (Dvorak 2002) and it is the most studied of all 
the angiogenic activators. It is a potent and very specific mitogen for vascular endothelial cells 
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that stimulates the full cascade of events required for angiogenesis (Leung et al. 1989, Conn et 
al. 1990, Nishida et al. 2006). VEGF expression can be triggered for example by hypoxia, 
resulting from the increasing distance between the growing tumor cells and the capillaries or 
from the inefficiency of new vessels. This results in induction of VEGF expression and its 
receptors via Hif-1α (Bottaro and Liotta 2003). 
 
Fig. 4.3: VEGF family members and their receptors. The mammalian VEGF family members include VEGF-A, -B, 
-C, -D, and placental growth factor (PlGF). VEGF-A can bind to VEGFR-1 and VEGFR-2. VEGF-B and PlGF only 
bind to VEGFR-1. VEGF-A, VEGF-B, VEGF-C induce proliferation of blood vessels when acting on their respective 
receptors. VEGF-C and -D bind to VEGFR-3 and VEGFR-2, thereby promoting blood- and lymphangiogenesis. 
Modified from Almodovar et al. 2009. 
 
Activation of endothelial cells by VEGF results in production of matrix metalloproteinases 
(MMPs) which are responsible for the breakdown of the extracellular matrix filling the space 
between cells. Matrix breakdown permits the migration of endothelial cells into the surrounding 
tissue. There they organize into hollow tubes which finally evolve into a mature blood vessel 
network. Platelet endothelial cell adhesion molecule (PECAM-1) participates in adhesive and 
signaling procedures required for the motility of endothelial cells and their subsequent 
organization into vascular tubes (DeLisser et al. 1997, Cao et al. 2002) as well as other adhesion 
factors like integrin α or β, which are also indispensable for this process (Mizejewski 1999, 
Nelson et al. 2000). Newly formed blood vessels are stabilized and governed to vascular growth 
by the angiogenic factor angiopoietin-1 (Ang-1) and its receptor Tie-2. Angiopoietin-2 (Ang-2) is 
a naturally occurring antagonist for Ang-1 and Tie-2 competing for Tie-2 binding (Suri et al. 1996, 
Maisonpierre et al. 1997, Tournaire et al. 2004). It is known to disrupt blood vessel formation 
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(Hu and Cheng 2009). Additionally to ligand-binding, Tie-2 forms a pre-formed hetero-oligomeric 
complex with the related receptor tyrosine kinase Tie-1 by physical interaction (Marron et al. 
2000, Chen-Konak et al. 2003). The role of Tie-1 in angiogenesis is not fully clear since the Tie-
1 ectodomain is unable to bind angiopoietins (Davis et al. 1996). The Tie-2:Tie-1 complex seems 
to partially block Ang-1 binding to Tie-2 (Marron et al. 2007). In response to VEGF, inflammatory 
stimuli or changes in shear stress the Tie-1 ectodomain can undergo regulated cleavage 
whereby it is removed. This has been shown to increase access of Ang-1 to Tie-2 resulting in 
enhanced Ang-1-activation of Tie-2 and Tie-2-mediated signaling (Marron et al. 2007, Hansen 
et al. 2010). 
It has been observed that all VEGF ligands and receptors, except for VEGFR-2, show extensive 
staining in human prostate specimens. In epithelial cells, VEGF-A and VEGFR-1 expression was 
higher in tumor tissue as compared to benign tissue whereas VEGF-D and VEGFR-3 expression 
was significantly higher in benign tissue as compared to tumors in the stroma and the 
endothelium of lymphatic and blood vessels. Additionally, the incidence of lymphatic vessels, 
but not blood vessels, was lower in tumor tissue as compared with benign tissue. These 
observations suggest that activation of VEGFR-1 by VEGF-A within the tumor, and activation of 
lymphatic endothelial cell receptor VEGFR-3 by VEGF-D within the adjacent benign stroma may 
be important signaling mechanisms involved in the progression and subsequent metastatic 
spread of PCa. Consequently, inhibition of these pathways may contribute to therapeutic 
strategies for the management of PCa (Woollard et al. 2013). 
 
4.3.1 Antiangiogenic treatment in cancer 
 
Since angiogenesis is essential for tumor growth and metastasis, controlling tumor-associated 
angiogenesis has been shown to inhibit tumor progression (Ferrara and Kerbel 2005). This 
makes anti-angiogenic treatment is an emerging, promising approach for the treatment of 
cancer.  
There are several ways one can inhibit angiogenesis: inhibition of pro-angiogenic factors such 
as VEGF, for example by use of an antibody, inhibition of receptors for pro-angiogenic factors 
(VEGF-receptors), by inhibiting endothelial cells, inhibition of proteases (inhibit the synthesis of 
MMP), by interrupting the signaling pathways, by raising the concentration of anti-angiogenic 
factors or directly by killing tumor-related vascular endothelial cells (Kluetz et al. 2010, Hwang 
and Heath 2010).  
Anti-angiogenic agents have proven to be effective in the treatment of several solid tumors, 
including renal cell carcinoma (Motzer et al. 2007), colorectal cancer (Hurwitz et al. 2004) and 
4. Discussion - 136 - 
 
 
non-small cell lung cancer (Sandler et al. 2006). Bevacizumab for example, an anti-VEGF 
antibody, which has been shown to be effective in multiple cancer cell lines, is currently Food 
and Drug Administration- (FDA) approved for treatment of several malignancies including 
colorectal carcinoma (Cohen et al. 2007a), non-squamous non-small cell lung cancer (Cohen et 
al. 2007b), metastatic breast cancer (Montero et al. 2012), recurrent glioblastoma (Chamberlain 
2011) and most recently metastatic renal cell carcinoma (Pichler, 2015).  
Angiogenesis plays an important role in the pathophysiology of PCa as several studies correlate 
markers of angiogenesis with metastatic disease, higher Gleason score and clinical outcome 
(Kluetz et al. 2010). Weidner et al. could show that tumor angiogenesis, measured by 
microvessel density (MVD), correlates with metastasis (Weidner et al. 1993). Besides, MVD of 
tumor samples at diagnosis was statistically significant correlated with stage, grade and disease-
specific survival, as revealed by a study following PCa patients for a median of 15 years (Borre 
et al. 1998). Plasma levels of VEGFs are increased in patients with metastatic PCa (Duque et 
al. 1999) making them an independent prognostic factor in men with metastatic PCa (George et 
al. 2001, El-Gohary et al. 2007). Lastly, HIF-1α, a key mediator of VEGF expression, was shown 
to have a higher expression in PCa than in benign prostate tissue (Du et al. 2003). Concluding 
from these findings, angiogenesis inhibition could be a powerful strategy to treat PCa. 
Surprisingly, clinical trials for angiogenesis-inhibition conducted with PCa patients have so far 
not been as successful as expected. A selected number of clinical trials of anti-angiogenic agents 
in development for PCa and their results/status are demonstrated in Table 4.4. The tested anti-
angiogenic agents can be grouped into different classes of which one class consists of anti-
VEGF antibodies, like bevacizumab, another class consists of immunomodulators like 
lenalidomide, thalidomide and tasqunimod and the biggest class consists of tyrosine-kinase-
inhibitors (TKIs) like sunitinib, sorafenib, cabozantinib, vandetanib, pazopanib and cediranib. 
Other agents tested include an mTor inhibitor (temsirolimus), a VEGF trap (aflibercept), an anti-
endoglin antibody (TCR105) and an anti-angiopoietin (AMG386, Table 4.4). Most of the studies 
are still ongoing and the ones already finished had mostly negative results. For example, a large 
phase III study in castration-resistant prostate cancer (CRPC) with bevacizumab in combination 
with docetaxel chemotherapy did not improve overall survival in men and was even associated 
with greater toxicity (Kelly et al. 2012). Combination of docetaxel with other anti-angiogenic 
agents also did not increase the overall survival or progression-free survival. Contrary, it might 
even increase the risk for treatment-related mortality (Lei et al. 2014). Clinical phase III trials 
using the anti-angiogenic agents sunitinib or lenalidomide on CRPC patients were even 
discontinued due to futility (Mukherji et al. 2013). Targeting the dual receptors VEGFR2/MET 
with the tyrosine kinase inhibitor cabozantinib was slightly more effective as improvements in 
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bone scans and pain response in PCa patients were observed (Lee and Smith 2013, Smith et 
al. 2013). 
In general, the role of anti-angiogenic treatment in PCa has yet to be defined. Although no 
angiogenesis-inhibitors have been approved for patients with metastatic CRPC, the rationale for 
the use of anti-angiogenic therapy in CRPC remains strong nonetheless and novel anti-
angiogenic agents are being constantly investigated (Bilusic and Wong 2014). 
 
Table 4.4: Selected clinical trials of anti-angiogenic agents in development for PCa therapy. This table shows 
selected clinical trials of anti-angiogenic agents in development for the therapy of PCa. The tested anti-angiogenic 
agent, its target, the study with its primary end point and the results or status of the study are displayed. mCRPC: 
metastatic castration-resistant prostate cancer, PDGFR: platelet derived growth factor receptor; EGFR: epidermal 
growth factor receptor; mAb: monoclonal antibody; OS: overall survival; PFS: Progression free survival; mTOR: 
mammalian target of rapamycin; TTP: time to progression. Modified from Mukherji et al. 2013. 
Drug Class  Study Primary 
end point 
Result/Status 
Bevacizumab VEGF mAb Phase III chemotherapy-naïve 
mCRPC: docetaxel/prednisone 
+/- bevacizumab 
OS OS 22.6 m vs. 21.6 
m (p=0.181), median 
PFS 9.9 m vs. 7.5 m 
(p<0.001). Increased 




1. VEGF mAb 
2. mTor inhibitor 
Phase I/II docetaxel-refractory 





Aflibercept VEGF trap Phase III chemotherapy naïve 
mCRPC: docetaxel/prednisone 
+/- aflibercept 






2. VEGF mAb 





PSA response rate: 
90%, median TTP 
18.3 m, median OS 
28.2 m, all patients 
grade ¾ neutropenia 
Lenalidomide Immuno-
modulator 
Phase III mCRPC, docetaxel +/- 
lenalidomide 
OS Negative (full results 
awaited) 
Sunitinib TKI (VEGFR/ 
PDGFR) 
Phase III mCRPC after 
progression on docetaxel: 
sunitinib + prednisone vs. 
placebo + prednisone 
OS Prematurely 
discontinued due to 
futility 
Sorafenib TKI (VEGFR/ 
PDGFR) 
Phase II pre-docetaxel mCRPC: 




Cabozantinib TKI (VEGFR2/ 
MET) 
1. Non-randomized expansion 
cohort (phase II) CRPC post-
docetaxel: cabozantinib single 
agent 
2. Phase III CRPC post-
docetaxel, post-
abiraterone/enzalutamide: 
cabozantinib vs. prednisone 
3. Phase III cabozantinib vs. 





















Vandetanib TKI (VEGFR2/ 
EGFR) 
Phase II mCRPC pre-docetaxel: 
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Pazopanib TKI (VEGFR/ 
PDGFR) 




Cediranib  TKI (VEGFR) Phase II mCRPC pre-docetaxel: 




1. Phase II mCRPC: 
tasquinimod vs placebo 
 
2. Phase III randomized 










TCR105 mAb against CD-
105 (endoglin) 
Phase II mCRPC PFS ongoing 




4.3.1.1 VPA as a possible anti-angiogenic treatment  
 
Since Witt et al. (2013) could observe a VPA-induced effect on the regulation of angiogenesis-
associated genes, namely Cp and Cxcl15 (described in 4.2.1), the influence of in vitro and in 
vivo VPA treatment on angiogenesis in PCa was subject to further investigation during the 
present study.  
To date, only little is known about the effects of VPA treatment on angiogenesis. VPA is known 
to up-regulate the anti-angiogenic proteins thrombospondin-1 and activin A (Cinatl et al. 2002). 
In vitro studies on human umbilical vein endothelial cells and in vivo studies in the chicken 
chorioallantoic membrane assay (CAM) and in a Matrigel plug assay showed that VPA inhibits 
angiogenesis in vitro and in vivo (Michaelis et al. 2004). In vitro VPA treatment inhibited 
proliferation, migration and tube formation. In vivo VPA treatment, as investigated by matrigel 
plug assay, showed that few distinct and perfused vessels were formed after VPA treatment. 
Additionally, the CAM assay showed reduced vessel ingrowth, the development of irregular and 
brittle vessels, and a markedly reduced perfusion as compared with control CAM (Michaelis et 
al. 2004). 
In terms of a VPA-induced effect on angiogenesis in PCa, Witt et al. (2013) could show that the 
expression of Cp and Cxcl15, two genes associated with angiogenesis, decreased in a time- 
and concentration-dependent manner in mouse PCa 2E cells after VPA treatment. This was 
accompanied by reduced Vegfa expression and increased Hif-1α expression. Besides from that, 
a study by Shabbeer et al. (2007) could show that angiogenesis was inhibited after VPA 
treatment (0.4% w/v) of PC-3 xenografted mice, as measured by microvessel density after CD31 
staining. However, inhibition of angiogenesis was only observed in PC-3 xenografts, but not in 
DU145 xenografts. 
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Another study by Gao et al. (2007) showed that PC-3 cell xenografts which were treated with 
VPA had a reduced expression of vascular endothelial growth factor, the main angiogenic 
stimulator.  
Since very little is known about the molecular mechanisms underlying the VPA-mediated anti-
angiogenic properties in PCa, they were further elucidated in the present project by in vitro and 
in vivo studies. As mentioned above, solely one in vitro study shows that VPA treatment exerts 
an effect on the expression on angiogenesis markers in PCa cells (Witt et al. 2013). Besides, to 
date only two in vivo studies demonstrated that VPA treatment displayed an inhibitory effect on 
tumor angiogenesis in PCa, which were both conducted with xenograft mice (Shabbeer et al. 
2007, Gao et al. 2007). In the present study, a PCa mouse model was used, namely the TRAMP 
mouse model, resembling the human PCa superiorly as compared to a xenograft model. 
Additionally, for the in vitro studies a suitable cell line was used, namely the 2E cell line, which 
was generated from a PCa of a TRAMP mouse (Hardenberg, 2010). 
The expression of several angiogenesis markers (Fig. 4.4), including Vegfa, Vegfc, Flt-1/Vegfr1, 
Kdr/Vegfr2, sVegfr2, Ang-1, Tie-2 and Pecam-1 was analyzed by quantitative real-time PCR 
after VPA treatment of mouse PCa cells 2E and human PCa cells PC-3. 
 
Fig. 4.4: Angiogenesis markers used for expression analyses of PCa cells, prostate tissue and prostate tumor 
tissue after in vitro and in vivo VPA treatment. The markers used for expression analyses included the angiogenic 
cytokines vascular endothelial growth factor A and C (Vegfa, Vegfc) and angiopoietin 1 (Ang1), three endothelial cell 
receptor tyrosine kinases (vascular endothelial growth factor receptor-1 (Flt-1/Vegfr1), vascular endothelial growth 
factor receptor-2 (Kdr/Vegfr2) and tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (Tie-1)), the 
soluble form of Vegfr2 (sVegfr2) and an endothelial cell adhesion molecule, platelet endothelial cell adhesion molecule 
(Pecam-1). Black, dark and light grey circles represent the angiogenic stimulators Vegfa, Vegfc and Ang1. 
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Analyzing the expression of the above mentioned angiogenesis markers in PCa cells or tissue 
after in vitro or in vivo VPA treatment is was expected to be reduced compared to controls in 
order to exert its anti-angiogenic properties. Indeed, it could be observed in 2E cells that upon 
VPA treatment the expression of Vegfa, Vegfc and Ang1 as well as Tie-1 and Pecam-1 was 
statistically significant downregulated, mostly in a time- and concentration- dependent manner. 
However, the two receptor tyrosine kinases Flt-1/Vegfr1 and Kdr/Vegfr2 were upregulated after 
VPA treatment (Fig.4.5). In PC-3 cells, VEGFA and FLT-1/VEGFR1 were also downregulated 
after VPA treatment, depending on the duration of VPA treatment. In contrast, KDR/VEGFR2 
was upregulated. VEGFC and sVEGFR expression, dependent on the duration of VPA 
treatment, were upregulated after 72 hours, but downregulated after 144 hours (Fig.4.5). 
sVEGFR2, an alternatively spliced variant of VEGFR2, is known to inhibit developmental and 
reparative lymphangiogenesis by blocking VEGFC function while competing for VEGFR2 
binding (Albuquerque et al. 2009). 
 
Fig. 4.5: Expression of angiogenesis markers in 2E and PC-3 cells after in vitro VPA treatment. The expression 
levels of several angiogenesis markers were analyzed in 2E cells (blue arrows) and PC-3 cells (green arrows) after 
VPA treatment and compared to untreated controls. Black, dark and light grey circles represent the angiogenic 
stimulators Vegfa, Vegfc and Ang1. 
 
Taken together, in 2E and PC-3 PCa cells not only blood- but also lymphangiogenesis must be 
impaired after VPA treatment, since the expression of blood- and lymphangiogenic-stimulators 
and of their respective receptors was mainly downregulated and the lymphangiogenesis inhibitor 
sVEGFR2 was upregulated. However, in PC-3 cells the duration of VPA treatment seems to 
have an important impact on the deregulation of angiogenesis markers as in some cases (Vegfc 
and sVegfr2) the expression deregulation observed after 72 hours VPA treatment was contrary 
to the observation after 144 hours of VPA treatment. 
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Nonetheless, the question remains unresolved why the expression of the receptors Flt-1/Vegfr1 
and Kdr/Vegfr2 is upregulated in 2E cells and PC-3 after VPA treatment. The KDR/VEGFR2 
signaling pathway was even shown to be activated after VPA treatment by an unknown 
mechanism. It is probably not activated by binding of Vegfa or Vegfc, since their expression was 
reduced. 
The effect of in vivo VPA treatment on the expression of the angiogenesis markers was also 
investigated. Therefore, prostate tumor tissue and prostate tissue of VPA-treated TRAMP mice 
was used. In prostate tissue, of the six analyzed angiogenesis markers (Vegfa, Flt-1/Vegfr1, 
Kdr/Vegfr2, Ang-1, Tie-2 and Pecam-1) only Flt-1/Vegfr1 was statistically significant 
downregulated in VPA-treated mice as compared to controls (Fig.4.6). Ang1, Tie-1, Kdr/Vegfr2 
and Pecam-1 all had a reduced expression after VPA treatment in the mouse prostate, but this 
effect was not statistically significant. Prostate tissue was isolated from mice at the age of 16 
weeks, when TRAMP mice should have developed PIN already, and almost no statistically 
significant effect of VPA treatment on the expression of angiogenesis markers was observed 
(except Flt-1/Vegfr1 downregulation). It can be hypothesized that the expression of angiogenesis 
markers is not severely affected in prostates of 16-week-old TRAMP mice, because at that age 
these mice did not develop adenocarcinomas and tumor angiogenesis seems to play an inferior 
role. 
In the prostate tumor tissue, the expression of Ang1, Vegfa, Tie-1 and Kdr/Vegfr2 was 
statistically significant reduced in VPA-treated TRAMP mice as compared to controls (Fig.4.6). 
Pecam-1 was also downregulated after VPA treatment, although not statistically significant, and 
Flt-1/VEGFR1 was similar expressed in prostate tumors of VPA-treated mice and control-treated 
mice. 
This indicates that VPA treatment is especially effective in downregulating angiogenesis related 
genes in more advanced PCa and not in the very early PCa stages (e.g. PIN) when there has 
no adenocarcinoma developed yet. The effect of VPA on angiogenesis especially in the more 
advanced PCa could imply a decrease or inhibition of tumor cell proliferation. 




Fig. 4.6: Expression of angiogenesis markers in prostate tissue and prostate tumor tissue of in vivo VPA 
treated TRAMP mice. The expression of several angiogenesis markers was analyzed in prostate tumor tissue (red 
arrows) and prostate tissue (purple arrow) of in vivo VPA-treated TRAMP mice and compared to untreated controls. 
Filled arrows indicate statistically significant results, unfilled arrows indicate not statistically significant results. Black, 
dark and light grey circles represent the angiogenic stimulators Vegfa, Vegfc and Ang1. 
 
Within the present study it could be shown that VPA treatment reduces the expression of several 
angiogenesis markers in PCa cells and in prostate tumor tissue, indicating an angiogenesis 
inhibition. In vitro VPA treatment reduced the expression of Vegfa, Vegfc, Ang1, Tie-1 and 
Pecam-1 in murine 2E PCa cells and of VEGFA and FLT-1/VEGFR1 in human PC-3 PCa cells. 
VEGFC and sVEGFR2 expression, dependent on the duration of VPA treatment, was increased 
after 72 hours and reduced after 144 hours of VPA treatment. In vivo VPA treatment exerts an 
angiogenesis inhibition since the expression of almost all angiogenesis markers tested was 
reduced as compared to controls. Especially in prostate tumor tissue this effect was statistically 
significant, indicating that VPA treatment is effective in downregulating angiogenesis-related 
genes in more advanced PCa as compared to the very early PCa stage. 
Solely the overexpression of the two receptors Flt-1/Vegfr1 and Kdr/Vegfr2 after VPA treatment 
in 2E cells and of KDR/VEGFR2 in PC-3 cells is contradictory to the picture of VPA as an anti-
angiogenic drug. This data is also contrary to what is known from the literature about the effect 
of VPA treatment on the expression of theses receptors in other cancer entities. A study by Dong 
et al. (2007) could show that VEGFR1 in human multiple myeloma KM3 cells was decreased 
upon VPA treatment (Dong et al., 2007). Additionally, in leukemia cell xenografts, a VPA-induced 
VEGFR2 downregulation has been shown (Zhang et al., 2014). As already mentioned above, 
the question why Flt-1/Vegfr1 and Kdr/Vegfr2 as well as KDR/VEGFR2 expression are 
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upregulated and activated (as seen by increased phosphorylation) in PCa cells after VPA 
treatment remains unsolved. 
To evaluate the influence of VPA on angiogenesis in more detail the chicken chorioallantoic 
membrane (CAM) assay, being one of the most famous angiogenesis assays, was applied in 
cooperation with Prof. Dr. Wilting from the Center of Anatomy, University Medical Center 
Göttingen. Here, both mouse and human PCa cells 2E and PC-3 were pre-treated for different 
time points with VPA (either no pre-treatment, pre-treatment for 24 hours or for one week) and 
then applied to the CAM, where they were forming tumors within one week. The tumors were 
harvested and subjected to macroscopic, immunohistochemical as well as molecular analysis to 
investigate the influence of VPA treatment on angiogenesis in vivo (Fig. 4.7).  
Generally, for each CAM experiment the number of harvested tumors was very low since many 
eggs had to be discarded due to either contamination or death of the embryo which made 
evaluation of the CAM experiments very difficult. 
 
Fig. 4.7: Different approaches used to investigate the influence of VPA treatment on angiogenesis in the CAM 
tumor. After conducting the CAM assay four different approaches were used to investigate the influence of VPA 
treatment on angiogenesis. Firstly, the morphology of the CAM tumor and the surrounding blood vessels was 
investigated. Secondly, the tumor volume itself was calculated. Thirdly, the blood and lymphatic vessels within the 
CAM tumor were visualized and analyzed by immunofluorescent staining with antibodies against Mep21 and Prox1. 
Finally, the expression of blood and lymphangiogenesis markers in CAM tumor tissue was investigated by quantitative 
real-time PCR. 
 
Macroscopic analysis revealed, that CAM tumors can be affected in three different ways, which 
included blood shot tumors, bloody spots within the tumor and tumors with disturbed blood 
vessel formation. However, when comparing the numbers of tumors affected by either one of 
the three phenotypes in tumors derived from VPA-treated cells with tumors grown from control 
cells, no general characteristic phenotype by VPA treatment could be observed. Within the 
experiments for one cell line the phenotypic characteristics did not correlate upon VPA treatment 
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and they also did not correlate within the two cell lines. The only exception was observed for PC-
3 cell tumors, which in both experiments showed a reduced number of bloodshot tumors when 
cells were treated with VPA.  
A study from Michaelis et al. (2004) in which VPA was applied to the CAM, showed reduced 
vessel ingrowth, the development of irregular and brittle vessels, and a markedly reduced 
perfusion as compared with control CAM (Michaelis et al. 2004). In the present study, in the third 
experiment with 2E cells and in the first PC-3 cell experiment an increase in disturbed blood 
vessels was detected when the cells were treated with VPA as compared to the control. 
However, irregular and brittle blood vessels were not characteristic for tumors of VPA-treated 
PCa cells since they were also seen in the control cells.  
The CAM tumor volume was calculated by using the modified ellipsoid formula 1/2(length × 
width2). Generally, tumors grown from VPA pre-treated PCa cells had a slightly, however not 
significantly reduced tumor volume as compared to controls. Furthermore, tumors grown from 
PCa cells that were not pre-treated with VPA, only on the day of application to the CAM and 
three days thereafter, exhibited a slightly, but not significant increase in tumor volume compared 
to controls. These results indicate, that VPA pre-treatment of PCa cells might be of great 
importance for tumor progression in the CAM model. It is known from several studies that in vivo 
and in vitro VPA treatment has a significant inhibitory effect on proliferation (Shabbeer et al. 
2007, Gao et al. 2007, Witt et al. 2013) which could only partially be observed in the present 
study. Nonetheless, this observation needs to be treated with caution since only few tumors were 
available for the tumor volume calculation from each experiment and each group (n=2-8). 
Besides, the modified ellipsoid formula was used, which is quite inaccurate since the tumor 
height is not considered within this formula. Also, length and width were measured from CAM 
tumor pictures taken on the microscope and not from the actual compound since this proved 
very difficult with a sliding caliper. Taking the measurements from CAM tumor cryo-sections on 
a slide could have been an alternative but this proved also to be difficult since some tumors 
slices were incomplete or deformed when transferred to the slide.  
Immunofluorescence staining of CAM tumor sections with the blood vessel marker Mep21 (CD34 
homolog) and with the lymphatic vessel marker Prox1 revealed that CAM tumors derived from 
untreated 2E cells had very strong Mep21 staining and tumors derived from untreated PC-3 cells 
had very strong Prox1 and Mep21 staining. This indicates that 2E cell tumors grow mainly by 
blood angiogenesis, whereas PC-3 cell tumors can grow also by blood angiogenesis and to a 
major part by lymphangiogenesis. Upon VPA treatment of PC-3 cells, but without pre-treatment, 
in the distal tumor part the number of Prox1-positive cells was reduced as compared to control 
tumors, whereas in the proximal CAM part and in the middle part of the tumor the number of 
4. Discussion - 145 - 
 
 
Pox1-positive cells was increased. This indicates that upon VPA treatment the progression of 
lymphatic vessels into the tumor might be inhibited.  
In support of the observation mentioned above, VPA-treated PC-3 cells showed an increased 
expression of the lymphangiogenesis inhibitor sVEGFR2. In contrast, an increased expression 
of VEGFC was also observed, leading to the assumption that VEGFC competes with sVEGFR2 
for the binding to VEGFR2. This could result in compensation of the VEGFC-VEGFR2 induced 
lymphangiogenesis, leading to either reduced lymphangiogenesis or unchanged 
lymphangiogenesis upon VPA treatment. And indeed, reduced lymphangiogenesis could be 
observed in the distal tumor part of VPA-treated CAM tumors as compared to controls.  
Since untreated PC-3 CAM tumors exhibit strong Prox1 staining, indicating that growth of these 
tumors depends on lymphangiogenesis, it would be interesting to study if lymphangiogenesis 
can be inhibited, for example by use of a lymphangiogenesis inhibitor such as sVEGFR2. To 
date, nothing is known about the effect of VPA treatment on lymphangiogenesis, neither on 
cancer growth in general nor on PCa development in particular. Lymphatic vessels provide an 
additional route for tumor cells to metastasize, therefore, inhibiting lymphangiogenesis in PCa 
could be a promising approach to prevent metastatic spread and thus, making it an interesting 
target and possible alternative treatment option to inhibition of blood angiogenesis in cancer 
therapy. 
Molecular evaluation of the CAM tumors exhibited some variability between the different 
experiments performed. Analyzing CAM tumors by quantitative real-time PCR showed that in 
VPA-treated PC-3 cell CAM tumors from the first CAM experiment (1 mM VPA pre-treatment for 
24 hours) none of the angiogenesis markers were statistically significant deregulated as 
compared to controls, although their expression was slightly increased. The same result was 
observed for 2E cell CAM tumors from the first experiment. Solely Cp expression was statistically 
significant downregulated in 2E cell CAM tumors upon VPA treatment. 
Increased Ccnd2 expression after VPA treatment of 2E cells was described by Witt et al. (2013) 
and was therefore used as positive control. Only 2E cell CAM tumors from the third experiment 
(3mM VPA pre-treatment for one week) exhibited a statistically significant increase in Ccnd2 
expression, indicating that at least in the third experiment VPA treatment was effective, 
suggesting that a longer VPA pre-treatment period as well as a higher VPA concentration is 
therefore necessary. 
Generally, the expression levels of the angiogenesis markers were rather increased in VPA-
treated CAM tumors, which is contrary to results mentioned above where the expression of 
angiogenesis markers after in vitro and in vivo VPA treatment was rather reduced. Besides, only 
4. Discussion - 146 - 
 
 
a small number of tumors were available for molecular evaluation (n= 2-5), which makes this 
study not quite representative. 
Taken together, data received from the CAM experiments need to be considered with caution 
since the results are not quite representative due to the small number of CAM tumors. Besides, 
the CAM model does not seem to be the appropriate model to study VPA-induced effects on 
blood and lymphangiogenesis, not just because of the above mentioned aspect, but also 
because previous described molecular mechanism observed upon in vitro and in vivo VPA 
treatment could not be confirmed. Also the known functional proliferation inhibition of VPA could 
not be observed in VPA-treated PCa cell-derived CAM tumors. 
 
4.4 The role of cyclin D2 in PCa 
 
4.4.1 The family of D-type cyclins 
 
Passage of any cell through the cell cycle is modulated by a series of proteins, of which the main 
players include cyclins, CDKs (cyclin-dependent kinases, positive regulators) and CDK inhibitors 
(negative regulators such as p21 and p27). Cyclin D2 belongs to the family of D-type cyclins 
alongside cyclin D1 and cyclin D3. D-type cyclins play an important role as cell cycle regulators 
controlling transition through G1 phase. Thereby D-type cyclins serve as regulatory co-factors 
for cyclin-dependent kinases (CDKs) which are inactive in the absence of a partner cyclin. 
Binding of the cyclin to its specific CDK activates the catalytic subunit of the CDK resulting in 
phosphorylation of target genes, especially of the retinoblastoma (Rb) growth-inhibitory complex 
(Matsushime et al. 1992). This leads to either activation or inactivation of target proteins, which 
ultimately leads to the progression to the next phase of the cell cycle. Different combinations of 
cyclin-CDK complexes, as well as the expression of CDK-inhibitors operate during different 
phases of the cell cycle and determine the target genes expressed during a specific phase.  
The three D-type cyclins differ not only in their structure (see Fig. 1.4), but also in their function. 
For example, cyclin D2 and cyclin D3 can not only bind to CDK4 and CDK6 but also to CDK2, 
which cyclin D1 cannot (Ewen et al. 1993). Phenotypic analyses of single cyclin D knockout mice 
revealed that each of the D-type cyclins is sufficient to drive normal development of the majority 
of tissues (Ciemerych et al. 2002). Besides, each cyclin D exhibits distinct and mutually exclusive 
expression patterns in mouse embryos and some organs of adult animals. Cells risen from the 
epiblast and trophoblast are solely positive for cyclin D3 expression. This indicates that individual 
cyclin Ds may have their specific functions (Wianny et al. 1998). These specific functions may 
not only be CDK-dependent as seen in case of cyclin D1 which conveys cell cycle- or CDK-
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independent functions. Cyclin D1 can directly influence the expression of estrogen and androgen 
receptors, regulate cellular metabolism, fat cell differentiation and cellular migration (Fu et al. 
2004).  
In tumor cells many of the regulatory mechanism of the cell cycle can be deregulated. Especially 
the abnormal expression of the D-type cyclins and their CDKs is linked to cancer development 
and progression (Musgrove et al. 2011). 
 
4.4.2 Does cyclin D2 act as an oncogene or a tumor suppressor gene in PCa? 
 
As already mentioned above the expression of cyclin D2 is deregulated in many cancer entities. 
High levels of cyclin D2 messenger RNA are frequently observed in ovarian epithelial 
carcinomas (Milde-Langosch and Riethdorf 2003), testicular cancer (Sicinski et al. 1996), colon 
cancer (Mermelshtein et al. 2005) and gastric cancer (Takano et al. 2000), indicating an 
oncogenic role of cyclin D2 in these tumors. In glioblastoma stem cells (GSCs), cyclin D2 was 
also shown to play a critical role in tumorigenicity. Suppression of cyclin D2 expression by RNA 
interference was shown to cause G1 arrest in vitro and growth retardation of GSCs xenografted 
into immunocompromised mice in vivo (Koyama-Nasu et al. 2013). 
However, in breast cancer (Evron et al. 2001, Fischer et al. 2002), lung cancer ((Virmani et al. 
2003), pancreatic cancer (Matsubayashi et al. 2003) and some gastrointestinal tumors (Yu et al. 
2003) cyclin D2 expression is frequently downregulated. Also in PCa the expression of cyclin D2 
is frequently downregulated due to hypermethylation of the cyclin D2 promoter. Thereby an 
increased methylation status correlates with the stage of the tumor which in turn correlates 
inversely with the expression levels in prostatic tissue (Padar et al. 2003, Henrique et al. 2006). 
Increased cyclin D2 promoter methylation in PCa was also shown to correlate with faster tumor 
progression and poor prognosis (Padar et al. 2003, Rosenbaum et al. 2005). In contrast, cyclin 
D1 is frequently overexpressed in PCa and cyclin D1 has been described to act as an oncogene 
not only in PCa (Drobnjak et al. 2000, Ewen and Lamb 2004) but also in breast, lung, colon and 
hematopoietic cancer (Gillett et al. 1996, Courjal et al. 1996, Fu et al. 2004, Arnold and 
Papanikolaou 2005, Santarius et al. 2010, Lehn et al. 2010). 
Witt et al. (2013) could show a specific re-expression of cyclin D2 after treatment with either VPA 
or other HDIs in PCa cells with undetectable low basal cyclin D2 expression. This phenomenon 
was accompanied by proliferation inhibition of PCa cells. Due to the fact that this could not be 
observed in fibroblast cells which exert a very high basal cyclin D2 expression, led to the 
hypothesis that increased cyclin D2 expression in PCa has anti-tumorigenic capacities indicating 
that cyclin D2 might act as a tumor suppressor (Table 4.5). 
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This hypothesis was reinforced by two further studies: Kobayashi et al. (2009) stated that 
restoration of cyclin D2 expression in the human PCa cell line LNCaP inhibits cell proliferation 
(Table 4.5) and Ko et al. (2012) demonstrated that a reduced cyclin D2 expression is correlated 
with a poor recurrence-free survival in non-small cell lung cancer (Table 4.5). To further elucidate 
the role of cyclin D2 in PCa cyclin D2 downregulation studies were conducted in the present 
thesis, expecting that non-cancerous cells with reduced cyclin D2 expression could display 
features comparable to cancer cells. Therefore, NIH/3T3 fibroblast cells were used since they 
exhibit high basal cyclin D2 expression. Simultaneously, cyclin D2 overexpression studies were 
conducted with human and mouse PCa cells, expecting that these cancer cells exhibit reduced 
features of a cancer cell when cyclin D2 expression is increased. If cyclin D2 is indeed a tumor 
suppressor in PCa, this knowledge would be of great value for possible treatment options for 
patients with PCa.  
Downregulating cyclin D2 expression in NIH/3T3 cells by the use of three different cyclin D2-
specific siRNAs resulted in an increased migration rate which was statistically significant for 
siRNA B and siRNA C. The increase in the migration rate was specific after cyclin D2 
downregulation, since downregulation of cyclin D1 had no effect on the migration behavior. From 
the literature such an effect of cyclin D2 expression on PCa cell migration was not reported. But 
a similar effect is known from a study with mammary epithelial cells. The authors could show 
that the Ets family transcription factor Pea3, which is involved in tumorigenesis especially during 
the metastatic process and induces migration and invasion in mammary epithelial cell models, 
stands in a negative feedback loop with cyclin D2. Cyclin D2 expression is lost during Pea-3-
induced tumorigenesis, but restoration of cyclin D2 expression resulted in decreased cell 
migration (Ladam et al. 2013). Here, we could show the opposing effect in fibroblast cells, i.e. 
reducing the cyclin D2 expression resulted in increased cell migration. Cyclin D1 is also known 
to influence cell migration in breast cancer cells, which is mediated through transforming growth 
factor beta (TGFβ) signaling (Dai et al. 2013), but does not seem to effect cell migration in 
fibroblast cells.  
One feature of cancer cells is their ability to grow anchorage-independent (colony forming 
capacity in semisolid media, Cifone and Fidler 1980). To test whether NIH/3T3 fibroblast cells 
with siRNA-mediated cyclin D2 downregulation possess transformation potential and can grow 
anchorage-independent, which normal NIH/3T3 cells would not, a soft agar assay was 
conducted. The capability of transformed NIH/3T3 cells, including ras-transformed NIH3T3 cells, 
to grow anchorage–independent has been demonstrated in many studies (Barr and Johnson 
2001, Song et al. 2002, Hoque et al. 2006). The colon carcinoma cells SW620 cells, which are 
known to grow anchorage-independent (Coffey et al. 1986, Bullard et al. 2003) formed visible 
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colonies after two weeks, whereas cyclin D2 siRNA-transfected NIH/3T3 cells exhibited no 
anchorage-independent growth. One possible explanation is that the transfected cells either 
possess no transformation potential or that the siRNA-mediated cyclin D2 downregulation is not 
effective over longer time periods. To exclude the latter possibility the efficiency of the cyclin D2-
specific siRNAs over longer time periods was tested by western blot analysis. Indeed, it could 
be demonstrated that the siRNA-mediated downregulation of cyclin D2 expression persists only 
for up to two weeks and thereafter cyclin D2 expression is restored.  
Since it is known that shRNA is significantly more potent than siRNA at mediating knockdown of 
gene expression (McAnuff et al. 2007), a pSingle-tTs-Ccnd2-shRNA plasmid was generated 
which was used for transfection of NIH/3T3 fibroblast cells. The doxycycline-inducible 
expression of the shRNA resulted in downregulation of cyclin D2 expression which was 
confirmed for one clone (clone No. 11) by quantitative real-time PCR and western blot analysis. 
Treatment of transfected NIH/3T3 cells with 0.1µg/ml doxycycline resulted in a 60% decrease in 
cyclin D2 expression. However, also shRNA-mediated cyclin D2 downregulation resulted in no 
aquired transformation potential of NIH/3T3 cells. Furthermore, cell colonies of clone No. 11 
were not even growing in soft agar when simultaneously transfected with an oncogene 
expressing plasmid, such as pEGFP-KRAS or pEGFP-KRAS-G12V, which could support 
transformation potential. At this point it is important to note that the transfection efficiency for 
transfection with pEGFP-KRAS or pEGFP-KRAS-G12V was very poor, since only few of the 
transfected cells showed green fluorescence.  
Additionally, the proliferation rate of doxycycline-treated NIH/3T3 clone No. 11 cells with 
downregulated cyclin D2 expression was comparable to control cells, although it was expected 
to be increased in case cyclin D2 possesses anti-proliferative functions.  
It could be possible that the shRNA-mediated cyclin D2 downregulation would lead to an 
increased proliferation rate of NIH/3T3 cells, but that doxycycline-treatment abolishes this effect. 
Doxycycline-treatment is known to reduce or inhibit cell proliferation (Fife et al. 1997, Chang et 
al. 2010, Ahler et al. 2013). The usage of a cyclin D2-specific inhibitor would be helpful to 
circumvent this problem, but to date there are no cyclin D2-specific inhibitors available, only 
inhibitors that also inhibit other D-type cyclins, which is not intended in the present studies. 
Taken together, the increased migration rate of NIH/3T3 cells transfected with a cyclin D2-
specific siRNA suggests that cyclin D2 possesses anti-tumorigenic capacities (Table 4.5) which 
could be neither confirmed nor proved invalid by both soft agar and proliferation assays. To 
better evaluate the functionalities of reduced cyclin D2 expression for PCa in general the studies 
should be repeated with a prostate epithelial cell line, for example with ATCC or PNT2 cells. But 
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first it needs to be evaluated whether either one of these two cell lines encompasses high basal 
cyclin D2 expression, making this cell model suitable for cyclin D2 downregulation studies. 
To investigate whether overexpression of cyclin D2 reduces tumorigenic features in PCa cells, 
cell clones and colonies were generated with stable or inducible cyclin D2 expression. Therefore, 
two different cyclin D2 expression vectors were generated, namely pIRES2-EGFP-CCND2 for 
constitutive cyclin D2 overexpression and pEBTetD-CCND2 for doxycycline-inducible cyclin D2 
overexpression in PCa cells. PCa cell lines were stably transfected with both constructs and 
suitable cell clones were established and verified for cyclin D2 overexpression. 
Studies on the functional effects of transient, stable and inducible cyclin D2 overexpression 
resulted in similar or increased proliferation rates compared to controls, opposing to what was 
expected. In the three LNCaP cells clones with stable overexpression of cyclin D2 a slightly 
increased proliferation was observed during the first 72 hours, whereas only after 92 hours the 
proliferation rate was slightly reduced for two of these LNCaP clones as compared to the control. 
In contrast, Kobayashi et al. (2009) could show that forced cyclin D2 expression in LNCaP cells 
suppressed the proliferative ability and induced cell death in LNCaP cells in a cdk-independent 
manner. When the forced cyclin D2 expression in LNCaP cells was knocked down again, this 
resulted in proliferation restoration (Kobayashi et al. 2009). A connection between increased 
cyclin D2 expression and proliferation inhibition has already been described in 1998 for primary 
and established fibroblast cells (Meyyappan et al. 1998). Inhibition of cell proliferation by either 
contact-inhibition or serum-deprivation was accompanied with increased cyclin D2 expression 
and G1 arrest. Additionally, Meyyappan and coworkers could show that passage number of the 
cells correlated with increased cyclin D2 expression and decreased proliferation (Meyyappan et 
al. 1998). In the present study, PC-3 cells with stable cyclin D2 overexpression had a not 
significantly increased proliferation rate. Furthermore, LNCaP colonies with doxycycline-
inducible overexpression of cyclin D2 showed a significantly increased proliferation rate as 
compared to control cells. In the latter experiment, the concentration of doxycycline was kept as 
low as possible since it is known that doxycycline treatment exhibits off target effects as 
observed for example by a reduction or inhibition of cell proliferation (Fife et al. 1997, Chang et 
al. 2010, Ahler et al. 2013). Nonetheless, the proliferation rate of LNCaP colonies with inducible 
overexpression of cyclin D2 was increased. 
In contrast to the expectation, the migration capability of LNCaP and PC-3 clones with stable 
cyclin D2 overexpression was also increased as compared to control cells.  
Taken together, the studies conducted with cyclin D2 overexpressing cells are opposing to the 
expectation that cyclin D2 encompasses anti-tumorigenic capacities in PCa cells. They rather 
suggest that cyclin D2 exerts oncogenic potential (Table 4.5). This hypothesis is supported by 
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two studies using micro RNAs (miRNAs) which target cyclin D2. Both studies could show that 
miRNAs (miRNA-154 and miRNA-let7a) downregulating cyclin D2 expression in human PCa 
cells inhibited PCa cell proliferation (Table 4.5, Dong et al. 2010, Zhu et al. 2014).  
Studies conducted during this thesis on the functional consequences of cyclin D2 
downregulation in mouse and human PCa cells revealed that their proliferation rate was reduced 
compared to luciferase control transfected cells. Upon VPA-treatment of these cells, their 
proliferation rate decreased further as compared to untreated control cells. However, it was 
expected that cells transfected with cyclin D2-specific siRNA would have an increased or 
comparable proliferation rate to controls after VPA treatment. The siRNA is thought to suppress 
VPA-induced re-expression of cyclin D2 which was shown to be accompanied with proliferation 
inhibition (Witt et al. 2013). Therefore, cell proliferation should not be inhibited but rather 
increased if cyclin D2 is directly responsible for the decreased proliferation rate observed in 2E 
cells. However, as already observed by Witt (2012), the cyclin D2-specific siRNA-mediated 
downregulation was not sufficient to suppress the VPA-induced re-expression of cyclin D2, as 
revealed by quantitative real-time PCR (data not shown). Therefore, a direct connection between 
VPA-induced re-expression of cyclin D2 and proliferation inhibition of PCa cells could not be 
demonstrated.  
Taken together, from the cyclin D2 downregulation and overexpression studies in both PCa and 
NIH/3T3 cells conducted during the present project and due to the above mentioned limitations 
during the soft agar assay it could not be determined whether cyclin D2 acts as a tumor 
suppressor or as an oncogene in PCa. There are advantages and disadvantages for both 
hypotheses and further studies need to be performed to finally identify the role of cyclin D2 in 
PCa (Table 4.5). It would be of great interest to repeat the soft agar experiment with newly 
generated oncogene plasmids to find out whether cells with cyclin D2 downregulation acquire 
transformation potential when co-transfected with an oncogene. Finally, a combined PCa mouse 
model (TRAMP) with a conditional cyclin D2 knockout in the prostate (Ccnd2fl/fl/Cre+/T+) would 
unveil with certainty its role in PCa development and progression (summarized in Table 4.5). 
This conditional cyclin D2 knockout mouse model (Ccnd2fl/fl/Cre+/T+) has already been 
established during the present project, but at the moment no conclusions can be drawn from this 
mouse model, because at 18 weeks of age the Ccnd2fl/fl/Cre+/T+ offspring is still too young to 
have developed a PCa (see Fig. 4.1). 
 
Table 4.5: Comparison of the facts that cyclin D2 might act as a tumor suppressor in PCa with facts that cyclin 
D2 might act as an oncogene in PCa. Several studies and also results from the present project suggest that cyclin 
D2 might act as a tumor suppressor in PCa, whereas there are also indications that cyclin D2 might act as an 
oncogene in PCa. To date, there is no clear fact that proves that cyclin D2 is either an oncogene or a tumor suppressor 
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and its role in PCa still remains unsolved. Two important questions that would elucidate the role of cyclin D2 in PCa 
could not be answered during the present project. On the one hand, the transformation potential of NIH/3T3 cells with 
reduced cyclin D2 expression and co-transfection with an oncogene could not be assessed by soft agar assay since 
transfection efficiency was very poor. On the other hand, the influence of lacking cyclin D2 expression in a conditional 
cyclin D2 knockout mouse model (Ccnd2fl/fl/Cre+/T+) on tumor development and progression could not yet be 
determined since the offspring is too young to have developed a PCa. 
 
Besides, it might be possible that upregulation of cyclin D2 alone cannot exert the VPA-induced 
effects described previously, only in combination with several other factors. Hypermethylation of 
genes is a general effect observed in cancer, therefore not only cyclin D2 should be 
hyperacetylated upon VPA treatment (Witt et al. 2013), but also several other genes which 
together with cyclin D2 might exert the anti-tumorigenic effects (Fig.4.8). 
 
Is cyclin D2 a tumor suppressor in PCa? Is cyclin D2 an oncogene in PCa? 
 Re-expression in PCa cells is associated with 
proliferation inhibition (Witt et al. 2013, Kobayashi 
et al. 2009)  
 
 Reduced expression in NIH/3T3 cells results in 
increased proliferation (Witt et al. 2013) 
 
 Reduced expression in NIH/3T3 cells results in 
increased migration rate (present study) 
 
 in non-small cell lung cancer, a reduced cyclin D2 
expression is correlated with a poor recurrence-
free survival (Ko et al. 2012) 
 Increased proliferation rate upon 
overexpression in PCa cells (present study) 
 
 Increased migration rate upon overexpression 
in PCa cells (present study) 
 
 miRNAs targeting cyclin D2 in human PCa cells 
inhibited PCa cell proliferation (Dong et al. 
2010, Zhu et al. 2014) 
 Transformation potential of NIH/3T3 cells with reduced cyclin D2 expression and co-transfected with 
an oncogene? (Needs to be repeated) 
  
 Earlier tumor development and more aggressive tumor in TRAMP mice with conditional cyclin D2 
knockout? (Ongoing experiment) 
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Fig. 4.8: Schematic presentation how VPA treatment might exert its anti-tumorigenic effects in PCa. The VPA 
mediated anti-tumorigenic effects in PCa might be exerted by combination of promoter hyperacetylation of several 
genes, of which only Ccnd2 has been identified (Witt et al. 2013). 
 
4.4.3 The physiological role of cyclin D2 
 
To elucidate the physiological role of cyclin D2 in the mouse prostate a conditional knockout 
mouse model with a prostate-specific cyclin D2 deletion was established during the present 
project. To investigate especially the effect of cyclin D2 deletion on PCa development and 
progression the cyclin D2 knockout mice were crossed with TRAMP mice.  
In the Apc(Min/+) mice, a popular animal model for studies of human colon cancer (Leclerc et 
al. 2004), it was shown that a knockout of cyclin D2 dramatically reduced tumor growth and 
development (Cole et al. 2010). Cyclin D2 is known to be overexpressed in 53% of colon cancers 
(Mermelshtein et al. 2005), whereas it is inactivated in PCa patients due to promoter 
hypermethylation (Padar et al. 2003). It was shown that restoration of the cyclin D2 expression 
in LNCaP PCa cells resulted in reduced proliferation. Witt et al. (2013) could also show that re-
expression of cyclin D2 in human and mouse PCa cells, induced by VPA treatment was 
associated with decreased proliferation rates, whereas fibroblast cells, in which cyclin D2 
expression was not further increased by VPA treatment, showed no such proliferation inhibition, 
except for the L-cells. Moreover, in non-small cell lung cancer, reduced cyclin D2 expression is 
correlated with a poor recurrence-free survival (Ko et al. 2012). These data indicate that at least 
in some cancers, including PCa, increased or restored cyclin D2 expression is associated with 
anti-tumorigenic effects. To examine whether this holds true in vivo, in the present study a 
prostate-specific cyclin D2 knockout mouse model was generated, because to date such a 
mouse model has not been established. These conditional knockout mice were further crossed 
with TRAMP mice to induce PCa formation and to study the consequences of a cyclin D2 
knockout on tumor development and tumor progression. If cyclin D2 indeed exerts a tumor 
suppressive function in PCa then TRAMP mice lacking cyclin D2 expression in the prostate 
epithelium should develop PCa at an earlier age or exhibit a more aggressive PCa.  
Multiple conventional knockout mouse models already exist with either a single D-type cyclin 
knockout, double D-type cyclin knockout or triple D-type cyclin knockout (cyclin D-null mouse). 
Studies on single D-type cyclin knockout mice showed that they were all viable but exhibited 
different phenotypes. In cyclin D1 knockout mice the proliferation of breast epithelium was 
impaired during pregnancy whereas in female cyclin D2 knockout mice the proliferation of 
ovarian granulosa cells in response to follicle-stimulating hormone (FSH) was inhibited, resulting 
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in infertility. Knockout of cyclin D2 resulted in cerebellar abnormalities and impaired 
neurogenesis (Huard et al. 1999, Kowalczyk et al. 2004). Cyclin D3 knockout mice exhibited 
disturbed development of immature T-lymphocytes. The predisposition for different cancer types 
was also divert in the single D-type cyclin knockout mice. A knockout of cyclin D1 expression led 
to resistance of developing breast cancer promoted by Ras and Neu oncogenes. Cyclin D2 
knockout mice had a decreased susceptibility for cancer of the gonads, whereas cyclin D3 
knockout mice had a decreased susceptibility for skin papilloma and Myc-promoted oral mucosa 
tumors (summarized from Kozar and Sicinski 2005).  
Studies on mice that express only a single D-type cyclin showed that cyclin D1-only mice 
developed severe megaloblastic anemia, cyclin D2-only mice presented neurological 
abnormalities, and cyclin D3-only mice lacked normal cerebella (Ciemerych et al. 2002). These 
studies indicate that the D-type cyclins possess some individual functions, but also general 
functions that can be compensated by the other D-type cyclins. Even the lack of all three D-type 
cyclins in cyclin D-null mice (cyclin D1(-/-)D2(-/-)D3(-/-) showed that cyclins are dispensable for 
cell cycle progression. These mice developed phenotypically and histopathologically 
comparable to control mice until embryonic day 13.5 (E13.5, Kozar et al. 2004) when most of 
the organs are already completely developed. At E17.5 cyclin D1(-/-)D2(-/-)D3(-/-) mice died due 
to heart abnormalities combined with a severe anemia. Furthermore, this study showed that D-
cyclins are critically required for the expansion of hematopoietic stem cells, whereas cyclin D-
deficient fibroblasts proliferate nearly normally. Additionally, mouse embryonic fibroblast (MEF) 
cells lacking D-cyclins displayed reduced susceptibility to oncogenic transformation (Kozar et al. 
2004). 
For the present study, Ccnd2fl/fl mice and PB-Cre4+ mice with a C57/Bl6 background were 
purchased and their colonies established by mating with C57/Bl6 wild type mice. PB-Cre4+ mice 
contain a second-generation composite probasin promoter, the ARR2PB promoter, which was 
modified to contain two androgen response elements (ARR) in the PB promoter (Zhang et al. 
2000). This 0.5-kb PB promoter fragment maintains reliable prostate-specificity and 
simultaneously provides very high transgene expression in transgenic mice (Zhang et al. 2000). 
Mating of Ccnd2fl/fl mice with PB-Cre4+ mice resulted in homozygous Ccnd2fl/fl/Cre+ mice as 
verified by genotyping PCR. The prostate-specific knockout of cyclin D2 could be partially 
confirmed by PCR analysis of different mouse tissues of homozygous Ccnd2fl/fl/Cre+. Only in the 
prostate tissue the band for the deleted Ccnd2 allele could be detected, however, also a specific 
band for the floxed Ccnd2 allele was observed. Quantitative real-time PCR and western blot 
analyses of different tissues revealed that cyclin D2 expression in the prostate was not reduced, 
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which is contrary to the expectation from a homozygous, prostate-specific cyclin D2 knockout 
mouse. 
One possible explanation for this observation could be that not a pure population of epithelial 
cells of the prostate was used for genotyping PCR, quantitative real-time PCR and western blot 
analyses. The probasin promoter in the knockout construct ensures specific expression of the 
Cre recombinase exclusively in prostate epithelial cells, therefore only these cells should exhibit 
a cyclin D2 knockout. For genotyping PCR, quantitative real-time PCR and western blot analyses 
the whole prostate gland was used, which consists of two generic cell types, i.e. epithelial cells 
and stromal cells. Epithelial cells form glands that are composed of the luminal secretory and 
basal cell types and rare neuroendocrine cells. The stroma surrounding the prostatic glands 
contains smooth muscle cells and fibroblasts (Cunha et al. 1996). Blood vessels, peripheral 
nerves and ganglia, and tissue-infiltrating white blood cells are additional constituent cell 
elements of the normal adult human prostate. The fact that the prostate is a solid organ makes 
the isolation of a specific cell type for a knockout verification problematic (Liu and True 2002).  
Ongoing experiments to verify the prostate-specific knockout of cyclin D2 include 
immunohistochemistry, but to date no suitable antibody for mouse cyclin D2 has been identified, 
and RNA in situ hybridization (RNA-ISH). The cyclin D2-specific RNA probes were generated 
during the present study, but still need to undergo digoxigenin (DIG) labeling for the actual ISH 
procedure. If neither one of these two approaches should be successful in demonstrating the 
prostate-specific cyclin D2 downregulation, then microdissection should be conducted as a last 
alternative approach. Using microdissection, a single cell type, in this case prostate epithelial 
cells, can be specifically isolated from tissues consisting of multiple cell types. The isolated pure 
prostate epithelial cells could then be used for repetition of PCR, quantitative real-time PCR and 
western blot analyses. 
The putative conditional cyclin D2 knockout mice were further mated with TRAMP mice (T+) to 
study the effects of prostate-specific loss of cyclin D2 expression in a PCa mouse model. 
Thereby, especially the effect on tumor development and progression ought to be studied. If 
cyclin D2 proves to be a tumor suppressor in PCa, then it is expected that mice lacking cyclin 
D2 expression in the prostate epithelium would develop PCa earlier as compared to normal 
TRAMP mice or exhibit a more aggressive PCa. The likelihood to receive homozygous 
Ccnd2fl/fl/Cre+/T+ mice when mating Ccnd2fl/+/Cre+/T+ mice with Ccnd2fl/fl mice is only 12.5%. To 
date, there are seven putative homozygous Ccnd2fl/fl/Cre+/T+ mice of which none has developed 
a palpable PCa. The oldest of these mice is 18 weeks old, therefore, this mouse is too young to 
have developed an adenocarcinoma yet, as compared to single-transgenic TRAMP mice which 
develop an adenocarcinoma at app. 28 weeks of age. Furthermore, one 16-week-old 
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heterozygous Ccnd2fl/+/Cre+/T+ mice had already developed a palpable PCa and had to be 
sacrificed. Based on the age of this heterozygous mouse it should not have developed a PCa 
but rather a PIN according to the tumorigenic time course in the TRAMP mouse model. 
Development of PCa in heterozygous double transgenic Ccnd2fl/+/Cre+/T+ mice at such a young 
age could suggest that even the loss of one cyclin D2 allele in the prostate of TRAMP mice could 
be sufficient to induce a more severe PCa as compared to single transgenic TRAMP mice. 
Nonetheless, at the present state of the experiment no definite conclusion can be drawn on the 
physiological role of cyclin D2 in PCa development and progression in vivo (Table 4.5, section 
4.4.2). 
The fact that not all TRAMP mice in our institute developed PCa and that these mice often 
develop seminal vesicle carcinoma, which very rarely is accompanied with development of PCa, 
as observed in our institute and also known from the literature (Tani et al. 2005, Yeh et al. 2009), 
led to the search for a more suitable PCa mouse model. In the literature there are other 
disadvantages of the TRAMP mouse model stated, for example that the carcinoma developed 
from TRAMP mice are of neuroendocrine origin (Chiaverotti et al. 2008) and not of epithelial 
origin as compared to the majority of human PCa cases (Abrahamsson 1999). Also, the PCa in 
TRAMP mice rarely metastasizes to the bone, as it is the case in humans, but rather to lymph 
nodes and lung (Gingrich et al. 1997). Another limiting factor for the use of TRAMP mice in PCa 
studies is the inherent use of the probasin promoter which is regulated by androgens (Matuo et 
al. 1989, Kasper et al. 1998). When it comes to interpreting consequences of castration this will 
be confounded by the possibility that observed androgen sensitivity is due to downregulation of 
transgene expression. Furthermore, as already mentioned, use of the non-physiological SV40 T 
antigen leads to prostate epithelium-specific inactivation of pRb and p53, the major targets of 
SV40 T antigen, resulting in formation of neuroendocrine tumors with metastasis potential to 
distant organs. The same is observed by prostate-specific inactivation of pRB and p53 (Zhou et 
al. 2006). Consequently, the phenotype of TRAMP mice may reflect the consequences of RB 
and p53 pathway inactivation. Besides, the relatively short kinetics of PCa development differ 
from the characteristically slow development of PCa in humans (Gingrich et al. 1999). 
The PCa mouse model in which the tumor suppressor gene phosphatase and tensin homolog 
deleted from chromosome 10 (Pten, Song et al. 2012) is excised seems to be a suitable 
alternative to the TRAMP mouse model. It is the most frequently used genetically-engineered 
mouse model, although very few human PCa patients have loss of both PTEN alleles. 
Approximately 23% of human high grade PIN, 69% of localized PCa (Yoshimoto et al. 2006) and 
86% of metastatic castration resistant PCa (Holcomb et al. 2009) exhibit PTEN deletions. PTEN 
is a phosphatase which removes a phosphate group from phosphatidylinositol 3,4,5-
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triphosphate (PIP3,4,5,) resulting in downregulation of the Akt/m-Tor signaling pathway, leading 
to decreased cell proliferation and survival (Cantley and Neel 1999). PTEN is of considerable 
importance for PCa because of its relevance for regulating androgen receptor signaling (Abate-
Shen and Shen 2000, Shen and Abate-Shen 2007, 2010) and its loss has been linked to many 
cancers, including PCa (Cairns et al. 1997). Due to the fact that Pten conditional knockout mice 
resemble the principal driving event of human PCa in PCa of mice and also represents the 
human course of the disease from PIN to metastatic, castration resistant PCa of epithelial origin 
(Wang et al. 2003, Trotman et al. 2003) it was chosen for mating with Ccnd2fl/fl/Cre+ mice instead 
of TRAMP mice. One other major benefit in using Pten conditional knockout mice instead of 
TRAMP mice for the generation of conditional cyclin D2 knockout mice is that there will be no 
further interference with other cell cycle- associated factors, solely the cyclin D2 knockout. PTEN 
is known to induce cell cycle arrest by negatively regulating especially cyclin D1, but also the 
other D-type cyclins (Radu et al. 2003, Diao and Chen 2007). PTEN was also shown to 
downregulate cyclin D2 expression (Huang et al. 2007). Therefore, loss of PTEN in conditional 
cyclin D2 knockout mice should have no further negative effect on cell cycle regulators. Using 
TRAMP mice, the SV40 T antigen would inactivate pRb and p53, two major cell cycle 
components, which would distort the outcome of a conditional cyclin D2 knockout. Thus, the 
phenotype of TRAMP mice with a conditional cyclin D2 knockout may also reflect the 
consequences of RB and p53 pathway inactivation. The idea is to solely interfere with cyclin D2 
and no other cell cycle components since the physiological role of cyclin D2 ought to be 
investigated. The Pten conditional knockout mice fulfills this criteria and was therefore purchased 
and the line just recently established. Due to the advanced stage of this thesis and the 
accompanied time limitation it was not possible to set up the mating of Pten conditional knockout 
mice with prostate-specific cyclin D2 knockout mice during this project. Once the physiological 
function of cyclin D2 in PCa is fully understood, this knowledge can be transferred to reveal its 
pathologic function and might help in the development of new therapeutic strategies for the 




4.5.1 The histone deacetylase inhibitor VPA in PCa 
 
The influence of in vitro and in vivo VPA treatment on PCa has been investigated by several 
research groups. In the present study, previously described molecular mechanism in mouse PCa 
2E cells induced by VPA treatment could be partially confirmed in prostate and prostate tumor 
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tissue of in vivo VPA-treated TRAMP mice. The expression of one candidate gene, namely cyclin 
D2, was also investigated in murine prostate tumor tissue by immunohistochemistry, but the 
used antibody was not specific. It would be important to verify the deregulation of the candidate 
genes upon VPA treatment in the prostate tumor tissue samples, therefore, new cyclin D2 
antibodies should be obtained for immunohistochemical evaluation of the prostate tumor tissue. 
During the present study it has been shown that VPA exerts anti-angiogenic effects in the mouse 
PCa 2E cells and the human PCa cells PC-3, but also in prostate tumor tissue of VPA-treated 
TRAMP mice, mainly by deregulation of angiogenesis markers. This emphasizes the need for 
further studies on VPA as a putative anti-angiogenic agent in PCa, since to date very little is 
known about the anti-angiogenic effects of VPA in cancer. At present, especially the influence 
of VPA on lymphangiogenesis and tumor growth has not been described in the literature, thus, 
opening a new field in cancer research since formation of new lymphatic vessels provides an 
additional route for tumor cells to metastasize. In the present study, VPA treatment has been 
shown to influence the expression of blood- and lymphangiogenesis-related genes in mouse and 
human PCa cells, highlighting the beneficial effect of VPA as an anti-cancer drug. Here, it would 
be also interesting to study if VPA directly influences the acetylation status of the angiogenesis-
related genes, which could be examined by chromatin immunoprecipitation studies. 
In mouse PCa 2E cells it was shown that VPA treatment reduced the expression of several 
angiogenesis markers, whereas the expression of the two receptor tyrosine kinases Flt-1/Vegfr1 
and Kdr/Vegfr2 was increased after VPA treatment. In case of Kdr/Vegfr2 this was accompanied 
by increased activation of the receptor signaling pathway, as seen by enhanced phosphorylation 
status of the receptor. Since the expression of the two ligands able to bind to Kdr/Vegfr2, namely 
Vegfa and Vegfc, was downregulated upon VPA treatment the question remains open which 
ligand-binding induces the receptor activation. Vegfd is also known to bind to Kdr/Vegfr2, 
therefore its expression status upon VPA treatment should be examined as well. To identify the 
candidate which activates the Vegf-receptor signaling pathway would be of great interest for 
further studies finding an approach to reduce Vegf-ligand expression or to prevent ligand-binding 
which would reduce or prevent signaling of the Vegf-receptor pathway and thereby inhibit 
formation of blood and lymphatic vessels. Furthermore, one should also investigate the 
expression of Vegfr3 upon VPA treatment to exclude that lymphangiogenesis is induced by this 
signaling pathway. 
One major interesting point to investigate would be whether in vivo VPA treatment influences 
angiogenesis at the protein level in prostate tumor tissue of TRAMP mice as compared to 
controls. Therefore, microvessel density could be calculated upon CD31 or CD34 staining of 
prostate tumor sections.  
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By immunofluorescent staining using a Prox1-specific antibody, which is a marker for lymphatic 
vessels, it was shown that PC-3 cell CAM tumors derived from untreated and VPA-treated cells, 
exhibit major staining for Prox1, indicating PC-3 cell derived tumors grow mainly by 
lymphangiogenesis. Further studies using a lymphangiogenesis inhibitor, such as sVegfr2 would 
be very important to demonstrate whether lymphangiogenesis can be inhibited or reduced in 
PCa cells. Therefore CAM experiments could be conducted using PC-3 cells treated with 
sVEGFR2 and compared to untreated controls. If indeed a reduction in lymphatic staining is 
observed in the sVEGFR2 treated tumors, then further studies are necessary to investigate the 
potential of lymphangiogenesis-inhibitors for the treatment of PCa, for example in mouse in vivo 
studies. 
The Prox1 staining was quantified for CAM tumor raised from PC-3 cells that were not pre-
treated with VPA. Thereby a reduction in Prox1-positive cells was observed in the distal tumor 
part of tumors derived from VPA-treated cells as compared to controls. It would be highly 
interesting if different VPA concentrations or different VPA pre-treatment procedures also 
influence lymphatic vessel formation. Therefore the number of Prox1 positive cells should be 
quantified also for other CAM experiments conducted, including 2E cell CAM experiments.  
 
4.5.2 The cell cycle regulator cyclin D2 in PCa  
 
One major aim of this study was to investigate the role of cyclin D2 in PCa. Previously, it was 
shown by Witt (2012) that cyclin D2 exerts a specific role in PCa and it was hypothesized to 
function as a putative tumor suppressor in PCa.  
Firstly, it would be interesting to identify direct interaction partners of cyclin D2, for example by 
a Yeast-two-Hybrid-experiment using a prostate-specific library. This could contribute to the 
understanding of specific functions of cyclin D2 in the prostate and how they are exerted. 
In the present study, cyclin D2 was overexpressed in PCa cells and the functional effects were 
analyzed. It was proposed that cyclin D2 overexpressing PCa cells would exhibit less features 
of cancer cells if cyclin D2 acts indeed as a tumor suppressor in PCa. However, migration and 
proliferation rates of cyclin D2 overexpressing PCa cell were rather increased than reduced, 
suggesting that cyclin D2 does not function as a tumor suppressor gene in PCa cells. Cyclin D2 
expression was also downregulated in fibroblast cells, since they exert high basal cyclin D2 
expression in contrast to PCa cells and the functional effects were analyzed. It was proposed 
that NIH/3T3 cells exhibiting reduced cyclin D2 expression would change their phenotype into 
the direction of cancer cells in case cyclin D2 is a tumor suppressor. Indeed, NIH/3T3 cells with 
reduced cyclin D2 expression displayed an increased migration rate. In contrast, the proliferation 
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rate of NIH/3T3 cells was unchanged and a shift in the transformation potential could also not 
be observed, not even after transfection with an oncogene, for which the very low transfection 
efficiency could be responsible. Therefore, it would be very important to generate or obtain new 
oncogene expression vectors and transfect NIH/3T3 cells with inducible cyclin D2 
downregulation with these vectors. When transfection efficiency is optimal it should be 
determined by soft agar assay whether fibroblast cells with reduced cyclin D2 expression exhibit 
a shift in the transformation potential. 
Generally, the studies in which cyclin D2 was downregulated, either by siRNA or shRNA, should 
be repeated with prostate epithelial cells. In the present study, fibroblast cells were used since 
they were available in the institute and exhibit high basal cyclin D2 expression. In order to 
optimize the evaluation regarding the functionalities of reduced cyclin D2 expression for PCa in 
general the studies should be repeated with a prostate epithelial cell line which exhibits high 
basal cyclin D2 expression. Human or mouse PCa cells are not suitable for these future 
experiments since they display undetectable low cyclin D2 expression levels. 
Downregulation of cyclin D2 by transfection with a shRNA expression vector could be not 
sufficient in completely silencing cyclin D2, since the expression of cyclin D2 was downregulated 
by only 60%. During this study the transcription activator-like effector nuclease (TALEN) 
technique was also consulted to induce cleavage of the cyclin D2 DNA sequence but it could not 
be applied, since molecular cloning of the specific domains was not successful. Another option 
to induce downregulation of cyclin D2 would be the use of a cyclin D2-specific inhibitor, but to 
date there are none available. At present, available cyclin inhibitors inhibit cyclin D2 as wells as 
other cyclin Ds simultaneously, but this phenomenon would distort the results. 
Taken together, the in vitro studies do not really confirm the hypothesis that cyclin D2 has a 
tumor suppressive function in PCa. Therefore, the in vivo studies on tumor development and 
progression in TRAMP mice with a prostate-specific knockout of cyclin D2 are of major 
importance to clarify the role of cyclin D2 in PCa.  
The most important aspect concerning the in vivo studies is the confirmation of the prostate-
specific deletion of cyclin D2 in the generated transgenic mice. By PCR analysis of prostate 
tissue the knockout could only be partially confirmed, presumably because a mixture of prostate 
cells was analyzed and not pure epithelial cells in which the cyclin D2 knockout should occur. 
Other approaches conducted during this study to verify the conditional deletion of cyclin D2 
include RNA in situ hybridization (RNA-ISH) and immunohistochemical staining of prostate 
sections with a cyclin D2-specific antibody. Both approaches are still ongoing and need to be 
continued. If neither one of these techniques is able to demonstrate the conditional knockout 
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then microdissection of prostate tissue should be conducted, where only prostate epithelial cells 
are being excised with a laser and which can then be used for repetition of PCR analyses.  
To date, the in vivo studies on tumor development and tumor progression in the conditional cyclin 
D2 knockout mice are still ongoing because the available mice are too young to have even 
developed an adenocarcinoma yet. Therefore, at the present state of the in vivo experiment no 
definite conclusion can be drawn on the physiological role of cyclin D2 in PCa which implies 
continuation of the in vivo studies. Besides, the TRAMP mouse model should be switched to the 
Pten knockout mouse model since it exhibits several benefits over the TRAMP mouse model 
described in section 4.4.3. The Pten knockout mouse model has just recently been established 
and can now be used for further in vivo studies. 
It would also be interesting to analyze the normal prostate tissue of conditional cyclin D2 
knockout mice (Ccnd2fl/fl/Cre+ and Ccnd2fl/fl/Cre+/T+) histologically, for example by H&E staining. 
Thereby the physiological role of cyclin D2 in normal prostate development can also be 
evaluated. 
 




In the first project of the present study, the influence of in vivo VPA treatment on the expression 
of previously identified candidate genes associated with PCa (Witt, 2009) was subject to 
investigation. Besides, VPA-mediated molecular effects on angiogenesis-related genes and on 
angiogenesis in vivo by use of the CAM model should be analyzed.  
In the second project, the role of cyclin D2 in PCa should be further elucidated. It was 
hypothesized that cyclin D2 exerts tumor suppressive function in PCa (Witt, 2012) which was 
further investigated in the present study by functional experiments of cells overexpressing cyclin 
D2 and of cells with reduced cyclin D2 expression. To elucidate the physiological role of cyclin 
D2 in PCa in vivo a conditional cyclin D2 knockout mouse model was generated and crossed 
with TRAMP mice. 
 
5.1 The histone deacetylase inhibitor valproic acid in PCa 
 
Studies on possible agents for PCa therapy are indispensable since treatment options for early 
PCa stages are associated with severe side effects and treatment options for mCRPC solely 
prolong the patients live and relieve pain, but they are not curative and death is inevitable. 
One of the two main parts of the present study was to investigate valproic acid (VPA) as a 
putative candidate for PCa therapy. VPA is a histone deacetylase inhibitor implicated by many 
studies as a putative agent for the treatment of cancer, including PCa. Previously, it has been 
described that VPA treatment decreases the expression of Cxcl15, Cp1, Cp2, Rcbtb2 and Lif  
and increases the expression of Uchl1, Ptprn and Ccnd2 in the murine PCa cells 2E in a time- 
and concentration-dependent manner (Witt et al. 2013).  
In the present study, the downregulation of Cp2 and Lif could be confirmed by quantitative real-
time PCR in prostate tumor tissue of VPA-treated TRAMP mice. Densitometrical evaluation of a 
western blot confirmed the increased Ccnd2 expression upon VPA treatment observed in 2E 
cells also in prostate tumor tissue of VPA-treated TRAMP mice. 
In prostate tissue of in vivo VPA-treated TRAMP mice the candidate gene expression pattern 
was more similar to the previously obtained microarray data (Witt. 2009). The downregulation of 
Cp2 as well as the upregulation of Ptprn and Uchl1 could be confirmed in prostate tissue of in 
vivo VPA-treaded TRAMP mice. 
Taken together, molecular effects observed by in vitro VPA treatment of mouse PCa cells (2E) 
could be partially confirmed in prostate tumor tissue and to a greater extend in prostate tissue 
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of in vivo VPA-treated TRAMP mice. These results demonstrate the benefits of VPA as a 
possible treatment opportunity for PCa especially in early PCa stages such as PIN. 
In the present study, the investigation of the influence of VPA treatment especially on tumor 
angiogenesis as well as on lymphangiogenesis was of major interest. The expression of several 
angiogenesis markers, including Vegfa, Vegfc, Ang1, Flt-1/Vegfr1, Kdr/Vegfr2, Tie-1, the soluble 
Vegfr2 receptor (sVegfr2) and Pecam-1 was analyzed by quantitative real-time PCR after in vitro 
VPA-treatment of murine 2E PCa cells and in vivo VPA treatment of TRAMP mice. In murine 
PCa 2E cells, the expression of almost all angiogenesis markers mentioned above (i.e. Vegfa, 
Vegfc, Ang1, Tie-1 and Pecam-1) was decreased in a concentration- and partially time-
dependent manner upon VPA treatment. However, both Flt-1/Vegfr1 and Kdr/Vegfr2 were 
significantly upregulated after VPA treatment and in case of Kdr/Vegfr2 it was accompanied by 
increased activation of the receptor signaling pathway as identified by western blot analysis. In 
human PC-3 cells, the downregulation of angiogenesis markers could be partially confirmed but 
dependent on the duration of VPA treatment. 
In vivo VPA treatment also reduced the expression of several angiogenesis markers, as can be 
seen by statistically significant reduced Flt-1/Vegfr1 expression in prostate tissue and Ang1, 
Vegfa, Tie-1 and Kdr/Vegfr2 expression in prostate tumor tissue. These results indicate, that 
VPA treatment has a greater effect on the downregulation of angiogenesis markers in more 
advanced PCa than in very early tumor stages. 
Taken together, in vivo and in vitro VPA treatment effects both blood and lymphangiogenesis, 
as it could be observed by reduced expression of the angiogenic ligands and their receptors and 
by the upregulation of sVEGFR2, a lymphangiogenesis inhibitor, the latter describing a novel 
effect of VPA treatment on lymphangiogenesis. 
For in vivo studies of VPA treatment regarding the influence on angiogenesis several CAM 
experiments were conducted with mouse 2E and human PC-3 PCa cells, which were treated 
with different concentrations of VPA and received different pre-treatments. The CAM 
experiments were not quite successful, because the tumor outcome was very low and 
macroscopic, immunohistochemical and molecular evaluation of these tumors did not yield the 
expected results, such as a reduced tumor volume or reduced expression of angiogenesis 
markers.  
Taken together, in vivo and in vitro VPA treatment was shown to modulate the expression of 
candidate genes associated with PCa. Furthermore, it was shown to modulate not only the 
expression of angiogenesis-related genes (i.e. Vegfa, Ang1, Flt-1/Vegfr1, Pecam-1 and Tie-1) 
but also of lymphangiogenesis related genes (i.e. Vegfc, Kdr/Vegfr2 and sVegfr2) which might 
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be associated with angiogenesis inhibition. These data further highlight the beneficial effect of 
VPA treatment for PCa therapy.  
 
5.2 The cell cycle regulator cyclin D2 in PCa 
 
Cyclin D2 is a known cell cycle regulator, which was proposed to have a special function in PCa, 
possibly acting as a tumor suppressor (Witt, 2012). 
To elucidate the role of cyclin D2 in PCa cells, LNCaP and PC-3 cell clones with a stable 
overexpression of cyclin D2 and LNCaP colonies with a doxycycline-inducible cyclin D2 
overexpression were generated.  
Contrary to the expectation, functional analysis of human PCa cells with a transient, stable or 
inducible cyclin D2 overexpression revealed that these cells exhibited a similar or slightly 
increased proliferation rate as compared to controls. PC-3 and LNCaP cells with stable cyclin 
D2 overexpression had an increased migration rate as compared to controls. These data rather 
indicate that cyclin D2 is not a tumor suppressor in PCa. 
Functional studies of NIH/3T3 cells transfected with cyclin D2-specific siRNAs showed that these 
cells had an increased migration rate as compared to luciferase control transfected cells, 
indicating that cyclin D2 might have anti-tumorigenic capacities, nonetheless. 
NIH/3T3 cells transfected with cyclin D2-specific siRNA acquired no shift in their transformation 
potential, which was investigated by soft agar assay, presumably because siRNA transfection is 
not effective over longer time periods. Therefore, NIH/3T3 clones with doxycycline-inducible 
cyclin D2 downregulation were generated. Their proliferation behavior was similar to that of 
control cells which were not treated with doxycycline. Again it was tested by soft agar assay if 
these cells acquired transformation potential, but this was not the case, not even when the cells 
were double transfected with the oncogene KRAS. For this phenomenon the insufficient 
transfection efficiency could be responsible. 
The functional consequence of cyclin D2 downregulation in VPA-treated 2E, LNCaP, PC-3 and 
DU145 cells was a reduced proliferation rate, indicating that cyclin D2 is not directly responsible 
for the known VPA-induced proliferation inhibition. But, since it was shown that the siRNA is not 
sufficient to prevent the VPA-induced re-expression of cyclin D2, this result needs to be 
considered with caution. 
The physiological role of cyclin D2 in the organism was investigated by the generation of a 
prostate-specific cyclin D2 knockout mouse model, the Ccnd2fl/fl/Cre+ mice. Ccnd2fl/fl/Cre+ mice 
were further bred to TRAMP+ mice to study the influence of the prostate-specific deletion of 
cyclin D2 on prostate tumor development and progression. To date, there are seven 
5. Summary - 165 - 
  
 
homozygous Ccnd2fl/fl/Cre+/T+ mice of which none has developed a palpable PCa so far. The 
oldest of these Ccnd2fl/fl/Cre+/T+ mice is 18 weeks old. 
Taken together, the hypothesis that cyclin D2 could act as a tumor suppressor in PCa remains 
unsolved. Functional studies of cells overexpressing cyclin D2 rather point to the opposite 
direction, whereas functional studies of cells in which cyclin D2 is downregulated indicate that it 
might have anti-tumorigenic capacities. Nonetheless, the downregulation studies exhibited 
several limitations and should be repeated with an epithelial prostate cell line in order to make a 
closing statement. Besides, from the in vivo studies, which could give a definite answer on the 
physiological role of cyclin D2 in PCa, no conclusions can be drawn at the present state of the 
in vivo experiment, because these studies are still ongoing. 
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